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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is a public health burden. Steatosis as the “first hit”, 
and oxidative stress, inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress 
as the “second hits” are the main contributors of the progression of fatty liver to non-alcoholic 
steatohepatitis (NASH). Dietary polyphenols have shown promise in protecting the liver against 
NAFLD. The relative effectiveness and mechanisms of different polyphenols however is mostly 
unknown.  
In this thesis HepG2 hepatocytes exposed to oleic or palmitic acid were used as a model system to 
explore the ability of selected polyphenols (resveratrol, quercetin, catechin, cyanidin, cyanidin-3-
glucoside, berberine) from different classes to protect against molecular aspects of NAFLD and 
NASH. In an investigation of the “first hit” (Chapter 3), different polyphenols protected similarly 
against oleic acid-induced intracellular lipid accumulation, but differed in their effects on the 
expression of genes and proteins involved in lipogenesis, fatty acid oxidation, mitochondrial 
biogenesis, and bioenergetics. In an investigation of “second hits” (Chapter 4), most of the 
polyphenols decreased reactive oxygen species (ROS), prevented the decrease in uncoupling 
protein 2 (UCP2) mRNA, prevented the increase in tumor necrosis factor alpha (TNFα) mRNA, 
reversed decreases in mitochondrial biogenesis and increased expression of mitochondrial 
respiratory complexes and manganese superoxide dismutase (MnSOD). The anthocyanins were 
unique in decreasing ROS without inducing mitochondrial biogenesis or Mn-SOD mRNA 
expression. 
In investigations with palmitic acid (Chapter 5), exposure of HepG2 cells to palmitic acid induced 
endoplasmic reticulum (ER) stress evidenced by upregulated mRNA for the ER chaperones 
glucose-regulated protein 94 and 78 (GRP94, GRP78) and oxygen-regulated protein 150 
(ORP150), cochaperone endoplasmic reticulum-localized DnaJ homologue 4 (ERdj4), and 
proapoptotic CCAAT-enhancer-binding protein homologous protein (CHOP). A few of the 
polyphenols (quercetin, catechin, cyanidin) protected against these changes.  
In a comparison of flavonoids with their phenolic breakdown/digestion products (Chapter 6), the 
polyphenols 2,4,6-trihydroxybenzaldehyde, protocatechuic acid, and caffeic acid protected 
similarly to quercetin and cyanidin against oleic and palmitic acid-induced steatosis and ROS 
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generation. Moreover, in a short-term 1 h exposure (to limit spontaneous degradation in the 
medium), only breakdown/digestion products prevented an oleic acid-induced decrease of 
mitochondrial biogenesis.  
In conclusion, different classes of dietary polyphenols were all able to protect against steatosis and 
ROS generation in this in vitro model of NAFLD. Part of the mechanism for some polyphenols 
was through effects on mitochondrial biogenesis and function, bioenergetics, and ER stress. 
Phenolic breakdown/digestion products of flavonoids were shown to contribute to the protective 
effects of parent polyphenols. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1.Rationale  
Non-alcoholic fatty liver disease (NAFLD) is a public health burden affecting 10-35% of the 
general population in different communities [1]. NAFLD is particularly rising in Western 
communities and may result in serious complications such as non-alcoholic steatohepatitis 
(NASH), cirrhosis, fibrosis, and hepatocellular carcinoma. The leading hypothesis regarding fatty 
liver disease initiation and development is the ‘‘two-hit’’ hypothesis suggesting that hepatic fat 
accumulation is the first hit which may predispose the liver to the “second hits” including but not 
limited to oxidative stress and inflammation [2]. More recently, other “hits” have been suggested 
to be involved including insulin resistance [3], mitochondrial dysfunction [4-6], and endoplasmic 
reticulum (ER) stress [7, 8] which interplay in a concerted manner to expedite the progression of 
simple steatosis to steatohepatitis, cirrhosis, and fibrosis.   
The liver cells are rich in mitochondria and approximately 800 mitochondria are available in each 
hepatocyte. These mitochondria occupy 18% of the volume of each hepatocyte [9]. A myriad of 
evidence suggests NAFLD/NASH as a mitochondrial disease due to the abnormality in function 
and morphology of hepatic mitochondria [5, 10, 11]. In fact, mitochondrial dysfunction contributes 
to the severity of NAFLD and its progression to NASH [12]. This is due to the pivotal role of 
mitochondria in lipid metabolism, lipid peroxidation, ROS and cytokine production, and apoptosis 
[13]. Defective mitochondrial oxidative phosphorylation (OXPHOS) and function have been 
reported in the liver of subjects with NASH [14], as well as in several in vitro and in vivo models 
of NAFLD including HepG2 hepatocytes treated with palmitate [15], in the liver of ob/ob mice 
with NAFLD [16], and in the liver of mice fed a high-fat diet [17]. Moreover, it has been shown 
that mitochondrial biogenesis, mRNA expression of mitochondrial DNA-encoded respiratory 
complex I-V subunits, and the activity of all mitochondrial complexes are decreased in NAFLD 
[17]. It was suggested that a decrease in mitochondrial biogenesis (the decreased number of the 
healthy and functional mitochondria) and impaired expression and assembly of mitochondrial 
respiratory complex subunits may result in depletion of ATP stores [18], increased ROS 
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production [19], collapsed mitochondrial membrane potential (ΔΨm) [20], and impaired fatty acid 
oxidation which are some of the major contributors of NAFLD progression to NASH. 
Inflammatory mechanisms also play a crucial role in the liver damage and activation of collagen-
producing hepatic stellate cells which consequently lead to hepatic fibrosis and NASH. Several 
studies have shown a positive correlation between serum and hepatic levels of TNFα and other 
inflammatory cytokines with the severity of necrosis and fibrosis in fatty liver disease [21].  
Besides mitochondrial dysfunction, endoplasmic reticulum stress has also been reported by 
numerous studies to facilitate progression of NAFLD to NASH [22]. The smooth endoplasmic 
reticulum is associated with the metabolism of proteins, lipids, and carbohydrates and is involved 
in proper folding and maturation of proteins [23]. Lipogenesis has been shown to be affected by 
ER stress and they appear to have a direct and positive correlation [24]. In addition, it seems that 
oxidative stress contributes to perturbation of endoplasmic reticulum homeostasis and therefore 
brings about the activation of a cellular response called unfolded protein response (UPR). The aim 
of this response is to decrease the load of unfolded/misfolded proteins to endoplasmic reticulum 
and to restore endoplasmic reticulum homeostasis [24]. Short term activation of UPR is necessary 
for homeostasis of metabolism but prolonged UPR may have harmful effects and may result in 
increased hepatic lipid accumulation, inflammation, insulin resistance, impaired lipid metabolism, 
and apoptosis. In chronic metabolic diseases, such as obesity, diabetes, and NAFLD, ER stress is 
increased implicating compromised ability of unfolded protein response (UPR) to resolve ER 
stress [7]. Initially, it was suggested that ER stress may have a possible contribution to hepatic 
steatosis and insulin resistance due to the activation of several ER stress markers in dietary (high-
fat diet) and genetic (ob/ob) models of murine obesity [25]. Since then, several studies have 
reported an increased ER stress in hepatocytes treated with palmitic acid [26], and in rodents [27, 
28] and humans [29, 30] with hepatic steatosis.  
Previously, experimental studies (genetic models and high-fat diet) have been designed to study 
the mechanisms of NAFLD development and its progression to NASH [31, 32]. More recently, in 
vitro models of NAFLD have been developed to study the effects of steatosis in hepatic cell line 
of human origin [33, 34] and explore the contributing mechanisms. These models include using 
monounsaturated (oleic acid), and saturated fatty acids (palmitic acid) to induce steatosis in 
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hepatocyte cell line (HepG2) and primary hepatocytes [33-38]. Although human primary 
hepatocytes are the closest to human liver [39], human hepatocyte-derived HepG2 cell line showed 
similar behavior to steatosis and appears to be a promising alternative option [40] particularly for 
investigating NAFLD [39]. HepG2 cell line was also suggested to be a reliable model for studying 
hepatic lipid metabolism [37]. In the present study, I used HepG2 cells because this cell line is 
frequently reported in the literature as an in vitro model of NAFLD [15, 36, 41, 42].   
Polyphenols are abundant micronutrients found in our daily diet such as in different fruits and 
vegetables, pulses, green and black tea, coffee, extra virgin olive oil, red wine and chocolate [43]. 
It has been reported that different polyphenols can prevent fatty liver disease in experimental 
models by showing strong anti-steatotic [44-46], antioxidant [47, 48], and anti-inflammatory 
effects [49, 50]. Although an accumulating body of evidence suggests that mitochondrial 
dysfunction and ER stress are very important contributors of NAFLD progression to NASH, only 
very few studies evaluated the effects of polyphenols on these outcomes. Also, most studies only 
evaluated the effect of one polyphenol or food extract on NAFLD or NASH. Although different 
polyphenols have been shown to ameliorate NAFLD in rodents and humans [51, 52] and could be 
promising treatments for fatty liver disease in future, it is not known which polyphenols are the 
most potent and through what molecular mechanisms they function. Due to previous lack of 
evidence, the main focus of this thesis was on comparison of different classes of polyphenols on 
different aspects of mitochondrial biogenesis and function, and endoplasmic reticulum stress. 
Another question is to elucidate whether the effects of polyphenols on protection against NAFLD 
is due to the parent polyphenols or their breakdown/digestion products. These are unresolved 
questions that this thesis is attempting to address.  
The polyphenols investigated in this thesis have been selected from different classes including: 
1.  FLAVONOIDS - a) flavonol (quercetin), b) flavanol (catechin), and c) anthocyanins 
(cyanidin and cyanidin-3-glucoside). These flavonoids share an ortho 3’,4’-dihydroxy 
structure in the B-ring. Cyanidin-3-glucoside is included because this glycoside has been 
observed to be absorbed intact to appear in the blood of animals and humans. Previous 
work in our laboratory suggests that cyanidin may be accumulated by mitochondria to a 
greater extent than other flavonoids. 
2. STILBENOID - resveratrol. Resveratrol is a potent activator of SIRT1 and stimulator of 
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mitochondrial biogenesis. 
3. ALKALOID - berberine. Although berberine (a methoxy alkaloid derivative) is not itself 
a polyphenol, it can be demethylated by the activity of cytochrome P450 in hepatocytes to 
produce an ortho dihydroxy polyphenolic compound. It also carries a positive charge so 
may be actively accumulated by mitochondria. 
Several chapters of this thesis are being submitted as manuscripts. The first manuscript 
(CHAPTER 3) deals with steatosis and lipid metabolism (the “first hit” of fatty liver disease), and 
the role of polyphenols in protection against it by affecting some aspects of mitochondrial 
dysfunction. The second manuscript (CHAPTER 4) talks about the “second hits” such as oxidative 
stress and inflammation, and deals with the comparison of different classes of polyphenols in 
ameliorating these hits by inducing mitochondrial biogenesis (content) and function. The third 
manuscript (CHAPTER 5) deals with palmitic acid-induced endoplasmic reticulum stress and 
mitochondrial dysfunction and how polyphenols protect against these outcomes. Finally, 
comparison of the parent flavonoids quercetin and cyanidin, and their breakdown/digestion 
products on steatosis, oxidative stress, and mitochondrial biogenesis and function is discussed in 
CHAPTER 6.  
1.2. Hypotheses 
The main hypothesis of my study was that different classes of dietary polyphenols, such as 
resveratrol, quercetin, catechin, cyanidin, cyanidin-3-glucoside (kuromanin), and berberine will 
protect against indices of non-alcoholic fatty liver disease in HepG2 cells, with different potencies 
and mechanisms.  
The detailed hypotheses of my study were: 
1. Some polyphenols will prevent steatosis, mitochondrial dysfunction, and oxidative stress 
in HepG2 hepatocytes exposed to oleic or palmitic acid. 
2. As part of their mechanism of protection, some polyphenols will improve hepatic 
mitochondrial function through increasing mitochondrial biogenesis and upregulating gene 
expression of mitochondrial proteins and mitochondrial respiratory complex I-V subunits. 
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3. In their inhibition of steatosis and oxidative stress in hepatocytes, some polyphenols will 
suppress hepatic endoplasmic reticulum (ER) stress and unfolded protein response (UPR).  
4. Mitochondriogenic (resveratrol) and mitochondrial antioxidant (cyanidin) polyphenols 
will together provide synergistic protection against non-alcoholic fatty liver disease. 
5. The breakdown/digestion products of polyphenols such as caffeic acid, protocatechuic 
acid, and 2,4,6 trihydroxybenzaldehyde will contribute to the inhibitory effect of the parent 
flavonoids (quercetin and cyanidin) against non-alcoholic fatty liver disease. 
 
 
1.3. Objectives 
Specific objectives were: 
1. To determine the effect of selected dietary polyphenols, resveratrol, quercetin, catechin, 
cyanidin, cyanidin 3-glucoside, and berberine on oleic acid-induced changes in HepG2 
hepatocytes including:  
• Intracellular lipid accumulation 
• Reactive oxygen species (ROS) 
• Mitochondrial membrane potential (ΔΨm) 
• The expression of genes involved in lipogenesis (such as FAS and PPARγ) 
• The expression of genes involved in fatty acid β-oxidation (such as PPARα and 
CPT1A1) 
• Uncoupling proteins (such as UCP2)  
• Antioxidant enzymes (such as Mn-SOD) 
• Inflammatory cytokines (such as TNFα) 
• Mitochondrial biogenesis (MitoTracker Green staining) and the contributing genes 
(such as PGC1α, NRF1, TFAM, SIRT1, SIRT3) 
• Activity of SIRT1 
• Mitochondrial dysfunction (gene expression of nuclear DNA-encoded respiratory 
complex I-V subunits) 
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• Intracellular energy stores (ATP content) with and without shutting down 
glycolysis (after 24 and 72 h) 
• Protein expression of phosphorylated (Thr172) AMP-activated protein kinase (p-
AMPKαThr172), and deacetylated PGC1α using Western blot methodology. 
 
2. To determine the effects of quercetin and cyanidin breakdown/digestion products such as 
caffeic acid, protocatechuic acid, and 2,4,6-trihydroxybenzaldehyde on oleic acid-induced 
changes in HepG2 hepatocytes including: 
• Intracellular triglyceride accumulation 
• Reactive oxygen species 
• Mitochondrial content (with 1 h or 24 h incubation with polyphenols and 
breakdown products) 
• Mitochondrial membrane potential 
 
3. To determine the effect of polyphenols such as resveratrol, quercetin, catechin, cyanidin, 
cyanidin 3-glucoside, and berberine on palmitic acid-induced changes in HepG2 
hepatocytes including:  
• Endoplasmic reticulum stress (measuring gene expression of unfolded protein 
response markers including ATF4, GRP58, ERdj4, GRP78, EDEM1, ORP150, 
GADD34, GRP94, and apoptotic CHOP) 
• Mitochondrial function (the expression of both nuclear and mitochondrial DNA-
encoded respiratory complex I-V subunits) 
• Mitochondrial biogenesis (MitoTracker Green staining) 
• Intracellular lipid accumulation 
• Reactive oxygen species 
• Mitochondrial membrane potential 
The first and second hypotheses (and their specific objectives) are addressed in the first and second 
manuscripts (CHAPTER 3 & 4). The third hypothesis (and its specific objectives) is addressed in 
the third manuscript (CHAPTER 5). For the fourth hypothesis, no synergism was found between 
resveratrol and cyanidin in protection against oleic acid-induced ROS generation. The fifth 
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hypothesis is addressed in the fourth manuscript (CHAPTER 6) showing breakdown/digestion 
products of polyphenols contribute to the protective effects of polyphenols against NAFLD.  
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CHAPTER 2: LITERATURE REVIEW 
 
 
2.1. Background  
Nonalcoholic fatty liver disease (NAFLD) which is identified as a public health problem is defined 
by ectopic accumulation of lipids >5 % of the liver weight [53]. NAFLD is defined as a range of 
clinical outcomes and histological abnormalities such as simple steatosis (micro- and macro-
vesicular), steatohepatitis, cirrhosis, fibrosis, and necrosis which is often caused by metabolic 
syndrome [54]. Initially a benign condition, NAFLD may progress to advanced stages such as 
nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma which can be life-threatening. 
For the first time in 1980, the term NASH was coined to describe the hepatic histological 
manifestations similar to alcoholic hepatitis (evidenced by fat accumulation, lobular hepatitis, and 
inflammatory infiltrates) in 20 patients referred to the Mayo clinic with having no history of 
alcohol abuse in a 10-year period [55]. They also found a different prevalence based on gender 
(60% in female). Interestingly, they found that most of the subjects (90%) were obese and had 
obesity-related comorbidities such as diabetes and hyperlipidemia. Prior to popularity of the 
NASH term for these patients, other terms had been suggested such as alcohol-like hepatitis, 
pseudo-alcoholic hepatitis, diabetic hepatitis, and fatty-liver hepatitis [56]. The prevalence of 
NAFLD and NASH is estimated to be about 20-30% and 2-3% of the general population in 
Western communities, respectively [57, 58]. The prevalence of NAFLD is estimated to be about 
70 % in obese subjects and 90% in diabetic patients [59, 60]. The prevalence of NAFLD in children 
is about 2.6 % with 53% of obese children diagnosed with NAFLD [61, 62]. 
Although prevention or treatment of NAFLD/NASH is of critical importance, no medication has 
been approved by the Food and Drug Administration (FDA) for prevention or treatment of 
NAFLD. Currently, lifestyle modifications and weight loss are suggested to be the most important 
treatments and the primary line of intervention, particularly in patients with obesity or metabolic 
diseases [63]. However, the effectiveness of weight loss and adherence to a successful weight 
reduction diet over the long term is still debated [64]. Moreover, the most effective weight loss 
strategy has not yet been determined [60]. Recently, dietary polyphenols have been the subject of 
9 
 
increasing number of studies with showing effectiveness in the amelioration of hepatic steatosis in 
rodents [48, 51] and could be a promising treatment for fatty liver disease in future. In this literature 
review, firstly I will talk about the contributing mechanisms in initiation of NAFLD and its 
progression to NASH, then the effects of dietary polyphenols in the prevention of the disease will 
be discussed in details. 
2.2. The “two-hit” vs. “multiple-hit” hypothesis in regard to initiation and progression of 
NAFLD 
As mentioned earlier, simple steatosis can progress to NASH and this aroused the curiosity of 
scientists to explore the contributing mechanisms leading to this progression. In 1998, Day and 
James suggested a “two-hit” hypothesis [2]. They suggested that the accumulation of fat (steatosis) 
is the “first hit” making the liver susceptible to the “second hits”. They also stated that although 
mere accumulation of fat may cause lipid peroxidation, not all patients with steatosis develop 
necrosis. They suggested that other factors (the “second hits”) may also contribute to the 
progression of simple steatosis to NASH. Accordingly, they proposed oxidative stress as one of 
the “second hits”, which by imposing deleterious effects on cellular DNA and lipids may play a 
pivotal role in the progression of NAFLD to steatohepatitis, cirrhosis, necrosis, and hepatocellular 
carcinoma [2]. These authors also suggested that oxidative stress induced by higher activity of 
cytochrome P450 2E1 (CYP2E1) and by enhanced mitochondrial and peroxisomal fatty acid β-
oxidation may result in the production of lipid peroxidation aldehydes which have a key role in 
the progression of NAFLD to NASH [65]. Lipid peroxidation products may further result in 
necrosis and megamitochondria. In addition, oxidative stress and lipid peroxidation products such 
as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) may activate hepatic stellate cells 
which are capable of producing collagen and generating Mallory bodies (a marker of fibrosis) [66]. 
Although mitochondrial dysfunction has a pivotal role in NAFLD and its progression to NASH, it 
was not suggested by Day and James (1998) as one of the contributing mechanisms [2]. Twelve 
years after introducing the “two-hit” hypothesis, Tilg & Moschen developed the “multiple parallel 
hits” hypothesis for the mechanisms of NAFLD progression to NASH [8]. The “multiple parallel 
hits” hypothesis suggests that NAFLD is a complex disease and it has other contributors other than 
just steatosis and oxidative stress. They proposed that inflammatory mediators generated mainly 
by the gut microflora and adipose tissue may have a central role in NAFLD. In this hypothesis, 
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hepatic steatosis (particularly lipotoxicity) predisposes the liver to the parallel hits including 
adipocytokines, endoplasmic reticulum stress, and innate immunity [8]. They believed all these 
factors act in parallel to develop NASH from simple steatosis. In my opinion, compared to the 
“two-hits” hypothesis, the ‘‘multiple parallel hits’’ hypothesis more appropriately reflects the 
mechanisms behind progression of simple fatty liver disease to NASH. However, the key role of 
mitochondrial dysfunction in progression of the disease is missing and is worth investigation. 
Dietary polyphenols have shown potent antioxidant and anti-inflammatory effects and they may 
be effective in protection against mitochondrial dysfunction in NAFLD. 
Another hypothesis (“distinct-hit”) was recently (in 2012) proposed to explain the pathogenesis of 
NAFLD/NASH [67]. In the “distinct-hit” hypothesis and similar to “multiple parallel hits”, insulin 
resistance is considered to be the main underlying mechanism. “Distinct hit” hypothesis suggests 
that NASH and simple steatosis arise from two independent conditions based on the evidence that 
inflammation may precede steatosis and some patients with NASH show a very low degree of 
steatosis [67]. In simple words, following insulin resistance, independent and distinct pathways 
are triggered resulting in the manifestation of either simple steatosis or NASH.   
In the more recent hypothesis (in 2013), it was suggested that in utero programming (prenatal 
metabolic disturbances) may be involved in the pathogenesis of NAFLD in the subsequent 
generation [68]. To further support this hypothesis, it was shown that exposure to excess energy 
during maternal life in mice resulted in the manifestation of NAFLD in their offspring [69]. 
2.3. The culprits of fatty liver disease development and progression to NASH 
Mechanisms that contribute to the progression of NAFLD to NASH are poorly understood. As 
discussed earlier, different contributors include hepatic lipid accumulation, insulin resistance, 
oxidative stress (ROS), adipocytokines, inflammation, mitochondrial dysfunction, and ER stress. 
In order to treat NAFLD and prevent its progression to NASH, these contributing mechanisms and 
their interrelation should be meticulously evaluated. Unfortunately, temporal order or relative 
contribution of these factors in the genesis of NAFLD is not clearly elucidated. For instance, in 
2004 Özcan et al. suggested a role for ER stress and unfolded protein response (UPR) in NAFLD 
development, while previously researchers considered no role for ER stress in fatty liver disease 
[25]. Another example is the lower activity of mitochondrial respiratory complexes in NASH 
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patients, which was firstly reported by Pérez‐Carreras more than a decade ago [14]. Recently, it 
was suggested that mitochondrial dysfunction may occur due to the lower expression of 
mitochondrial DNA-encoded respiratory complexes subunits [17]. In summary, further studies are 
needed to elucidate the association between the intertwined networks of contributors in the 
development and progression of fatty liver disease. In the following sections, the roles of most 
important mechanisms involved in NAFLD initiation and progression are discussed in more detail.  
2.4. Different sources of fatty acids in the liver 
All animals including humans have regulatory mechanisms controlling the equilibrium between 
energy intake and output. Insulin is the main regulator of this equilibrium and controls the 
metabolism of fats, carbohydrates, and proteins. Different sources of fatty acids in the liver 
include: food intake, de novo lipogenesis, and lipolysis in adipose tissue. General understanding 
of these sources is important since the relative importance of these sources is different in the fed 
and fasted state, and in healthy and in fatty liver disease [70]. 
2.4.1. Food intake 
Following the absorption of fatty acids from the small intestine, chylomicrons are formed which 
first transfer their fatty acids via the blood stream to adipose tissue, and then the chylomicron 
remnants are taken up by the liver [71]. Evidence reports that 59% of hepatic fat in NAFLD 
patients originates from the circulating non-esterified fatty acid (NEFA) pool coming from 
lipolysis of peripheral fat stored in adipocytes, followed by de novo lipogenesis (26%), and dietary 
intake (15%) [72]. 
2.4.2. De novo lipogenesis 
Since steatosis was suggested as the “first hit” and the main contributor of fatty liver disease [2], 
triglyceride synthesis may play a key role in fatty liver disease development. Modulating the 
expression and activity of lipogenic enzymes has been the subject of many studies aiming to 
prevent fatty liver disease [73]. Two important sources of hepatic triglyceride synthesis are free 
fatty acids (FFA) released from adipose tissue as well as dietary FFA [74]. Triglyceride synthesis 
in the liver has different steps. Esterification of free fatty acids and glycerol is driven by glycerol-
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3-phosphate acyltransferase (GPAT). Insulin upregulates while glucagon inhibits GPAT 
expression [75]. It was shown that increased flow of FFA to the liver induces fatty acid 
esterification by GPAT [76]. 
Insulin induces the metabolism of glucose to pyruvate and acetyl-CoA which the latter is further 
converted to fatty acid. Following activation by insulin, the  transcription factor sterol regulatory 
element-binding protein 1-c (SREBP1-c) induces the expression of all enzymes involved in 
lipogenesis [5]. Enzymes induced by SREBP1-c include pyruvate kinase, fatty acid synthase 
(FAS), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD) [77]. After production 
by insulin action, pyruvate enters mitochondria to produce acetyl-CoA. Acetyl-CoA further reacts 
with oxaloacetate (OAA) to produce citrate. After leaving mitochondria for the cytosol, citrate 
moves to the cytosol and produces acetyl-CoA, which is further converted to malonyl-CoA by the 
activity of the cytosolic enzyme ACC [74]. Malonyl-CoA is a key regulator of free fatty acid entry 
toward either esterification or β-oxidation [78]. A high concentration of malonyl-CoA stimulates 
lipogenesis while inhibiting β-oxidation through the inactivation of carnitine palmitoyltransferase-
1 (CPT-1). Malonyl-CoA is then converted to palmitoyl-CoA by the activity of fatty acid synthase 
and palmitoyl-CoA is further converted to monounsaturated fatty acids, mainly oleate (C18:1) and 
palmitoleate (C16:1) by stearoyl-CoA desaturase [79]. SCD-1 has been shown to play a key role 
in the onset of diet-induced hepatic insulin resistance [80]. Higher activity of SCD-1 has been 
shown in NAFLD subjects (concomitant with elevated levels of hepatic oleate) [81] and in fatty 
livers of ob/ob mice [82]. SCD-1 knock-out mice are resistant to hepatic steatosis and adiposity 
[83, 84]. Moreover, lowering hepatic scd-1 gene expression using sequence-specific antisense 
oligodeoxynucleotide in rats and mice on a high-fat diet was shown to induce insulin sensitivity, 
improve insulin signaling, and decrease gluconeogenesis [80]. Dietary polyphenols can protect 
against steatosis by decreasing the expression of genes involved in lipogenesis. For example, 
epigallocatechin gallate found in green tea decreased mRNA expression of SCD1 in the liver of 
diet-induced obese mice suggesting a role in inhibiting lipogenesis in these mice [85] 
Although hepatic steatosis is the main feature of NAFLD and NASH, the source of fat (triglyceride 
or toxic free fatty acid) has a critical role in developing NASH. The final step of triglyceride 
synthesis in the liver is catalyzed by diacylglycerol acyltransferase (DGAT). For instance, it was 
shown that DGAT antisense oligonucleotide decreased hepatic triglyceride content but increased 
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hepatic free fatty acids (FFA) which finally led to oxidative stress and fibrosis in methionine 
choline-deficient (MCD)-fed mice due to lipotoxicity [86]. Figure 2.1 depicts the glycolysis 
pathway and how its main product pyruvate generates fatty acids by a concerted action of lipogenic 
enzymes regulated by insulin and transcription factor SREBP-1c.     
Studies report that in patients with NAFLD the capacity of the liver to export fats as very low-
density lipoproteins (VLDL) is not increased in line with increased hepatic lipogenesis. Therefore, 
it appears that hepatic VLDL synthesis and secretion increases linearly with increased hepatic 
triglyceride content in normal subjects but reaches a plateau when hepatic triglyceride content 
exceeds 10% in NAFLD [87].  
Formation of triglyceride is a temporary strategy for the liver to avoid lipotoxicity of free fatty 
acids in circulation. Although this strategy is beneficial for a short period, if the liver does not 
handle this lipid accumulation, metabolic disturbances ensue which lead to further liver damage 
and NASH [88]. 
 
Figure 2. 1. Schematic figure of lipogenesis in hepatocytes.  
This figure is adapted from Tessari et al. [79]. GK, glucokinase; PHI, phosphohexose isomerase; 
6-PFK, phosphofructokinase; L-PK, liver pyruvate kinase, OAA, oxaloacetic acid; ACC, acetyl-
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CoA carboxylase; FAS, fatty acid synthase; SCD, stearoyl-CoA desaturase; DAG, diacylglycerol; 
DGAT, diacylglycerol acyltransferase. Following uptake by hepatocytes, glucose undergoes 
glycolysis to produce pyruvate. The pyruvate then enters mitochondria to produce acetyl-CoA (by 
the pyruvate dehydrogenase, PDH) that reacts with OAA to produce citrate which leaves 
mitochondria to the cytosol to regenerate acetyl-CoA again. Acetyl-CoA then produces malonyl-
CoA through the activity of ACC. Malonyl-CoA is the inhibitor of fatty acid β-oxidation and 
alternatively induces lipogenesis. Under the activity of FAS and SCD, palmitate and oleate are 
synthesized which are finally re-esterified to produce triglyceride. These reactions and the 
expression and activity of lipogenic enzymes are regulated by insulin through the transcription 
factors SREBP-1c and ChREBP. 
2.4.3. Adipose tissue lipolysis  
Triglycerides stored in adipocytes can be mobilized to the liver by different factors including lower 
level of insulin and increased level of glucagon, leptin, and TNFα [89]. Lipolysis of peripheral fat 
stored in adipose tissue is the most important source of the plasma non-esterified fatty acid pool 
and hepatic lipid accumulation [90]. In patients with NAFLD, insulin is unable to prevent adipose 
tissue lipolysis [70]. Therefore, due to decreased sensitivity of hormone sensitive lipase (HSL) to 
insulin, insulin resistance enhances hepatic accumulation of fat. 
2.5. The transcription factors controlling lipid metabolism and their contribution to NAFLD 
SREBP1-c is an important regulator of lipogenesis which is activated by insulin in a 
phosphatidylinositol 3-kinase (PI3K)-dependent pathway [5]. SREBP1-c expression is 
upregulated in NAFLD due to a higher load of FFA to the liver and hyperinsulinemia. Studies in 
rodents show that any changes in nutritional status results in the regulation of SREBP1-c 
expression in the liver, adipose tissue, and muscle [91]. Fasting downregulates while refeeding 
with a high-carbohydrate diet upregulates SREBP1-c expression. In contrast to insulin, glucagon 
inhibits SREBP1-c transcription through the cyclic adenosine monophosphate (cAMP). 
Correspondingly, activation of AMP-activated protein kinase (AMPK) by the higher cellular 
AMP/ATP ratio inhibits SREBP1-c transcription [92, 93]. SREBP1-c has a pivotal role in the 
pathogenesis of NAFLD in experimental models. It has been reported that the hepatic expression 
of SREBP1-c is increased in obese insulin resistant ob/ob mice [94] and in diet-induced mice [95]. 
Liver X receptor (LXR) is also a member of the nuclear receptor family of transcription factors 
which has an important role in regulating fatty acid, cholesterol, and glucose metabolism [96, 97]. 
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LXR can bind retinoid X receptor (RXR) and the resultant LXR/RXR heterodimer translocates to 
the nucleus to promote de novo lipogenesis by inducing the expression of transcription factor 
SREBP-1c and subsequent upregulation of its target lipogenic genes FAS and ACC [5].  
SREBP1-c knock-out mice only show 50% reduction in lipogenesis [98]. This shows that other 
transcription factors such as the carbohydrate-responsive element-binding protein (ChREBP) is 
also involved in lipogenesis. Following serine residue 196 (Ser-196) dephosphorylation and 
consequent activation of ChREBP by glucose (by an insulin-independent mechanism), ChREBP 
translocates from the cytosol into the nucleus inducing lipogenic enzymes by binding to the 
carbohydrate response elements (ChoRE) [99]. Studies on obese mice models demonstrate the 
importance of ChREBP in lipogenesis and hepatic steatosis. Decreased expression of lipogenic 
pyruvate kinase, FAS, and ACC in response to glucose, as well as reduced hepatic lipogenesis, 
were observed following hepatic ChREBP gene deletion in mice [100, 101]. Nuclear expression 
of SREBP1-c and ChREBP was increased following the fed state in obese mice, indicating these 
two transcriptional regulators have very important roles in lipogenesis and hepatic steatosis.  
2.6. Fatty acid β-oxidation in NAFLD 
As discussed earlier, oxidation of fatty acids occurs in mitochondria and peroxisomes by β-
oxidation, and in microsomes by ω-oxidation. Under normal physiologic condition, β-oxidation in 
mitochondria is the dominant oxidative pathway for the oxidation of fatty acids to produce ATP 
[9].   
While short (< C8) and medium (C8-C12) chain fatty acids can freely enter mitochondria, the story 
for long chain fatty acids (C12-C20) is different. Carnitine palmitoyltransferase-1 (CPT-1) is the 
rate-limiting enzyme in mitochondrial β-oxidation. CPT-1 is located in the outer mitochondrial 
membrane and helps transporting long chain fatty acids into mitochondria. Malonyl CoA which is 
produced in lipogenesis, allosterically inhibits CPT-1 [78]. By phosphorylation and inactivation 
of lipogenic ACC, AMPK decreases malonyl CoA leading to increased β-oxidation of fatty acids 
[92]. Accordingly, it is demonstrated that there is an inverse association between mitochondrial β-
oxidation and de novo lipogenesis [4]. Metformin is a medication for type 2 diabetes and is shown 
to decrease lipogenesis and hepatic gluconeogenesis by activating AMPK in hepatocytes [102].  
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A few studies reported the extent of β-oxidation in NAFLD. With indirect methods, these studies 
showed increased β-oxidation in fatty liver disease as an adaptive mechanism [103, 104]. One 
important limitation is that due to the lower expression and activity of mitochondrial complexes, 
this increased β-oxidation contributes to enhanced production of ROS through electron leakage 
from complex I and III. This damage to mitochondria further causes mitochondrial DNA (mtDNA) 
depletion and consequent defective mitochondrial function [105].  
Another protein involved in β-oxidation is uncoupling protein 2 (UCP2). Uncoupling proteins are 
a family of mitochondrial proteins which uncouple oxidative phosphorylation from ATP synthesis. 
UCP2 decreases mitochondrial membrane potential (ΔΨ) leading to increased flow of electrons 
through the mitochondrial respiratory chain. This increased flow of electrons results in the 
increased re-oxidation of NADH to NAD+ [10]. By providing substrate (NAD+) for continuing 
mitochondrial β-oxidation, UCP2 induces the oxidation of excess fats in fatty liver disease. 
2.7. Reactive oxygen species (ROS) and their pivotal role in NAFLD progression to NASH 
Oxidative stress is the imbalance between generation of reactive oxygen and nitrogen species 
(ROS, RNS) and antioxidant enzymes [106]. Physiological levels of ROS have been widely 
implicated in some important processes including cell signaling [106, 107]. ROS is a term which 
refers to species such as singlet oxygen (1O2), superoxide (O2•−), hydrogen peroxide (H2O2), and 
hydroxyl radicals (OH•−). Following leakage of electrons by mitochondrial complex I and III and 
premature transfer to oxygen, superoxide radicals are generated [105].  
Although it was evidenced for a long time that only complex I and III produce ROS, complex II 
was also shown to have an important role in substantial generation of H2O2 [108]. While 
superoxide radical is moderately active and is considered as a primary ROS, it can generate 
secondary ROS such as H2O2 [109]. However, although the superoxide radical has a very short 
half-life and can damage the iron-sulfur center of proteins, particularly mitochondrial complexes, 
it is rapidly dismutated to H2O2 by the superoxide dismutases. H2O2 can be completely reduced 
to water by the activity of catalase and glutathione peroxidase, or may be converted to very active 
hydroxyl radical by the Fenton reaction in the presence of iron [105].   
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Iron deposition was reported in the liver of 30% of NAFLD patients. It seems that NASH patients 
have more hepatic iron stores compared to NAFLD patients [110]. The mechanism of increased 
iron stores in these patients is not clearly understood but insulin resistance, genetic factors, 
erythrophagocytosis by Kupffer cells, and disturbance in molecules which regulate iron status, 
may have contribution [110]. This increase in iron stores as the form of ferritin (hyperferritinemia) 
is shown to be highly associated with metabolic syndrome, insulin resistance, and type 2 diabetes 
[111]. Accumulated iron may be responsible for a higher production of hydroxyl radicals by the 
Fenton reaction and consequent hepatic fibrosis and hepatocellular carcinoma in NASH patients. 
Hydroxyl radical is the most potent and dangerous radical in nature with very short in vivo half-
life (10-9 s) which can attack every macromolecule such as fats, proteins, and DNA [105]. Although 
antioxidant enzymes help preventing formation of OH•− radicals, once generated its damage is 
unavoidable.  
Increased levels of oxidative stress and lipid peroxidation products, and decreased levels of 
antioxidant enzymes such as the superoxide dismutase (SOD) and catalase have been reported in 
patients with NAFLD and NASH compared to healthy subjects [112]. Some studies have looked 
at several oxidative stress markers to find indicators distinguishing between NAFLD and NASH. 
Some oxidative stress markers such as serum thioredoxin have been shown to discriminate 
between NAFLD and NASH and elevated serum thioredoxin is suggested to be an indicator for 
the severity of NASH [113]. Higher levels in NASH patients of heme oxigenase-1 (HO-1), which 
protects cells against oxidative stress is also suggested to reflect the severity of NASH (as an 
adaptive response) compared to NAFLD [114]. Some animal and human studies also showed a 
correlation between oxidative stress and lipid peroxidation biomarkers such as MDA and 4-HNE 
with the stage of NAFLD and NASH [112, 115]. Oxidative stress is the major contributor in the 
progression of simple steatosis to necrosis and fibrosis. Therefore, by inhibiting oxidative stress, 
progression of NAFLD to NASH may be halted [90]. Figure 2.2 depicts the interrelation between 
oxidative stress and inflammation in inducing the progression of simple fatty liver to NASH.  
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Figure 2.2. Schematic depicts the interrelationship between oxidative stress and 
inflammation in the progression of NAFLD to NASH  
This figure is adapted from Ucar et al. [116]. Insulin resistance facilitates lipolysis in adipocytes 
which along with a high-fat and high-sugar diet increases the accumulation of fat in the liver. The 
excess fat undergoes β-oxidation in hepatic mitochondria and peroxisomes leading to 
mitochondrial dysfunction and production of ROS. ROS in turn may damage membrane lipids and 
produce lipid peroxidation products such as MDA and 4-HNE. Although ROS have a short half-
life, lipid peroxides have a longer half-life and can leave hepatocytes and therefore prolong ROS-
mediated damage. Lipid peroxides can further induce Kupffer cells (liver residing macrophages) 
to produce inflammatory cytokines such as TNFα and IL6. Lipid peroxides may also activate 
hepatic stellate cells which produce collagen and finally leading to scar tissue and fibrosis. 
Incorporation of saturated fatty acids into the endoplasmic reticulum (ER) membrane can also 
enhance the stiffness of the membrane leading to ER stress and release of calcium from ER which 
then accumulate in mitochondrial matrix. The increase in calcium results in opening of 
mitochondrial permeability transition pores (MPT) and consequent release of cytochrome c which 
may induce apoptosis. ER stress may also increase phosphorylation and activation of JNK causing 
inflammation which along with higher ROS produced by defective mitochondria may facilitate 
progression of simple steatosis to NASH.  
The redox state of the mitochondrial respiratory chain mainly determines ROS production. Chronic 
intake of a high-fat high-sucrose diet (a frequent contributor to obesity and fatty liver) increases 
the flow of electrons to mitochondria which exceed the capacity of the mitochondrial electron 
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transport chain. In this case, increased production of NADH and FADH2 in the tricarboxylic acid 
cycle and higher transfer of electrons to complex I and II leads to over-reduction of mitochondrial 
complexes (reviewed in [105]). Due to increased entry of electrons to the electron transport chain 
as well as increased load of protons in the intermembrane space, the dissipation of the proton 
gradient by complex V (ATP synthase) is not sufficient to overcome this load of electrons. This 
phenomenon results in over-reduction of mitochondrial complexes, leakage of electrons, and 
subsequent ROS production. This increased ROS generation cannot be sufficiently scavenged by 
mitochondrial antioxidant enzymes leading to mtDNA damage (reviewed in [105]). This damage 
to mtDNA may decrease the synthesis and assembly of mitochondrial complex subunits causing 
further ROS production. This vicious cycle caused by reactive oxygen and nitrogen species (RNS) 
in NASH patients may lead to lower activity of respiratory complexes and perturbation of 
mitochondrial homeostasis.  
By activation of enzymes involved in lipid peroxidation such as lipoxygenase, cyclooxygenase, 
and cytochrome P450, ROS may cause NAFLD progression to NASH [117]. Furthermore, by 
inducing serine phosphorylation of insulin receptor substrate-1 (IRS-1), ROS may induce insulin 
resistance which is one of the main contributors of fatty liver disease [48]. 
2.7.1. Sources of reactive oxygen species in NAFLD 
2.7.1.1. Mitochondria 
Although several sources of intracellular ROS have been identified including the endoplasmic 
reticulum, cytosol, and peroxisomes [118, 119], mitochondria are quantitatively the most 
important source of ROS (by about 90 %) due to the higher oxygen consumption [120]. Under 
normal physiologic conditions only 1-2 % of oxygen consumed leads to ROS production [120]. 
This mitochondrial-generated ROS is primarily determined by the metabolic state. Complex I and 
III produce the highest amount of ROS in mitochondria [118]. 
2.7.1.2. Peroxisomes 
During fatty liver disease both mitochondria and peroxisomes work in concert to metabolize excess 
fatty acids. However, due to the increased activity of peroxisomal acyl-CoA oxidase, which is a 
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key enzyme in peroxisomal β-oxidation, excess ROS is produced [121]. Like mitochondria, 
peroxisomes have a series of antioxidant enzymes including catalase to detoxify ROS generated 
by peroxisomal fatty acids β-oxidation. It was reported that in some pathological conditions a five-
fold increase in peroxisomal β-oxidation results in less than a 10% increase in mRNA expression 
of peroxisomal antioxidant enzymes. This disequilibrium between peroxisomal ROS generation 
and removal systems show that peroxisomes can be a potential source of ROS generation during 
lipid over accumulation states such as steatohepatitis [122].  
2.8. Antioxidant enzymes in NAFLD  
Oxidative stress can be the consequence of an imbalance between ROS generation and antioxidant 
enzymes [116]. As discussed earlier, oxidative stress following mitochondrial dysfunction in 
NAFLD/NASH may damage mitochondrial and nuclear DNA, proteins, fats, and causes apoptosis 
[5]. ROS generated by mitochondria may be neutralized by antioxidant enzymes. Mitochondria 
possess a number of antioxidant enzymes and therefore are considered as a sink for ROS removal 
instead of ROS producing organelles in normal physiologic conditions. The major antioxidant 
enzymes in the cells include the superoxide dismutase 1 (Cu/Zn-SOD) and superoxide dismutase 
2 (Mn-SOD) which are mainly found in the cytosol and mitochondria respectively and can 
dismutate superoxide radical to H2O2 [116].   
Deletion of Mn-SOD leads to neonatal death in mice [123]. The lethality is apparently due to the 
damage mediated by oxidative stress [123]. Moreover, mice deficient in Mn-SOD suffer from 
metabolic dysfunction and the accumulation of intracellular fat in the liver and muscle [124]. These 
symptoms are attributed to the reduced activity of aconitase [an iron-sulphur (Fe-S) protein] that 
is very sensitive to superoxide radicals [125]. Therefore, it was suggested by the authors that one 
of the main functions of Mn-SOD is to prevent any oxidative damage to aconitase. Besides 
aconitase, other proteins and complexes in the mitochondrial transport chain contain Fe-S proteins. 
Accordingly, Mn-SOD activity is very important to keep these complexes functioning to 
metabolize excess fatty acids in NAFLD. Takami et al. reported higher serum levels of Mn-SOD 
in NAFLD and NASH patients compared to simple steatosis suggesting this level may be a 
distinguishing marker of NASH [126]. 
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Besides catalase, mitochondria possess other enzymes to detoxify H2O2. These enzymes include 
mitochondrial glutathione peroxidase (GPx) and glutathione reductase, which utilize glutathione 
as an electron donor, and mitochondrial thioredoxin peroxidase and thioredoxin reductase, which 
use thioredoxin as an electron donor, to detoxify H2O2 [120]. It has been reported that GPx activity 
is unchanged or decreased in the serum of NASH patients compared to the control group [127-
129]. 
In other studies related to NASH, decreased liver glutathione and lower activity of antioxidant 
enzymes GPx, SOD, and catalase was reported and this decrease was in association with the 
severity and stage of NASH [105, 130]. One explanation for decreased activity of GPx in NASH 
is due to a decrease in reduced mitochondrial glutathione which is needed for GPx activity. Lower 
import of cytosolic glutathione to mitochondria may contribute to the decline in mitochondrial 
glutathione levels in NASH [131].  
2.9. Effect of inflammatory cytokines in NAFLD 
Cytokines are soluble molecules produced by different cells such as hepatocytes that have 
important roles in intercellular communications. Under normal circumstances, the expression of 
cytokines in the liver is absent or very low. Cytokines play a central role in the initiation and 
progression of NAFLD by the activation of liver inflammation, necrosis, fibrosis, and apoptosis 
[132]. 
Increased ROS production in NAFLD induces the expression of inflammatory cytokines such as 
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFα) which are able to perturb insulin 
signaling and consequently contribute to the lipid and glucose metabolism disruption [133]. 
Besides ROS, lipid peroxidation aldehydes also induce the expression of inflammatory cytokines 
leading to inflammation, neutrophil chemotaxis, and necrosis in NASH (reviewed in [2]). 
TNFα can be secreted by any of  hepatocytes, Kupffer cells, or visceral fat adipocytes [134]. The 
expression of TNFα in adipocytes and hepatocytes of NASH patients was shown to be higher 
compared to the normal group and this was associated with hepatic fibrosis [135]. Some studies 
demonstrated the association between TNFα expression and insulin resistance in NASH [136]. In 
addition, an accumulating body of evidence shows the central role of TNFα and other 
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inflammatory cytokines in the progression of simple steatosis to NASH. There is a strong 
association between circulating level of inflammatory cytokines and the severity of fatty liver 
disease and fibrosis [21]. 
Moreover, by the activation of nuclear factor kappa B (NF-κB), increased load of fatty acids in 
hepatocytes brings about hepatic insulin resistance [137]. Once activated, transcription factor NF-
κB translocates to the nucleus and induces the expression of several pro-inflammatory genes such 
as TNFα, IL6, IL8, transforming growth factor-β (TGF-β) and Fas ligand. By inducing the 
expression of TGF- β, Kupffer cells activate hepatic stellate cells to produce collagen resulting in 
fibrosis in NASH. Lipid peroxidation aldehydes and ROS can activate hepatic stellate cells to 
produce collagen [137].  
2.10. Mitochondria and their contribution to fatty liver disease 
2.10.1. Mitochondria are powerhouse of the cells 
Liver is rich in mitochondria and approximately 800 mitochondria are available in each 
hepatocyte. These mitochondria occupy 18% of the volume of each hepatocyte [9]. Mitochondria 
are involved in both free fatty acid β-oxidation and ROS generation [3].  
The mitochondrial respiratory chain consists of five complexes (I-V) which transfer electrons from 
NADH and FADH2 to oxygen to produce water. During this process NADH and FADH2 are 
converted to oxidized NAD+ and FAD. According to the chemiosmotic theory of Mitchel, during 
this transfer of electrons, protons (H+) are pumped out of the mitochondrial matrix into the 
intermembrane space by complex I, III, and IV generating higher mitochondrial membrane 
potential (ΔΨ) [138]. When energy is needed, protons enter mitochondria through the Fo subunit 
of ATP synthase (complex V) and this drives phosphorylation of ADP to ATP [139]. If electron 
flow through mitochondrial complexes is interrupted at any point, electrons transfer to oxygen 
prematurely and this causes generation of reactive oxygen species such as superoxide radicals or 
hydrogen peroxide [140]. 
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2.10.2. Mitochondrial biogenesis helps to fuel hepatocytes with healthy and functional 
mitochondria  
Mitochondrial biogenesis involves two processes: mitochondrial replication and differentiation. 
Mitochondrial replication is defined as synthesizing mtDNA and new biomolecules, while 
differentiation affects pre-existing mitochondria and improves mitochondrial function by 
increasing the mitochondrial inner membrane with more cristae and overexpression of 
mitochondrial proteins such as the respiratory complex subunits [141]. Fatty liver has been 
associated with reduced PGC1α mRNA or activity in the muscle and liver of rodents, and therefore 
reduced mitochondrial biogenesis [142, 143]. PGC-1α is a transcriptional factor which is very 
important for regulating the expression of genes involved in mitochondrial biogenesis, function, 
and energy metabolism [144]. PGC-1α co-activates nuclear respiratory factors (NRF1, NRF2) 
leading to increased synthesis of nuclear DNA-encoded proteins involved in the electron transport 
chain. Moreover, NRFs induce mitochondrial transcription factor A (TFAM) which in turn induces 
the expression of mitochondrial DNA-encoded subunits of the electron transport chain [10]. 
TFAM also regulates stability, transcription, and replication of mtDNA [143]. Activation of 
PGC1α induces the expression of genes involved in fatty acid β-oxidation, antioxidant enzymes, 
lipid transport, and gluconeogenesis [144-147]. For instance, PGC-1α cooperates with PPARα to 
induce the expression of CPT1 and medium chain acyl-CoA dehydrogenase [10]. The result of 
these concerted mechanisms is the increased number of healthy and functional mitochondria and 
consequent metabolism of excess fat [10]. 
2.10.3. NAFLD/NASH: a mitochondrial disease 
An accumulating body of evidence suggests NAFLD as a mitochondrial disease due to the 
abnormality in function and morphology of hepatic mitochondria [5, 9, 10]. This is due to the 
pivotal role of mitochondria in lipid metabolism, ROS generation, lipid peroxidation, cytokine 
production, and apoptosis [4, 13].  
One of the mechanisms by which mitochondrial dysfunction exacerbates NAFLD is due to the 
higher ROS production by defective mitochondria. ROS and RNS may damage mitochondrial 
DNA leading to mitochondrial DNA depletion and consequent downregulation of mitochondrial 
complex subunits expression [15, 17]. Moreover, as mentioned earlier, ROS can damage the iron-
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sulfur cluster enzymes [148] in the mitochondrial electron transport chain leading to mitochondrial 
dysfunction. Figure 2.3 depicts the mechanisms by which a high-fat high-sugar diet may cause 
mitochondrial dysfunction, oxidative stress, and the depletion of ATP stores in hepatocytes. 
 
Figure 2. 3. Mechanisms of the vicious cycle of mitochondrial dysfunction and damage 
induced by nutrient excess. 
Higher intake of a high-fat high-sugar diet produces more electron donors (NADH and FADH2) 
to the mitochondrial electron transport chain which causes more protons to be pumped out to the 
intermembrane space through complex I, III, and IV. Due to reduced activity of all mitochondrial 
complexes in NAFLD, electron flow slows down in mitochondria leading to premature transfer of 
electrons to oxygen to produce ROS which can damage mitochondrial DNA to produce more ROS. 
Moreover, due to the lower activity of ATP synthase, less protons can enter mitochondria through 
this complex leading to the depletion of ATP stores in NASH which makes hepatocytes susceptible 
to oxidative damage and necrosis. 
Mitochondrial DNA depletion which is very difficult to be repaired causes reduced expression of 
complex I, III, IV, and V subunits (due to encoding 13 polypeptides involved in the electron 
transport chain by mitochondrial DNA) [3]. Pérez‐Carreras et al. for the first time reported the 
lower activity of all the mitochondrial respiratory complexes in the liver of patients with NASH 
[14]. Following this finding, studies were conducted to explore the mechanisms of mitochondrial 
dysfunction in animal models of NASH. It was later shown that increased TNFα and inducible 
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nitric oxide synthase (iNOS) and tyrosine-nitrated proteins in the liver of ob/ob mice [16] are some 
of the contributors for mitochondrial complex dysfunction. For instance, it was reported that TNFα 
induces the mitochondrial release of cytochrome c leading to a decreased flow of electrons in 
mitochondria [16]. 
Cellular ATP levels are also important in maintaining the integrity of hepatic tissue and ATP 
depletion may result in hepatocellular injury. Evidence shows that the hepatic ATP stores become 
depleted in experimental models of NAFLD using methionine-choline deficient diet [149]. One 
study comparing hepatic ATP stores between normal and NASH subjects showed similar depletion 
of hepatic ATP stores but delayed recovery in ATP stores in NASH [150]. This inability in 
restoring ATP stores after a stress such as oxidative stress may make hepatic cells vulnerable to 
hepatocellular injury and cirrhosis in NASH. Mitochondrial injury is considered as an important 
contributor in depleted hepatic ATP stores in NASH [151]. 
The lower hepatic ATP levels in NASH may also be due to the increased expression of UCP2. 
UCP2 which is discussed in details in section 2.12 is a mitochondrial membrane protein which 
uncouples oxidative phosphorylation from ATP generation. It is shown that UCP2 expression 
increases in experimental models of NAFLD [48]. This enhanced expression of UCP2 may 
contribute to the dissipation of energy which in turn reduces ATP synthesis in NAFLD. During 
uncoupling, each mitochondrion may generate a lower amount of ATP for a given amount of 
oxygen consumed [151].  
Interestingly, several studies report morphological abnormality of mitochondria in patients with 
fatty liver disease. These mitochondria are enlarged, rounded and swollen (megamitochondria), 
scarce in number, hypodense in matrix, with loss of cristae which impairs mitochondrial function 
in NAFLD/NASH patients [9, 103, 152, 153]. 
2.10.4. Evidence regarding impaired mitochondrial oxidative phosphorylation (OXPHOS) 
capacity in NASH 
There have been conflicting findings about OXPHOS dysfunction in different tissues in patients 
with NASH. For the first time, Caldwell et al. showed normal activity of complex I and III in the 
platelets of subjects with NASH [152]. Sanyal et al. also could not show any defect in the muscle 
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mitochondrial respiratory chain in a patient with NASH [103]. Perez-Carreras et al. however 
showed decreased activity of all of the five mitochondrial complexes in liver tissues of patients 
with NASH [14]. Researchers also showed that mitochondrial DNA is severely depleted in the 
muscle of patients with alcoholic fatty liver disease and this in turn resulted in impairment of 
mitochondrial function [154]. 
Dietary studies in laboratory animals have also shown differing results. Chavin et al. [155] showed 
increased activity of mitochondrial complexes in the liver of obese mice, suggesting an adaptive 
mechanism to metabolize increased load of fatty acids [139]. In contrast, García-Ruiz et al. 
demonstrated reduced assembly and activity of all mitochondrial complexes by 50-60% in mice 
fed a high-fat diet [17]. They found reduced mRNA expression of mitochondrial DNA-encoded 
complex subunits but not nuclear DNA-encoded ones. In line with this result, they found oxidative 
damage to mitochondrial DNA but not nuclear DNA. They concluded that the high-fat diet 
decreased OXPHOS complexes activity due to the reduced expression of their subunits which 
results in impaired full assembly of mitochondrial complexes. Decreased mitochondrial complex 
activity in obese ob/ob mice is partially due to an increased oxidative stress, and treatment with 
antioxidants prevented the decrease [16]. 
2.11. Role of PPARs in metabolism  
PPARs are members of a nuclear receptor subfamily. There are three isoforms of PPARs: PPARα, 
PPARβ/δ, and PPARγ. Fatty acids are natural ligands of PPARs. Synthetic activators of PPARα 
and PPARγ are fibrates and thiazolidinediones (TZDs), respectively [156]. PPARs have a pivotal 
role in metabolism since it was shown that the activation of PPARα and PPARγ by fibrates and 
TZDs alleviates diabetes type 2 and dyslipidemia [157]. Furthermore, transcriptional control of 
genes by PPARs plays a key role in lipid metabolism (particularly hepatic steatosis), inflammation, 
and fibrosis [156].  
2.11.1. The importance of PPARα in protection against NAFLD 
PPARα is highly expressed in metabolically active tissues such as the liver and skeletal muscles. 
Higher PPARα expression plays a central role in inducing hepatic fatty acid β-oxidation in NAFLD 
[156]. Once activated, PPARα binds to retinoid X receptor alpha (RXR-α) and induces fatty acid 
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oxidation in mitochondria, peroxisomes and endoplasmic reticulum, as well as inducing 
lipoprotein lipase, and gluconeogenesis [158]. These effects will together result in more 
availability of fatty acids for β-oxidation and consequently alleviation of hepatic fatty liver. It is 
shown that the expression of PPARα is decreased in experimental models of steatosis [95].   
2.11.2. The controversial role of hepatic PPARγ in NAFLD  
Although PPARγ is a regulator of adipogenesis in adipocytes, its expression in hepatocytes is very 
low except in pathological conditions, in which its expression increases and regulates metabolic 
homeostasis [157]. The role of hepatic PPARγ in fatty liver disease is controversial. Many studies 
show that hepatic PPARγ expression increases in diabetic or obesity models of NAFLD which 
results in increased hepatic lipogenesis [44, 95, 159]. In contrast, adenovirus-mediated over-
expression of PPARγ in rodents with NASH decreased hepatic steatosis, inflammation, and 
necrosis [160]. In line with this study, heterozygous mice deficient for PPARγ (PPARγ+/-) showed 
lower hepatic mRNA and protein for PPARγ concomitant with more severe hepatic steatosis with 
a methionine- and choline-deficient diet. The effects were alleviated after adenovirus-mediated 
over-expression of PPARγ [161]. Interestingly, by reducing the proliferation of hepatic stellate 
cells, PPARγ over-expression in the liver by adenovirus-expressing PPARγ was shown to prevent 
hepatic fibrosis in mice [162]. One of the mechanisms of protective effect of PPARγ against 
NAFLD is due to increased insulin sensitivity in the adipose tissue and skeletal muscles [163, 164] 
and consequent reduction of adipocyte lipolysis. While it appears that enhanced level of PPARγ 
in the liver may promote lipogenesis, its expression in the adipose tissue contributes to adipocyte 
differentiation, promotes fat storage in adipocytes, and increases insulin sensitivity [165], all 
favoring reduced adipocyte lipolysis and amelioration of NAFLD. In conclusion, evidence about 
PPARγ effects on the hepatic steatosis is controversial and needs to be further investigated. 
2.12. Uncoupling proteins (UCPs) 
As discussed earlier, uncoupling proteins are mitochondrial inner-membrane proteins that 
uncouple mitochondrial respiration from oxidative phosphorylation and therefore reduce ATP 
synthesis [166]. There are several isoforms of UCPs such as UCP1 (brown adipose tissue), UCP2 
(ubiquitous), UCP3 (brown adipose tissue and skeletal muscle), UCP4 and UCP5 (brain) [167]. 
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Although UCP2 is ubiquitous, its expression is very low in hepatocytes and mostly localized in 
the Kupffer cells [166].  
2.12.1. UCP2 impact on hepatic reactive oxygen species and ATP stores 
UCP2 is localized in the inner mitochondrial membrane and was shown to increase the flow of 
electrons through the mitochondrial respiratory chain inhibiting premature transfer of electrons to 
oxygen through complexes I and III. This higher flow of electrons leads to less production of ROS 
in mitochondria [168]. Moreover, by uncoupling the electron transport chain from ATP 
production, UCP2 decreases the electrochemical potential (ΔΨ) [90, 169]. Studies report that even 
small changes in ΔΨ can have an order of magnitude effect on mitochondrial ROS generation 
[168]. This decrease in ΔΨ by increased UCP2 expression is responsible for a decline in ROS 
generation.  
As discussed earlier one of the limitations of increased UCP2 expression is dissipating energy and 
therefore decreasing ATP stores. ATP stores are very important in NAFLD as evidence shows that 
impaired ATP homeostasis is observed in NAFLD and NASH [18, 170]. It is reported that a decline 
in ATP stores makes the liver vulnerable to inflammation, fibrosis and necrosis and helps 
progression of simple steatosis to steatohepatitis (NASH) [150]. Interestingly, it is suggested that 
this decline in energy is not always the case in hepatic steatosis but it can manifest when the liver 
is in an acute need for energy at the advanced stages of NAFLD [139].  
2.12.2. UCP2 and amelioration of fatty liver disease 
An accumulating body of evidence reports increased expression of UCP2 in fatty liver disease [48, 
171]. This up-regulation of hepatic UCP2 may induce fatty acid β-oxidation and alleviate fatty 
liver disease and diabetes [166, 168]. The mechanisms which were suggested include: 1) Proton 
leak through UCP2 may be a contributing factor in the induction of β-oxidation of fatty acids in 
mitochondria. This induction in β-oxidation is mediated through higher re-oxidation of 
NADH/NAD+, leading to increased ratio of NAD+/NADH which is needed for ongoing β-
oxidation [10]. 2) It seems that UCP2 prevents intra-mitochondrial accumulation of free fatty acid 
and therefore facilitates the export of FFA from the mitochondrial matrix to the cytosol, leading 
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to decreased mitochondrial lipotoxicity and subsequently prevents mitochondrial dysfunction 
[171]. 
Moreover, by preventing apoptosis [172, 173] possibly through reducing ROS [174], UCP2 is 
suggested to be beneficial against NASH [166]. However, this decrease in apoptosis may increase 
the chance of hepatocellular carcinoma. Therefore, UCP2 is considered as a double-edge sword 
since it can exert both beneficial and deleterious effects and its role in fatty liver disease should be 
further evaluated. In total, UCPs are considered as a beneficial mechanism for cells to adapt with 
high amount of intracellular fatty acid accumulation [166].   
2.13. Effect of sirtuins and AMP-activated protein kinase (AMPK) in NAFLD 
Silent information regulator 2 proteins (sirtuins) are a group of NAD+-dependent deacetylases. 
There are different isoforms of sirtuins: SIRT1-SIRT7. SIRT1 (localized in cytoplasm and 
nucleus), SIRT3 (mitochondria, nucleus), and SIRT6 (nucleus) have important roles in 
metabolism. Mitochondria are one of the main targets of sirtuins action (particularly SIRT1, 
SIRT3, SIRT4, and SIRT5) leading to the regulation of metabolism [175].   
SIRT1 is the most studied sirtuin which has a pivotal role in the metabolic pathways such as lipid 
and glucose metabolism [176, 177]. SIRT1 induces mitochondrial biogenesis through activating 
AMPK and PGC1α and therefore increases fatty acid β-oxidation that might be of great importance 
for alleviating NAFLD [178]. It is shown that prolonged fasting results in SIRT1-mediated 
deacetylation and consequent activation of PGC1α and PPARα leading to increased β-oxidation 
of fatty acids and the regulation of glucose metabolism [179, 180].  
SIRT1 and AMPK can activate each other. Excess calorie intake was shown to increase the 
NADH/NAD+ ratio which decreases deacetylase activity of SIRT1. Reduced activity of SIRT1 in 
turn reduces phosphorylation of AMPK by its upstream serine/threonine liver kinase (LKB1) 
leading to higher lipogenesis and decreasing fatty acid β-oxidation. Vice versa, during starvation 
or exercise, increased NAD+/NADH ratio activates SIRT1 which in turn deacetylates LKB1 
leading to increased phosphorylation of threonine 172 (Thr172) on AMPK catalytic α subunit and 
its subsequent activation (reviewed in [181]). AMPK which is an important regulator of energy 
homeostasis and is sensitive to increased levels of intracellular cAMP, increases during starvation 
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causing inhibition of all the ATP-consuming pathways such as lipogenesis, and induces the ATP-
producing pathways such as β-oxidation. (reviewed in[181]). The major effect of SIRT1 on hepatic 
lipid metabolism was demonstrated by SIRT1 knock-out mice. In one study, knocking-out hepatic 
SIRT1 resulted in reduced β-oxidation of fatty acids due to the impaired PPARα signaling. 
Therefore, these mice were more susceptible to a high-fat diet-induced hepatic steatosis [182]. In 
addition to the effects on mitochondrial biogenesis, fatty acid oxidation, and cholesterol 
metabolism, SIRT1 inhibits the transcription of all genes involved in lipogenesis by direct 
deacetylation of SREBP [183, 184].  
SIRT3 is mostly localized in mitochondria but also has a very important role in energy metabolism 
including fatty acid β-oxidation, ketogenesis, tricarboxylic acid cycle (TCA), and the 
mitochondrial respiratory chain [185]. For instance, several studies have shown a pivotal role of 
SIRT3 in hepatic fatty acid β-oxidation of experimental animals fed a high-fat diet. SIRT3-/- mice 
develop hepatic lipid dysregulation due to disrupted β-oxidation of fatty acids [186]. Moreover, 
SIRT3 regulates mitochondrial electron flow and oxidative stress [185]. Evidence shows that over-
expression of SIRT3 induces PGC-1α-mediated mitochondrial gene expression and subsequent 
mitochondrial electron transport chain activity while ROS generation was suppressed [187]. 
SIRT3 has a major role in mitochondrial energy metabolism following the observation that SIRT3 
knock-out mice develop 50% less ATP content in the liver, kidney, and heart [188]. One of the 
mechanisms by which SIRT3 increases ATP generation is through the activation of AMPK [185].  
2.14. Endoplasmic reticulum (ER) stress 
Ozcan et al. for the first time suggested that ER stress may be a missing link in hepatic steatosis 
and insulin resistance due to the activation of ER stress arms in obese rats fed a high-fat diet [25]. 
Since then, several studies reported increased ER stress in animals [27, 28] and humans [29, 30] 
with hepatic steatosis.  
The smooth endoplasmic reticulum is involved in the metabolism of proteins, lipids, and 
carbohydrates, and in protein folding and maturation [23]. Lipogenesis is shown to be affected by 
ER stress and the two processes appear to have a direct and positive correlation. Moreover, it seems 
that oxidative stress results in the disruption of ER homeostasis and therefore brings about the 
activation of a cellular response called the unfolded protein response (UPR). The aim of this 
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response is to decrease the load of proteins to endoplasmic reticulum and to restore endoplasmic 
reticulum homeostasis [24].  
2.14.1. Different arms of ER stress and their role in NAFLD and insulin resistance 
Unfolded protein response (UPR) has three signaling pathways (3 arms) initiated by the activation 
of endoplasmic reticulum transmembrane proteins: 1) protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), 2) inositol requiring enzyme 1 (IRE1) and 3) activating transcription 
factor 6 (ATF6) [189]. Bound to the chaperone glucose-regulated protein 78 kDa (GRP78), all of 
these three arms remain inactive. It was shown that over-expression of GRP78 improves hepatic 
steatosis due to suppressing SREBP-1c activity [27]. Phosphorylation of eukaryotic translation 
initiation factor 2α (eIF2α), a downstream target of PERK causes increased expression of CCAAT 
enhancer-binding-proteins (C/EBPs), PPARγ, and SREBP-1c leading to hepatic steatosis by a 
high-fat diet [190]. Therefore, the PERK-eIF2α pathway induces lipogenesis in the liver and other 
tissues.  
Regarding the 2nd arm, phosphorylation of IRE1 results in splicing and activation of its 
downstream effector, X-box binding protein 1 (XBP1), which controls lipogenesis. Therefore, 
XBP1s is also steatotic and causes the activation of lipogenic enzymes [24]. Regarding the 3rd arm, 
once being dissociated from GRP78, ATF6 translocates to the Golgi apparatus to be activated. 
ATF6 causes protection against steatosis and leads to increased β-oxidation (Reviewed in [190]).  
Evidence also shows that insulin resistance (one of the main factors implicated in the 
pathophysiology of NAFLD) is closely associated with ER stress [191]. Insulin resistance can be 
directly affected by the activation of ER stress in adipocytes. Indeed, elevated ER stress evidenced 
by IRE1 activation was shown to activate JNK which induces insulin resistance [191]. It is revealed 
that treatment of obese and diabetic ob/ob mice which develop ER stress with active chemical 
chaperones such as 4-phenyl butyric acid (4-PBA) and taurine-conjugated ursodeoxycholic acid 
(TUDCA) alleviates ER stress and consequently resolves hyperglycemia, insulin resistance, and 
fatty liver disease [192]. Chemical chaperones also decrease ER stress and inflammation in adipose 
tissue, and reduce hepatic lipid content of mice fed a high-fat diet for 14 weeks [193]. Figure 2.4 
depicts the interrelationship between different arms of UPR and how they affect hepatic lipid 
metabolism to finally induce hepatic steatosis. 
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Figure 2. 4. Crosstalk between ER stress arms and lipogenesis 
This Figure is adapted from Basseri & Austin [190]. Higher intake of saturated fatty acids and 
enhanced ROS generation increases the load of misfolded proteins to ER. Accordingly, the 
chaperone GRP78 dissociates from different arms of ER (PERK, IRE1, ATF6) in order to help 
proper folding of the misfolded proteins. While attached to GRP78, these arms are inactive and 
following dissociation become activated. Following dissociation from GRP78, PERK induces 
phosphorylation of eIF2α which can further increase lipogenesis and gluconeogenesis through 
increased expression of ATF4 and SREBP. Although IRE1 inhibits the expression of lipogenic 
enzymes, its downstream effector (XBP1s) activates JNK leading to impaired insulin signaling, 
inflammation, and apoptosis. XBP1s can also increase the expression of lipogenic enzymes further 
exacerbating hepatic steatosis. Moreover, following cleavage and activation by the Golgi 
apparatus, ATF6 inhibits lipogenesis and gluconeogenesis, and induces fatty acid oxidation 
through activating PGC1α and higher expression of PPARα. 
2.15. Models for studying NAFLD and the molecular mechanisms underlying the disease 
2.15.1. Experimental models of NAFLD/NASH 
An ideal animal model should represent the pathophysiology of both human NAFLD and NASH. 
Accordingly, along with hepatic steatosis, inflammation, hepatocellular ballooning and fibrosis, 
an ideal animal model should reflect metabolic abnormalities such as obesity, insulin resistance, 
dyslipidemia, and aberrant adipokines profile [194]. Generally, available models are categorized 
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into genetic models including ob/ob and db/db as well as KK-Ay mice, and dietary models 
including methionine- and choline-deficient diet (MCD), and high-fat diet [194]. 
2.15.1.1. Genetic models of NAFLD 
2.15.1.1.1. Ob/ob and db/db mice 
Ob/ob mice have a mutation in the leptin gene (leptin deficient) while db/db mice have a mutation 
in the leptin receptor (leptin resistant) and these mice show obesity, insulin resistance, and NAFLD 
[195]. Leptin is an adipokine produced by the white adipose tissue that has anorexic effects on the 
hypothalamus which is the center for satiety and hunger [196]. Ob/ob mice are hyperphagic, 
inactive, and extremely obese while showing metabolic abnormalities such as insulin resistance, 
dyslipidemia, and hyperglycemia [195]. Although hepatic steatosis is a main feature in these mice, 
it can not spontaneously progress to NASH and some triggers are essential including a high-fat or 
MCD diet to develop NASH [197]. Ob/ob mice are protected against hepatic fibrosis which led to 
elucidating a major role for leptin in hepatic fibrogenesis.  
Db/db mice have normal level of leptin but they are resistant to it. These mice are obese and insulin 
resistant and develop hepatic steatosis. Along with the administration of a second insult such as 
MCD diet, these mice develop hepatic fibrosis [198]. One of the main advantages of ob/ob and 
db/db mice is that they show metabolic abnormalities similar to human metabolic syndrome while 
the disadvantage of using them is that they do not spontaneously develop hepatic fibrosis [194]. 
2.15.1.2. Dietary models of NASH 
2.15.1.2.1. Methionine- and choline-deficient diet 
This diet lacks methionine and choline which are essential for fatty acid β-oxidation and VLDL 
synthesis [196]. Therefore, excess fat accumulates in the liver and along with oxidative stress and 
increased adipocytokines result in fibrosis [199]. The main advantage of this model is that it can 
lead to accumulation of large amount of fat in the liver, and they may develop fibrogenesis 
compared to other models. However, the disadvantage of them is that rodents on this model show 
reduced body weight (20%) and food intake, and they do not show metabolic abnormalities similar 
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to human metabolic syndrome and they have low leptin and insulin levels with low fasting blood 
glucose [194]. In order to cope with these disadvantages, genetically obese animals are chosen to 
put on a MCD diet. 
2.15.1.2.2. High-fat diet 
A high-fat diet is used by a wide range of experimental studies to simulate the obesity and fatty 
liver disease induced by a Western diet in humans [194]. According to fat content and composition, 
rodent strains, and duration, a high-fat diet result is variable results regarding hepatic steatosis, 
oxidative stress, inflammation, and fibrogenesis [194]. For example, Sprague-Dawley rats are 
specifically more susceptible to a high-fat diet-induced obesity and steatohepatitis compared to 
Wistar rats [199, 200].  
2.15.2. In vitro models 
Previously, experimental studies (genetic models and high-fat diet) have been designed to study 
NAFLD development and its progression to NASH [31, 32]. More recently, in vitro models of 
NAFLD have been developed to study the effects of steatosis in hepatic cell lines of human origin 
[33, 34] and to explore the molecular mechanisms underlying NAFLD. These models include 
using monounsaturated (oleic), and saturated (palmitic) fatty acids to induce steatosis in a 
hepatocyte cell line (HepG2) and in primary hepatocytes [33-38]. Oleic and palmitic acids are the 
most abundant fatty acids in the hepatic triglycerides of healthy subjects and patients with fatty 
liver disease [201]. Palmitic acid is the most prevalent saturated fatty acid found in triglycerides 
of meats and dairy products, as well as in palm oils that are widely used by the food industry. Upon 
consumption of saturated fats, the liver is exposed to high levels of palmitic acid that can contribute 
to NAFLD. The liver can also convert palmitic acid to monounsaturated fatty acids, mainly oleic 
acid (C18:1) by the activity of stearoyl-CoA desaturase (SCD-1) [79]. SCD-1 has been shown to 
play a key role in the onset of diet-induced hepatic insulin resistance [80]. Higher activity of SCD-
1 has been shown in NAFLD subjects, concomitant with elevated levels of hepatic oleic acid [81], 
and in fatty livers of ob/ob mice [82]. SCD-1 knock-out mice are resistant to hepatic steatosis and 
adiposity [83, 84]. Moreover, lowering hepatic scd-1 gene expression using sequence-specific 
antisense oligodeoxynucleotide in rats and mice on a high-fat diet was shown to induce insulin 
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sensitivity, improve insulin signaling, and decrease gluconeogenesis [80]. Therefore, it seems that 
accumulation of both palmitic and oleic acid in the liver can induce NAFLD and accordingly these 
free fatty acids are widely used in vitro studies to investigate the molecular mechanisms underlying 
NAFLD.  
2.16. Polyphenols as important components in diet 
Polyphenols are considered as the plants’ secondary metabolites which have important roles in 
protection against ultraviolet light and pathogens [202]. After reports of beneficial effects on 
human health by different studies in the 1990s, polyphenols have attracted great attention in 
research. Polyphenols are found in our daily diet in fruits and vegetables, pulses, green and black 
tea, coffee, extra virgin olive oil, and chocolate [43]. Although widespread in our diet, they have 
been the subject of many studies only in the last few decades [203]. 
Polyphenols may be effective in prevention of cancer, and cardiovascular diseases [43, 204]. 
Polyphenols are potent antioxidants in vitro and their dietary intake is related to lower rate of 
morbidity and mortality due to coronary heart diseases [205]. More than 8000 polyphenols are 
found in plants [206]. 
2.16.1. Classification of polyphenols 
Flavonoids, phenolic acids, lignans, and stilbenes are the major groups of polyphenols [203]. The 
structure of some of the polyphenols of interest in this thesis is shown in Figure 2.5. 
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Figure 2. 5. The structure of some of the main polyphenols and a methoxy alkaloid derivative 
(berberine) 
2.16.1.1. Flavonoids 
The structure of flavonoids consists of two benzene rings attached together by a pyrone ring. 
Flavonoids are usually found as glycosidic forms rather than aglycones. The six major subclasses 
of flavonoids include: flavan-3-ols (e.g., epicatechin, gallocatechin), flavonols (e.g., quercetin, 
myricetin), flavones (e.g., apigenin, luteolin), flavanones (e.g., naringenin, hesperidin), 
isoflavones (e.g., genistein, daidzein), and anthocyanins (e.g., cyanidin, pelargonidin) based on 
differences in the pyrone ring structure. The most abundant flavonoids include quercetin, 
kaempferol, isorhamnetin, and myricetin that are usually found in edible plants as glycosides. 
Although there are only a few aglycones, almost 200 sugar conjugates were identified for 
kaempferol [207].    
One of the richest sources of flavonols is onion which contains high amounts of quercetin [207]. 
Flavanones are generally found in citrus fruits and grapefruit.  
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Anthocyanins are natural pigments in plants which have red, blue, or a purplish color [203]. 
Anthocyanins are found in different berries, pomegranates, purple grapes, apple skins, cherries 
[208], red wine, and some types of vegetables including purple onions, radishes, and cabbages 
[203]. Some of the most important anthocyanins are cyanidin, malvidin, delphinidin, petunidin, 
pelargonidin, and peonidin [209]. Anthocyanins were shown to have antioxidant [210] and anti-
inflammatory effects and can prevent obesity, diabetes, and insulin resistance [46]. 
2.16.1.2. Phenolic acids 
There are two classes of phenolic acids: a) derivatives of benzoic acid, and b) derivatives of 
cinnamic acid. Some foods such as onions, black radish, and some red fruits have a high content 
of hydroxybenzoic acid derivatives [202]. Tea leaves are very good source of gallic acid (3,4,5-
trihydroxybenzoic acid), containing 4.5 g gallic acid/kg dry weight [202]. 
Hydroxycinnamic acids are more ubiquitous in foods compared to hydroxybenzoic acids. 
Hydroxycinnamic acids consist of caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid. The 
highest content of hydroxycinnamic acids can be found in cherries, blueberries, apples, plums, and 
kiwis [211]. The most common form of hydroxycinnamic acid is caffeic acid which consists 75-
100% of hydroxycinnamic acid in most fruits. Moreover, the most abundant phenolic acid in 
cereals is ferulic acid which consists 90 % of the total polyphenols in wheat [202]. 
2.16.1.3. Stilbenes 
Stilbenes are produced in plants in response to stress, disease and injury [212] and they are 
available in our diet from some sources. Resveratrol is the main stilbene in our diet which is 
available in red grapes and red wine [207]. Red wine contains several stilbene derivatives although 
their concentration is low compared to other polyphenolic components [213].    
2.16.2. Bioavailability, metabolism, and absorption of flavonoids 
Different factors including food processing, sex, age, and the composition of intestinal microflora 
are associated with the bioavailability of polyphenols [214]. The bioavailability of flavonoids is 
quite low [209]. It is estimated that approximately 5-10% of the total ingested polyphenols is 
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absorbed in the small intestine and the remaining (90-95%) will accumulate in the colon where 
they can produce breakdown/digestion products by colonic microbiota [215].   
Except flavanols, all flavonoids are found in foods as glycosylated form. Most glycosides escape 
acid hydrolysis in the stomach and therefore can enter the small intestine in the intact form [203]. 
Studies in rodents show that some polyphenols can be absorbed in the stomach, such as quercetin 
(not in the glycosylated form) and anthocyanins [203, 216]. 
As mentioned earlier, most polyphenols are often found in foods as glycosylated, ester, or polymer 
forms. Polyphenols generally cannot be absorbed in these forms (except some  glucosides)  and 
need to be hydrolyzed by intestinal enzymes or the microflora to form aglycones [43]. 
Exceptionally, anthocyanins can be absorbed and found in the blood as glycoside forms [217].  
Flavonoid glycosides can be cleaved to aglycones by lactase phloridzin hydrolase (LPH) in the 
brush border of small intestine cells. LPH has broad specificity for flavonoid glycosides and due 
to their lipophilic properties, resultant aglycones can be absorbed by passive diffusion [207]. One 
of the alternatives of this pathway is metabolizing flavonoid glycosides by the cytosolic-β-
glucosidase (CBG) within the intestinal epithelial cells. In order to be metabolized by this pathway, 
glycosides must be transported to the epithelial cells by active sodium-dependant glucose 
transporter 1 (SGLT1) [218]. After metabolism by LPH and cytosolic β-glucosidase and before 
transporting to the blood stream, flavonoid aglycones may be conjugated by phase II enzymes to 
sulfate, glucuronide, and methylated metabolites by the action of sulfotransferases (SULT), 
uridine-5′-diphosphate glucuronosyltransferases (UGT), and catechol-O-methyltransferases 
(COMTs) [207].  
Flavonoids are rarely found in the plasma as the parent aglycones, and tend to be conjugated as 
glucuronides, and methyl or sulphate esters in the small intestine, colon and later in the liver. After 
conjugation in the small intestine and liver to glucuronides and sulphate products, flavonoids are 
deconjugated by the vascular and tissue β-glucuronidases [219]. The “flavonoid paradox” suggests 
that conjugation of flavonoids may be a reversible process and these conjugated flavonoids (e.g. 
quercetin) can be deconjugated to active aglycones at the tissue cells. Interestingly, since vessel 
walls can deconjugate flavonoid glucuronides prior to their uptake by cells, aglycones are expected 
to be found inside the tissue cells even without the non-vascular β-glucuronidases activity [219].  
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Substantial quantities of polyphenol glycosides which are resistant to hydrolysis by LPH/CBG will 
enter the colon in which they are metabolized by colonic microflora. The resultant aglycones can 
undergo ring fission by colonic microbiota producing small molecules including phenolic acids 
and hydroxycinnamic acids [207]. These breakdown/digestion products (phenolic acids) can be 
absorbed and metabolized in the liver and may contribute to the protective effects of the parent 
polyphenols against NAFLD (discussed in CHAPTER 6). 
2.16.3. Circulation and concentration of polyphenols in the plasma  
Polyphenol metabolites circulate in the plasma bound to proteins, mainly albumin. Albumin is the 
primary protein for the plasma transportation of polyphenols and depending on chemical 
structures, different polyphenols have different affinity to albumin [220]. Polyphenol-albumin 
complexes may have consequences on cellular and tissue uptake of polyphenols. It may be possible 
that the unbound concentration of polyphenols determines their cellular uptake [203]. In order to 
keep high plasma concentration of flavonoids, one must regularly ingest sources of flavonoids 
[221]. For most polyphenols, the highest plasma concentration is reached 1-2 h after their ingestion 
[222]. However, determining the concentration and bioavailability of polyphenols in tissues may 
be more important than their plasma concentration [203]. Flavonoids may accumulate in tissues 
(especially lipid soluble forms), so the clearance can be substantially delayed. Unfortunately, 
evidence regarding tissue uptake and accumulation of polyphenols is very scarce, not only in 
humans but even in animals [203]. For instance, it was evidenced that after treatment with 
quercetin, it is metabolized in the intestine and liver and can gradually accumulate in the liver. 
Therefore, it is suggested that the liver can be a major tissue for the accumulation and metabolism 
of quercetin after ingesting a quercetin-rich diet [48].  
2.16.4. Polyphenols as potent antioxidants 
Polyphenols may be acting through their antioxidant properties or may synergistically enhance the 
effect of other antioxidants. Several mechanisms have been proposed as their antioxidant activity 
including: a) inhibiting generation of ROS b) scavenging ROS and c) protecting or enhancing 
antioxidant enzymes [223]. Flavonoids have been shown to fulfill most of the criteria mentioned 
above. In addition to radical scavenging, flavonoids are also known as metal chelators. Chelation 
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of metals such as Fe2+ can directly decrease the rate of the Fenton reaction, thus resulting in the 
prevention of highly reactive hydroxyl radicals [224]. In addition, flavonoids do not act alone. 
Therefore, as was indicated in the study by Bandy & Bechara, flavonoids can really function as a 
co-antioxidant, and are involved in the regeneration of essential vitamins [225]. 
2.17. Beneficial effects of polyphenols 
2.17.1. Beneficial effects of polyphenols on oxidative stress and antioxidant enzymes 
An accumulating body of evidence shows that polyphenols possess strong antioxidant activities 
and may have a therapeutic effect in NAFLD and NASH. In one study, oral supplementation of 
resveratrol at 15 and 45 mg/kgbw/d for 6 weeks decreased hepatic thiobarbituric acid reactive 
substances (TBARS) formation in obese Zucker rats showing its antioxidant activities. In this 
study, resveratrol also attenuated hepatic steatosis and increased the reduced to oxidized 
glutathione ratio (GSH/GSSG) which is a reliable indicator of oxidative stress [226]. Beside 
resveratrol, other polyphenols also have been shown to exert antioxidant effects. For instance, it is 
shown that due to their gallate ester moiety, catechins such as epicatechin gallate (ECG) and 
epigallocatechin gallate (EGCG) have very strong antioxidant properties and can effectively 
prevent lipid peroxidation [227] which may be beneficial in protecting against NASH. Other 
studies also point to the beneficial effects of green tea polyphenols in steatohepatitis and fibrosis 
in regard to ameliorating oxidative stress. Nakamoto et al. [228] investigated the effects of 
fermented green tea (Camellia sinensis) extract (100 and 300 mg/kg/d) for 6 weeks in rats fed a 
choline-deficient high-fat diet. For inducing NASH, oxidative stress was induced by 
intraperitoneal injection of nitrite. Fermented green tea extract (300 mg/kgbw/d) attenuated serum 
levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (which are two 
reliable markers of liver damage and necrosis), hepatic lipid accumulation, lipid peroxidation 
products (MDA and 4-HNE) and mitochondrial ROS production, and increased plasma SOD 
activity. Fermented green tea extract also inhibited cirrhosis development showing it can be 
effective against progression of NASH. The authors concluded green tea extract prevents NASH, 
and liver cirrhosis via attenuation of oxidative stress.  
In vitro studies also show protective effects of polyphenols against oxidative stress. For instance, 
quercetin treatment at 10 µM was effective to reduce lipid accumulation, TNF-α, IL-8, lipid 
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peroxides, and increase activity of antioxidant defense such as catalase, SOD, and GPx, and 
increased intracellular GSH concentration in oleic acid-induced fatty liver condition in HepG2 
cells [35]. Quercetin contains several phenolic hydroxyl groups which are the reason behind its 
potent antioxidant activity. Similar to catechin that we discussed previously, quercetin possess 
anti-inflammatory and anti-fibrosis effect in mice with non-alcoholic steatohepatitis [229] showing 
these effects may be attributed to its potent antioxidant effect. 
Experimental studies in rodents also support in vitro studies in regard to antioxidant effect of 
quercetin. Quercetin dietary treatment (0.05%) to mice fed a high-fat diet for 4, 8, and 20 weeks 
decreased hepatic lipid peroxidation (TBARS), increased hepatic total glutathione level, and 
hepatic mRNA expression of glutathione peroxidase 1 and catalase, and decreased hepatic gene 
expression of UCP2. These concerted effects of quercetin reversed high-fat diet-induced oxidative 
stress [48]. The antioxidant effects of polyphenols are sometimes conflicting however, as Marcolin 
et al. showed that 4-week dietary quercetin treatment to rats fed a methionine- and choline-
deficient diet (MCD) reversed increasing TBARS, but had no effect on SOD and catalase activity 
[230]. Similar to quercetin, kaempferol which is found in different fruits and vegetables including 
tea and broccoli, and taxifolin (at 5, 25, and 50 µM) was shown to inhibit inflammatory cytokine 
mixture-induced production of nitric oxide, superoxide anions and lipid peroxidation in cultured 
Chang liver cells resulting in improved cellular oxidative stress [231].  
Another factor which has an important role in progression of NAFLD to NASH is over-expression 
of hepatic cytochrome P450 (CYP2E1). As discussed earlier, this is a less efficient pathway to 
metabolize excess fatty acids in endoplasmic reticulum while producing high amount of ROS. 
Epigallocatechin has been demonstrated to inhibit oxidative stress (as was evidenced with lower 
plasma and liver MDA, and higher GSH level) by inhibiting high-fat diet-induced hepatic CYP2E1 
over-expression in NASH and therefore inhibiting oxidative stress [232]. There is over-expression 
of CYP2E1 in NASH which results in damage to cells due to higher ROS production [233]. It is 
shown that ketone bodies and fatty acids are substrates for CYP2E1 and increase its expression 
[32]. Therefore, it appears that polyphenols can inhibit CYP2E1 expression. 
Similar to lipogenesis and fatty acid oxidation, polyphenols can also affect the expression of 
transcription factors involved in oxidative stress. For instance, oral administration of resveratrol at 
10 mg/kg/day for 8 weeks was shown to increase Nuclear factor E2-related factor 2 (Nrf2) in 
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hepatic nuclear protein extract which resulted in increasing antioxidant enzymes activity such as 
SOD, catalase, GSH and consequently protected against fructose-induced oxidative stress in rats 
[47]. Nrf2 is an important transcription factor for protecting against oxidative stress. Through 
increasing the gene expression of downstream antioxidant enzymes, the transcription factor Nrf2 
results in maintaining cellular redox status [234]. Sequestered in the cytoplasm, Nrf2 is inactive 
and during oxidative stress it translocates to the nucleus and binds to antioxidant response elements 
(AREs) in regulatory regions of targets genes and upregulates the expression of antioxidant 
enzymes [235]. The pivotal role of Nrf2 in NAFLD has been revealed by genetic studies showing 
Nrf2 knockout mice (Nrf2-/-) develop more severe oxidative stress, steatosis (evidenced by 
reduction of fatty acid oxidation and induction of lipogenesis), and inflammation on a high-fat diet 
compared to wild type mice [236, 237]. This shows a key role of oxidative stress (second hit) in 
inducing fatty liver disease and inflammation while polyphenols can protect against it.  
Coffee polyphenols extract (4.2 mg of polyphenols/d corresponding to 6 cups of espresso coffee 
or approximately 2 cups of filtered coffee for a 70kg person) for 8 weeks also reduced hepatic fat, 
systemic and liver oxidative stress, and inflammation in Wistar rats fed a high-fat diet for 12 weeks 
[238]. Coffee polyphenols extract attenuated oxidative stress by increasing GSH/GSSG ratio and 
ferric reducing antioxidant power (FRAP) in serum, and decreasing serum MDA. Cyanidin-3-O-
β-glucoside (C3G) has also been shown to protect against hepatic steatosis, neutrophil infiltration 
and hepatocyte apoptosis in db/db mice and high glucose-treated HepG2 cells in which the effects 
were attributed to the prevention of oxidative stress, ROS production, and induction of glutamate-
cysteine ligase expression and subsequently glutathione synthesis [239].  
In addition to antioxidant properties some polyphenols chelate metal ions (Fe3+, Cu2+) bringing 
about prevention of oxidative stress. Studies show that strong iron-binding properties of quercetin 
and other polyphenols such as rutin are due to their iron-binding motifs in their chemical structure 
[240].  
2.17.2. Beneficial effects of polyphenols on intracellular triglyceride and enzymes involved 
in β-oxidation and lipogenesis 
As discussed earlier, adipocyte lipolysis, hepatic de novo lipogenesis, and fatty acid β-oxidation 
are three important pathways which have pivotal roles in hepatic lipid accumulation. Therefore, 
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modulating these pathways can prevent NAFLD. Since hepatic lipid accumulation is recognized 
as the “first hit” of NAFLD, quite a lot of studies evaluated the preventive effects of polyphenols 
on hepatic lipid accumulation and the enzymes involved in lipogenesis and β-oxidation.  
Some polyphenols were shown to be effective in decreasing hepatic accumulation of fatty acids. 
For instance, in an in vitro model of steatosis it was shown that 40 µM resveratrol decreased 
palmitate-induced accumulation of intracellular lipids to basal levels mainly by inhibiting the 
expression and activity of the transcription factor SREBP-1c [241]. One of the main limitations of 
this study was using 40 µM resveratrol which is higher than the relevant physiological dose (≤10 
µM).  
Alberdi et al. [45] reported the same effect of resveratrol on decreasing hepatic steatosis in vivo. 
The authors showed that six-week administration of 30 mg/kg bw resveratrol to Sprague Dawley 
rats taking an obesogenic diet for 6 week increases the phosphorylated ACC (inactivated) and 
AMPK (activated) compared to total ACC and AMPK protein. Moreover, the authors found 
resveratrol treatment increased activities of liver proteins involved in fatty acid oxidation 
(mitochondrial CPT1A and peroxisomal acyl-CoA oxidase) while having no effect on lipogenic 
FAS.  
Preventive effects on hepatic lipid accumulation have also been shown using anthocyanins. For 
instance, purple sweet potato anthocyanins (anthocyanin fraction 200 mg/kg/d) was shown to 
phosphorylate hepatic AMPK and ACC and consequently decrease hepatic lipid accumulation in 
mice taking a high-fat diet for 4 weeks [46]. AMPK activation was shown to indirectly inhibit FAS 
and ACC expression through inhibition of the transcription factor SREBPs [242]. In one study in 
HepG2 cells and obese mice it was shown that using anti-AMPK treatment inhibits the effect of 
anthocyanin rich purple sweet potato on lipid accumulation and expression of FAS and SREBP-1 
protein [46].  
In addition to modulating lipogenesis, polyphenols are also able to induce enzymes involved in 
fatty acid β-oxidation. Açaí berry aqueous extract treatment (3g/kgbw/d for 6 weeks) of mice fed 
a high-fat diet increased hepatic mRNA for adiponectin receptor protein 2 (AdipoR2), CPT-1A1 
(the specific isoform found in the liver), and PPARα, showing increased β-oxidation via 
adiponectin-mediated up-regulation of PPARα [243]. Moreover, resveratrol delivered orally at 30 
44 
 
mg/kgbw for 6 weeks enhanced hepatic activity of acyl-CoA oxidase and CPT1A in rats fed a 
high-fat diet [45]. 
Polyphenol treatment does not always result in increased CPT-1 expression. For instance, 
treatment of Wistar rats fed a high-fat diet with grape polyphenol extract (2g/kg diet) for 6-week 
was shown to decrease muscle CPT-1 protein expression. This was explained by the authors to be 
due to the decreased protein expression of muscle fatty acid translocase (FAT/CD36). FAT/CD36 
is an integral protein found on the surface of different cells responsible for the uptake of fatty acids. 
Therefore, decreased expression of FAT/CD36 leads to inhibition of fatty acid translocation to 
cells resulting in decreased lipid accumulation and consequent decline of CPT-1 protein expression 
[51].  
Anthocyanins may also act as PPARα agonists to induce genes involved in β-oxidation. In a model 
of insulin resistance and hyperlipidemia with Dahl rats, feeding tart cherries at 1% of the diet for 
90 days induced mRNA expression and activity of hepatic PPARα [244]. Anthocyanins may have 
a direct agonist effect on PPARα, since cyanidin (but not the degradation products protocatechuic 
acid or phloroglucinaldehyde) was shown to bind to and transactivate purified PPAR proteins, 
especially PPARα, as well as induce PPAR responsive genes in HepG2 cells [245]. 
Quercetin was also found to alter the gene expression of transcription factors involved in β-
oxidation or lipogenesis. In the previously mentioned study by Kobori et al., gene expression of 
lipogenic transcription factors such as PPARγ and SREBP1-c was decreased by dietary quercetin 
in the liver of mice fed a high-fat diet for 20 weeks [48].  
Polyphenols also can be beneficial in decreasing adipogenesis. Apigenin, a flavone which is found 
in foods such as celery and parsley, at 10 and 50 µM inhibited lipolysis by decreasing hormone-
sensitive lipase mRNA and inducing AMPK phosphorylation in 3T3-L1 adipocytes [246]. This 
can be beneficial for hepatic steatosis since the most important source of hepatic fatty acids (59%) 
are fatty acids generated from adipocyte lipolysis. Moreover, apigenin decreased mRNA and 
protein expression of PPARγ and stearoyl-CoA desaturase (SCD) both involved in lipogenesis.   
UCP2 is another enzyme influencing lipid metabolism that can be affected by polyphenols. Oral 
administration of epigallocatechin gallate purified from green tea (supplemented 0.5-1% in the 
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diet) to New Zealand black mice fed a high-fat diet for 4 weeks also increased hepatic UCP2 
mRNA which explains higher metabolism of fatty acids in these mice. Epigallocatechin gallate 
also decreased hepatic mRNA expression of SCD1 and glucokinase in the liver suggesting a role 
in inhibiting lipogenesis in these mice [85]. Resveratrol was also found to increase hepatic UCP2 
mRNA which suggests it can inhibit mitochondrial dysfunction in high-fat diet-induced hepatic 
steatosis [171].  
2.17.3. Beneficial effects of dietary polyphenols on insulin resistance 
Polyphenols can also prevent fatty liver by affecting insulin resistance. By inducing hepatic insulin 
signalling (IRS/PI3K/Akt), resveratrol (2-4 g/kg diet) delivered orally for 12 weeks increased 
insulin sensitivity and decreased serum insulin and hepatic glycogen in obese insulin-resistant KK-
Ay mice fed a high-fat diet [247, 248]. The authors observed increased hepatic SIRT1, 
phosphorylated Akt (p-Akt), p-IRS1, and p-AMPK, all favoring improved insulin sensitivity and 
signaling.  
Dietary supplementation of cyanidin 3-glucoside (0.2% in diet) for 5 weeks was also shown to 
improve hepatic steatosis via regulation of forkhead box protein 1 (FoxO1) in adipose tissue of 
both C57BL/6J mice fed a high-fat diet and leptin-resistant db/db mice [249]. The authors found 
that by increasing pAkt/Akt protein expression after refeeding, cyanidin 3-glucoside 
phosphorylates and inactivates FoxO1 in adipocytes leading to reduced hepatic steatosis and 
insulin resistance in these mice. Moreover, insulin resistance in these mice was mediated by 
increased phosphorylated JNK (p-JNK) which was inhibited by treatment with cyanidin 3-
glucoside.  
2.17.4. Beneficial effects of polyphenols on inflammation  
Polyphenols are effective against inflammation in NAFLD and NASH. It is reported that a high-
fat diet induces a low-grade inflammation characterized with obesity and the induction of the NF-
κB/iNOS pathway. Once activated this pathway induces transcription of TNFα and IL6 which are 
the main pro-inflammatory cytokines to damage tissues in metabolic diseases such as obesity, 
diabetes, and fatty liver disease [136].  
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Several polyphenols have been reported to inhibit inflammation and inflammatory signaling 
pathways in models of NAFLD and NASH. It is observed that dietary quercetin (30-60 mg/kg bw) 
in gerbils fed a high-fat diet for 14 days inhibited the NF-κB/iNOS pathway preventing 
inflammation in hepatocytes, along with up-regulating the expression of SIRT1 [250]. In this study 
quercetin reversed the high-fat diet hepatic steatosis and induction of serum TNFα and IL6, and 
decreased NF-κB p65 protein expression and collagen deposition in hepatocytes preventing 
hepatic fibrosis. Quercetin (0.05% of diet) delivered orally was also shown to decrease hepatic 
thiobarbituric acid reactive substances and plasma TNFα and increased plasma adiponectin level 
in Wistar rats fed a high-fat high-sucrose diet for 20 weeks [48]. Taken collectively, it seems that 
polyphenols can alleviate NAFLD/NASH by modulating genes or transcription factors involved 
in inflammation or inflammatory signalling pathways.  
2.17.5. Beneficial effects of polyphenols on mitochondrial biogenesis and function in NAFLD 
The effect of polyphenols on hepatic mitochondrial biogenesis in fatty liver disease has been 
looked at in only a few studies. Liver and skeletal muscle are the main tissues studied for the effect 
of polyphenols on mitochondrial biogenesis in NAFLD since inducing mitochondrial biogenesis 
and subsequent lipid metabolism in these tissues protect against lipid accumulation. Studies on 
resveratrol have given conflicting results. One study reported that oral administration of resveratrol 
(30 mg/kg bw/d) had no effect on the gene expression of PGC1α, SIRT1, mitochondrial 
transcription factor A (TFAM), and cytochrome oxidase subunit II (complex IV) in the liver of 
rats fed a high-fat diet for 6 weeks [45]. Lagouge et al. [251] however reported that resveratrol 
(56-80 mg/kg bw/d) induces the activity of citrate synthase and mRNA expression of SIRT1, PGC-
1α, estrogen-related receptor α (ERRα), NRF1, and TFAM in the muscle of mice fed a high-fat 
diet for 15 weeks. Consequently, it was suggested that resveratrol could prevent metabolic 
diseases, obesity, and insulin resistance by improving mitochondrial biogenesis and function. 
Compared to the Lagouge study, the Alberdi study treated the animals with a high-fat diet and 
resveratrol for a shorter period (6 vs. 15 wk), twice the amount of resveratrol and evaluated 
different tissues (liver vs. muscle) which may partly explain the difference between the results on 
mitochondrial biogenesis.    
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In one other study relevant to NAFLD, treating rats with a high-fat high-sucrose diet for 6 weeks 
reduced mRNA expression of the muscle genes involved in mitochondrial biogenesis including 
PGC1α and NRF1, but had no effect on TFAM [51]. The authors found that grape polyphenol 
extract induced NRF1 mRNA expression but had no effect on TFAM and PGC1α. Moreover, 
mitochondrial respiratory complex II, II+III, and IV activity was unchanged in the muscle tissue 
after using either a high-fat diet or grape polyphenols alone. 
One study has looked at the effect of berberine. Gomes et al. reported that treatment of Sprague 
Dawley rats with a high-fat diet for 16 weeks decreases mitochondrial function and ATP content 
in the skeletal muscle, while treatment with berberine (100 mg/kg bw/d) improved mitochondrial 
function and increased the succinate dehydrogenase (complex II), cytochrome oxidase (complex 
IV), and ATPase (complex V) activity as well as TFAM and PGC1α mRNA expression [252]. In 
the same study, the authors evaluated the effect of 5 µM berberine on hyperglycemia-induced (25 
mM glucose) mitochondrial dysfunction in C2C12 myotubes. Berberine reversed hyperglycemia-
induced decrease of mitochondrial DNA content and mitochondrial mass. Interestingly, berberine 
had no effect on mitochondrial DNA content and mass in cells knocked-down for SIRT1. In 
addition, while hyperglycemia in myotubes prevented the expression of genes involved in 
mitochondrial biogenesis such as PGC1α, NRF1, NRF2, and TFAM, berberine reversed this 
prevention. Berberine also protected against hyperglycemia-induced decrease of nuclear DNA-
encoded complex subunits (NDUFS8 and COX5b), and mitochondrial DNA-encoded subunits 
(MTND1, MTCO1) mRNA expression. 
Anthocyanins were also shown to induce mitochondrial biogenesis in vivo. Peng [253] observed 
that due to their partially positive charge, anthocyanins can accumulate within mitochondria which 
have negative charge inside their matrix. It was revealed that treatment with purified anthocyanins 
from black currant and bilberry to Wistar rats fed a choline- and methionine-deficient diet 
protected against NASH due to increasing mitochondrial biogenesis evidenced by elevated 
PGC1α, NRF1, NRF2, and TFAM hepatic gene expression in a PGC1α/p-AMPK mediated 
pathway [254]. Purified anthocyanins from black currant and bilberry also increased mitochondrial 
complex I and IV protein expression in the liver, and along with increased mitochondrial 
biogenesis they increased the expression of proteins involved in fatty acid β-oxidation such as 
PPARα, CPT-1, and MCAD.  
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Curcumin also showed promising results in improving mitochondrial function. In one study, 
treatment with 1-3 % w/w curcumin along with a high-fat diet protected against the decrease in 
hepatic mtDNA, ATP content, and complex I activity leading to attenuation of hepatic fat content 
in genetically obese mice [18]. It was shown by the authors that a decrease in hepatic protein 
expression of TNFα, and IL-6, and NF-κB activity is responsible for the protective effect of 
curcumin on mitochondrial function.  
In vitro studies also support the notion that polyphenols can improve mitochondrial function. In 
one study, eriocitrin (eriodictyol 7-rutinoside) which is a major flavonoid in lemon (citrus limon) 
inhibited palmitate-induced (400 µM) lipid accumulation in HepG2 cells by increasing the 
expression of genes involved in mitochondrial biogenesis (NRF1, TFAM), and ATP synthesis 
(ATP5J, COX4I1) [255]. Eriocitrin Also increased mitochondrial size, mtDNA copy number, and 
increased intracellular ATP content showing improved function of OXPHOS complexes. 
2.17.6. Beneficial effects of dietary polyphenols in protection against ER stress 
Currently, only very few studies have assessed the effect of polyphenols on hepatic ER stress [256-
258]. What is interesting is that all studies that have evaluated the effect of polyphenols on ER 
stress have been published recently (after 2010). Available studies suggest that treatment with 
polyphenols may alleviate ER stress. In one study, it was observed that treatment of rats fed a high-
fat diet for 12 weeks with 100 mg/kg per day resveratrol (for 8 weeks) decreased protein expression 
of ER stress markers such as GRP78, ATF4, p-PERK, and CCAAT-enhancer-binding protein 
homologous protein (CHOP) in the liver [256]. Resveratrol reduced ER stress markers protein 
expression along with attenuating hepatic lipid accumulation, lobular inflammation and ballooning 
score (fibrosis), and inhibiting expression of genes involved in inflammation such as suppressor 
of cytokine signaling-3 (SOCS-3), TNFα, and IL-1β. Suppression of ER stress was suggested by 
the authors to be one of the mechanisms by which resveratrol protected against high-fat diet-
induced hepatic steatosis in rodents. Resveratrol was also shown to alleviate palmitate-induced ER 
stress in HepG2 hepatocytes by decreasing gene expression of the apoptotic CHOP, and protein 
expression of p-PERK and p-eIF2α as well as increasing 150-kDa oxygen-regulated protein 
(ORP150) gene expression in a SIRT1-dependant mechanism [257].  
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In a recent study, berberine has also been shown to prevent progression of simple hepatic steatosis 
to NASH by suppressing ER stress [258]. The authors showed that beneficial effects of berberine 
(200 mg/kg/d) in prevention of hepatic steatosis, inflammation, and fibrosis in db/db mice and 
methionine choline-deficient mice is due to the protective effect of berberine against hepatic ER 
stress. They found decreased mRNA for ATF6, ATF4, XBP1, and CHOP, and protein expression 
of p-PERK, p-eIF2α, GRP78, in the liver of ob/ob mice following treatment with berberine. This 
was concomitant with reduced expression of genes involved in lipogenesis (SREBP1, ChREBP, 
FAS, C/EBPβ), inflammation (IL-6, TNFα, IL-1β, and ICAM-1), fibrosis, and oxidative stress 
(catalase, CYP2E1, CYP4A10). In another experiment and in an in vitro model of ER stress using 
free fatty acids (mixture of oleic and palmitic acid at 0.5-1 mM) the same authors showed potential 
chaperone activity of polyphenols and showed that berberine exhibits chaperone activity and 
consequently decreases accumulation of unfolded proteins and consequently intracellular lipid in 
primary hepatocytes and HepG2 cells. They reported for the first time that berberine has potent 
chaperone activity which reduces ER stress by its protein-stabilizing activity and therefore 
decreases unfolded/aggregated proteins responsible for initiation of ER stress. Interestingly, the 
chaperone activity of berberine in that study was comparable to chemical chaperone 4-PBA 
representing potential effect of polyphenols in alleviating ER stress [258].  
Some in vitro studies also use tunicamycin instead of palmitic acid to induce ER stress. The results 
of these studies further elucidate the mechanisms by which ER stress impairs insulin signaling. 
For instance, in one study, Wang et al. reported the protective effect of berberine against 
tunicamycin-induced ER stress in HepG2 cells [259]. They found that while treatment of HepG2 
cells with tunicamycin increases gene and protein expression of chaperone ORP150, activates 
JNK, and increases phosphorylation of PERK and eIF2α, pre-treatment with 10-20 µM berberine 
for 14 h protected against all of these changes. Pre-treatment of HepG2 cells with berberine also 
decreased phosphorylation of IRS-1 Ser307, whereas increased IRS-1 tyrosine phosphorylation 
showing it can alleviate tunicamycin-induced impaired insulin signaling in HepG2 cells. 
Accordingly, berberine decreased ER stress-mediated insulin resistance and glucose production in 
these cells in the presence of insulin. The authors concluded that antidiabetic effects of berberine 
may be mediated through the decrease in ER stress and improvement in insulin signaling 
transduction [259]. 
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More recently, it was shown that maternal quercetin (50-200 mg/kg bw) administration along with 
a high-fat diet during gestation and lactation decreased birth weight, postnatal weight gain, insulin 
resistance, inflammation, and improved lipid metabolism via suppressing ER stress in the liver and 
adipose tissue of mature rat offspring of obese rats [260]. The maternal high-fat diet increased 
protein expression of ER stress markers such as Bip/GRP78, p-PERK, p-IRE1 in the liver and 
adipose tissue of the offspring while treatment with quercetin could protect against these changes. 
Therefore, by alleviating impaired early programming and ER stress, polyphenols such as 
quercetin may have the potential to decrease the risk for chronic metabolic diseases in adult 
offspring [260].  
These beneficial effects of polyphenols against ER stress have also been investigated in the skeletal 
muscle tissue. Increased ER stress in the skeletal muscle results in impaired insulin sensitivity and 
therefore enhances lipid accumulation and inflammation in the tissue further exacerbating 
metabolic homeostasis in obesity, diabetes, and fatty liver disease. Rodriguez et al. for instance, 
demonstrated that while a high-fat diet for 20 weeks increases mRNA expression of ER stress 
markers such as BiP, ATF4, XBP1s (spliced) and XBP1u (unspliced) in the skeletal muscle of 
mice, administration of pomegranate and green tea extracts could protect against these increases 
[261].  
In conclusion, very few studies are available that have investigated the effect of polyphenols on 
hepatic, adipose tissue, and skeletal muscle ER stress and most of them show promising results. 
Therefore, due to the lack of evidence in this field, more studies are needed in order to find the 
effect of polyphenols on ER stress in metabolic diseases and to explore the contributing 
mechanisms. 
 
 
 
51 
 
CHAPTER 3: DIETARY POLYPHENOLS PROTECT AGAINST OLEIC ACID-
INDUCED STEATOSIS BY MODULATING LIPID METABOLISM AND 
MITOCHONDRIAL DYSFUNCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ATP, Adenosine triphosphate; CPT1A1, Carnitine palmitoyltransferase-1 (liver); 
FAS, Fatty acid synthase; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; mRNA, 
Messenger ribonucleic acid; NAFLD, Non-alcoholic fatty liver disease; NASH, Nonalcoholic 
steatohepatitis; OXPHOS, Oxidative phosphorylation; p-AMPK, Phospho-AMP-activated 
protein kinase; PGC1α, Peroxisome proliferator-activated receptor gamma coactivator 1; PPARα, 
Peroxisome proliferator-activated receptor alpha; PPARγ, Peroxisome proliferator-activated 
receptor gamma; SIRT1, Sirtuin 1; SIRT3, Sirtuin 3; ΔΨm, Mitochondrial membrane potential 
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Abstract 
Scope: Dietary polyphenols have been shown to protect against NAFLD, but the mechanisms of 
action and their relative effectiveness on mitochondrial metabolism and cellular bioenergetics are 
largely unknown.  
Methods and results: Treatment of HepG2 cells with 1.5 mM oleic acid increased intracellular 
lipid, distorted HepG2 cell morphology, and decreased the mitochondrial membrane potential. Co-
treatment with 10 µM of selected polyphenols all strongly protected against these changes. In 
investigations into lipid metabolism, oleic acid induced mRNA for FAS and CPT1A, and 
decreased mRNA for PPARγ. Polyphenols, except cyanidin inhibited the effects on FAS and 
PPARγ, and further increased the expression of CPT1A1, suggesting a shift toward increased β-
oxidation. Oleic acid also depleted ATP stores in the cells grown on galactose but not glucose, 
while all polyphenols except kuromanin and berberine maintained the ATP stores. While oleic 
acid had no effect on the expression and activity of SIRT1 or on the formation of p-AMPKαThr172, 
resveratrol, catechin and berberine increased these factors. Catechin was unique in increasing the 
expression of SIRT3. 
Conclusion: While different polyphenols protected similarly against intracellular lipid 
accumulation, they differed in their effects on the expression of genes and proteins involved in 
lipogenesis, fatty acid oxidation, mitochondrial biogenesis, and bioenergetics, showing that they 
act through different mechanisms.  
 
Keywords: NAFLD, polyphenols, steatosis, mitochondrial dysfunction, ATP stores. 
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3.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) occurs following ectopic accumulation of intracellular 
fat in the liver (>5% of the liver weight) which is the manifestation of an imbalance between lipid 
influx and removal mechanisms [78]. Initially a benign condition, it can progress to nonalcoholic 
steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma [262]. The “two-hit” 
hypothesis suggests steatosis as the “first hit” making the liver susceptible to the “second hits” 
including oxidative stress, gut-derived endotoxins, or pro-inflammatory cytokines [2].  
Hepatic lipid metabolism is delicately regulated by the interaction among different transcription 
factors including the peroxisome proliferator-activated receptors (PPARs) and nuclear receptors, 
and genes involved in lipogenesis and fatty acid β-oxidation [71]. Any disturbances in these 
intertwined and precisely regulated pathways may initiate or promote NAFLD progression to 
NASH and cirrhosis. Although mitochondrial fatty acid β-oxidation has been shown to increase in 
high-fat diet-induced obesity and insulin resistance [263, 264], it cannot proportionately 
metabolize an increasing load of free fatty acids and its capacity may be disrupted by mitochondrial 
dysfunction and OXPHOS incompetence [105].  
More recently, mitochondrial dysfunction was suggested to contribute to the progression of simple 
steatosis to NASH [4-6]. Mitochondrial dysfunction has a pivotal role in progression of NAFLD. 
Due to the major roles of mitochondria in energy and lipid metabolism, ROS production, and 
apoptosis [13], mitochondrial dysfunction is suggested to be linked with the severity of 
NAFLD/NASH [12]. This mitochondrial dysfunction may also result in collapse of the 
mitochondrial membrane potential [265], ending up with exacerbation of NAFLD. Due to the 
impaired oxidative phosphorylation, hepatic ATP stores which are critical in maintaining the 
integrity of hepatic tissue, become depleted in NAFLD and NASH making the condition worse 
[18, 266]. Moreover, mitochondrial biogenesis decreases in NAFLD due to a higher ROS 
production and mitochondrial DNA damage, meaning that fewer functional mitochondria are 
available in hepatocytes (reviewed in [19]). Therapies to induce mitochondrial biogenesis 
therefore, may facilitate metabolizing excess fat and have a major role in the prevention of NAFLD 
progression to NASH [267]. 
54 
 
Found in foods such as fruits and vegetables, green and black tea, chocolate, coffee, pulses, and 
extra virgin olive oil [43], polyphenols have been the subject of many studies only in the last few 
decades [203]. As well as being potent antioxidants [43, 47], polyphenols have previously been 
observed to protect against intracellular lipid accumulation [37, 48] which make them candidates 
for prevention and treatment of NAFLD. However, very few studies have investigated the effect 
of different polyphenols on aspects of mitochondrial biogenesis and dysfunction, and lipid 
metabolism. It is not known which polyphenols are the most potent in prevention of NAFLD and 
by what molecular mechanisms. The aim of the present study was to compare different classes of 
polyphenols for their abilities to prevent oleic acid-induced steatosis and mitochondrial 
dysfunction, induce mitochondrial biogenesis, and preserve HepG2 cell morphology. The 
contributing mechanisms were investigated by evaluating mitochondrial biogenesis, the 
mitochondrial membrane potential, intracellular ATP stores, and the expression of proteins 
involved in mitochondrial biogenesis, lipogenesis and fatty acid β-oxidation.  
3.2. Materials and Methods 
3.2.1. Materials 
Eagle’s minimum essential medium (MEM) for growing HepG2 cells was purchased from 
Hyclone, Logan, USA. Fluorescent Nile Red dye was from MP Biomedical, USA. Fetal bovine 
serum (FBS), mixture of antibiotic (penicillin/streptomycin), fatty acid-free bovine serum albumin 
(BSA), oleic acid, resveratrol, catechin, berberine, and quercetin were from Sigma-Aldrich, USA. 
Cyanidin, and cyanidin-3-glucoside (kuromanin) were purchased from Extrasynthese, France. 
RNAeasy mini kit for isolating RNA was from Qiagen. VILO cDNA synthesis kit, TRIzol reagent, 
Power SYBR Green PCR master mix for polymerase chain reaction, and tetramethlyrhodamine 
ethyl ester (TMRE) were purchased from Invitrogen, USA. CellTiter-Glo Luminescent Cell 
Viability Assay kit for quantification of intracellular ATP was from Promega, USA. SIRT1 direct 
fluorescent screening assay kit was from Cayman, USA. Manufacturers of materials used for 
Western blot are mentioned in section 3.2.10. 
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3.2.2. HepG2 cell culture conditions 
HepG2 cells were cultured in T75 flasks using minimum essential medium with Earle's balanced 
salts (MEM/EBSS) which contained 2 mM glutamine, 1 g/L glucose (5.5 mM), 10% fetal bovine 
serum (FBS), and 1% penicillin/streptomycin (100 units/mL penicillin, and 100 mg/mL 
streptomycin) in a humidified incubator with 5% CO2 at a temperature of 37ºC. When 70-80% 
confluent, HepG2 cells were detached with trypsin, harvested and used for different experiments.  
3.2.3. Treatment with oleic acid/BSA and polyphenols 
Oleic acid was dissolved in dimethyl sulfoxide (DMSO) in order to prepare a 300 mM stock 
solution and kept at -20°C for further use. HepG2 cells at 3×104 cells/well were cultured in the 96-
well optical-bottom plates for 24 h. Old medium was then replaced with fresh medium containing 
10% FBS and 1% fatty acid-free bovine serum albumin (BSA). One percent BSA was used to 
ensure the solubility of oleic acid in the medium. HepG2 cells were then pre-treated with different 
polyphenols at 10 µM for 2 h. After treatment of the cells with polyphenols for 2 h (polyphenols 
were not removed thereafter and the cells were incubated with them for the next 24 h), the cells 
were treated with or without 1.5 mM oleic acid for 24 h.  
3.2.4. Measuring intracellular lipid content  
Intracellular triglyceride was measured using the lipophilic fluorescent dye Nile Red (MP 
Biomedicals, USA) according to the manufacturer’s protocol, which stains the cytosolic neutral 
lipids [268]. Intracellular lipid content is therefore proportional to the Nile Red fluorescence. 
HepG2 hepatocytes at 3×104 were cultured in black 96-well clear-bottom plates. After 24 h, the 
medium was replaced with fresh medium containing 10% FBS and 1% BSA and hepatocytes were 
pre-treated with different polyphenols at 10 µM concentration for 2 h. To avoid a toxic effect of 
dimethyl sulfoxide (DMSO) in which the polyphenols were solubilized, the final concentration of 
DMSO in the medium was set at 0.5% and to control for any possible effect of DMSO, the same 
volume was added to untreated and control cells. After 2 h of treatment with polyphenols, the cells 
were treated with or without 1.5 mM oleic acid for 24h. After 24 h the old medium was replaced 
with fresh medium containing 1 µg/mL Nile Red and the cells were covered and incubated for 20 
min at 37oC. The cells were then washed carefully 2-3 times with phosphate buffered saline (PBS) 
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and the fluorescence of each well was read at 9 different spots using a microplate reader at 
excitation 488 nm and emission 585 nm. Fluorescence images were then captured using a ZOE 
Fluorescent Cell Imager (BioRad, USA). Each experiment was repeated in triplicate with 3 
replicate wells per experiment. 
3.2.5. HepG2 cell forward and side scattering using flow cytometry 
To get a measure of cell size and granularity, forward and side scattering of HepG2 cells was 
measured by flow cytometry. After seeding 5x105 cells in each well (in 6-well plates) for 24 h, the 
cells were pretreated with 10 µM polyphenols for 2 h. The cells were then treated with oleic acid 
at 1.5 mM dissolved in the medium containing 1% BSA. After 24h, the cells were washed twice 
with PBS and harvested by trypsinization. After adding 2 ml medium and centrifugation at 1200 
rpm for 5 min, the supernatant was discarded and the pellet was suspended in PBS. Then, 0.5 ml 
of the cell suspension was transferred to a flow cytometry tube and the forward and side scattering 
was determined using a FACS system. Data were collected for 10,000 cells per sample. 
3.2.6. RT-qPCR 
3.2.6.1. Total RNA isolation  
For determining mRNA expression, total RNA was isolated from HepG2 cells using TRIzol 
reagent and RNAeasy mini kit according to the manufacturer’s instructions (Qiagen, USA). For 
isolating RNA, 1x106 cells per well were plated in a 6-well plate for the first 48 h to grow. On the 
third day, the medium was replaced with fresh medium and the cells were pre-treated with 10 µM 
polyphenols for 2 h followed by treatment with 1.5 µM oleic acid for 24 h. After 24 h, the cells 
were washed twice with PBS and 1 ml of TRIzol was added to each well for 2 min to lyse the cells. 
Then, the cell lysates were transferred to a clean RNase-free 1.5 ml Eppendorf tube and 200 µl 
chloroform was added to each sample lysate followed by vigorous shaking for 10 seconds. After 
incubation at room temperature for 3 min, the lysates were vortexed again and centrifuged at 
12,000 g for 10 min at 4 oC. Then, the clear aqueous upper layer was carefully separated and 
transferred to a new Eppendorf tube and 500 µl isopropanol was added to each microtube. After 
incubating for 5 min at room temperature, each sample was applied to a spin column and 
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centrifuged at 8000 g for 15s at 4 oC. Then, the flow-through was discarded and 350 µl RW1 buffer 
(provided with the kit) was added to each sample and centrifuged again at 8000 g for 15s and the 
flow-through was discarded. To remove any DNA contamination, the samples were treated with 
80 µl DNase 1x (Invitrogen, USA) and incubated at room temperature for 15 min. Then, the 
samples were washed with 350 µl of RW1 buffer and centrifuged at 8000 g for 15s at 4°C.  After 
discarding the flow-through, the samples were washed with RPE buffer (provided with the kit), 
spin-dried for 1 min and the spin columns were transferred to a fresh RNase-free Eppendorf tube. 
Finally, 50 µl nuclease free water (Invitrogen, USA) was added to each spin column which was 
then centrifuged at 8000 g for 1 min and the flow-through containing purified total RNA was stored 
at -80 for later use.  
3.2.6.2. Synthesis of complementary DNA (cDNA) 
Frozen RNA samples were thawed and RNA concentration and purity were measured using a Nano 
Drop spectrophotometer (BioRad, USA) and the A260/A280 absorbance ratio. The A260/A280 
absorbance ratio for all extracted RNAs was between 2-2.1 showing the total RNA was highly 
pure (within the acceptable ratio range of 1.8-2.1). Each 1x106 HepG2 cells yielded approximately 
18 µg total RNA. Using a VILO cDNA synthesis kit (Invitrogen, USA) and a Thermocycler 
(BioRad, USA), reverse transcription of 2 μg mRNA to cDNA was performed in 20 µl reactions 
according to the manufacturer’s instructions. For cDNA synthesis, thermal cycling was adjusted 
as follows: one cycle at 25oC for 10 min, one cycle at 42oC for 60 min (optimal for synthesis of 
cDNA), and one cycle at 85oC for 5 min (to inactivate DNA polymerase). The cDNA samples 
were kept in a -80 oC freezer and were diluted 20 times before use according to the VILO cDNA 
synthesis kit protocol to remove the PCR inhibitory effects of reverse transcription. All primers 
were provided by Integrated DNA Technologies (IDT, Canada).   
3.2.6.3. Polymerase Chain Reaction (PCR)  
The PCR was performed using a PCR system (ABI 7300; Applied Biosystem) using the Power 
SYBR Green real-time PCR master mix (Life Technologies, USA) in 20 µl reactions according to 
the manufacturer’s protocol. The thermal cycling used for the PCR was as follows: one cycle at 
95oC for 5 min (for enzyme activation), followed by 40 cycles at 95oC for 15s and 60oC for 30s. 
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The melting curves of all PCR products were evaluated to confirm amplification and primer 
quality. A comparative method (2−ΔΔCT) was used to analyze the relative expression of genes of 
interest using GAPDH as the reference gene. Since the expression of β-actin did not show the same 
trend in all groups in this study, GAPDH was used as the reference gene which showed similar 
expression in different groups and is routinely used as reference gene in studies on fatty liver 
disease. All results were normalized to the GAPDH. Each experiment was repeated in duplicate 
with 3 replicate wells per experiment. Sequences of the primers of interest are shown in appendix 
Table 7.1. 
3.2.7. Culturing the cells in galactose medium  
Cells which are grown in glucose medium can compensate for their mitochondrial dysfunction by 
higher production of ATP from glycolysis and may be resistant to mitochondrial defects. In order 
to bypass glycolysis, HepG2 cells were grown in DMEM medium (Gibco, USA) without glucose 
supplemented with 25 mM galactose, 2 mM glutamine, 10% FBS, and 1% penicillin/streptomycin 
(100 units/mL penicillin, and 100 mg/mL streptomycin) in a humidified incubator with 5% CO2 
at a temperature of 37ºC. 
3.2.8. Quantification of intracellular ATP  
ATP content was quantified using the CellTiter-Glo Luminescent Cell Viability Assay kit based 
on the manufacturer’s instructions. This kit results in lysis of the cells and generation of a "glow-
type" luminescent signal proportional to the amount of ATP present. Therefore, if there are equal 
number of cells in different wells, the signals may be interpreted as relative ATP content. Briefly, 
1x104 cells per well were seeded in white 96-well clear-bottom plates with either glucose or 
galactose. The next day, the cells were pre-treated with polyphenols for 2 h and treated with oleic 
acid for 24 h or 72 h. Rotenone (inhibitor of mitochondrial complex I) and antimycin A (inhibitor 
of complex III) were used as positive controls. Intracellular ATP content was then measured using 
the kit based on the manufacturer’s instructions. Briefly, the cells were lysed using the reagent 
included in the kit and after 3 min of vigorous shaking and 10 min incubating in room temperature 
while covered (to stabilize the luminescence signals), the luminescence generated from the ATP-
mediated chemical reaction was read using a microplate reader under standard luminescence 
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settings. Each experiment was repeated in triplicate with 3 replicate wells per experiment. 
3.2.9. SIRT1 deacetylase activity 
SIRT1 activity was measured using a SIRT1 direct fluorescence screening assay kit (Caymen, 
USA) according to manufacturer’s protocol. In this method, deacetylation of acetylated p53 
peptide by SIRT1 in the unknown sample sensitizes its binding to a fluorometric probe and the 
resultant fluorescence is proportional to the SIRT1 activity in the sample. The assay was performed 
by incubation of 5 µl of protein lysates with 15 µl substrate solution containing the fluorogenic 
acetylated p53 peptide (Arg-His-Lys-Lys(ε-acetyl)-AMC) and co-substrate NAD+, and 25 µl 
assay buffer (50 mM Tris-HCl, pH 8.0, containing 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl2). 
The plate was covered and incubated on a shaker at room temperature for 45 min. After 45 min, 
50 µl of the developer was added to each well and plate was incubated at room temperature for 30 
min to release AMC from the deacetylated peptide. Using a fluorescence reader, the intensity of 
fluorescence was measured at excitation 360 nm and emission detection at 460 nm. Protein 
concentration in samples was quantified using a bicinchoninic acid (BCA) protein assay kit and 
the results of SIRT1 activity were normalized to protein concentrations. Each experiment was 
repeated in triplicate with 3 replicate wells per experiment. 
3.2.10. Protein extraction, quantification, and Western blot 
HepG2 cells were seeded in T25 flasks and exposed to polyphenols at 10 μM for 2 h followed by 
treatment with 1.5 mM oleic acid for 24 h. For total protein extraction, the cells were homogenized 
using ice-cold RIPA buffer 1x (10x solution was diluted to 1x with ddH2O) (Millipore, USA) for 
30 min on ice, supplemented with Halt protease and phosphatase inhibitor and EDTA (Thermo 
Fisher Scientific, USA). After centrifugation at 14,000 rpm for 15 minutes at 4°C, the supernatant 
containing protein was gently obtained, aliquoted and used for protein quantification and western 
blot. Protein content was quantified using a BCA protein assay kit (Thermo Fisher Scientific). 
Protein samples were then normalized, mixed with the loading buffer (2x Laemmli buffer 
supplemented with 10% β-mercaptoethanol), and denatured by heating at 70 °C for 10 min. Equal 
amount of proteins (40 μg in 40 μl volume) were loaded into each well of 8% or 4-12% Novex 
WedgeWell Tris-Glycine Pre-Cast gels (Invitrogen, USA) and then transferred to a 0.45 µm 
nitrocellulose membrane by the wet transfer method using Tris-Glycine running buffer. Following 
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transfer, nonspecific protein binding sites in the membrane were blocked with Tris-buffered saline 
containing Tween-20 (TBST) and 5% bovine serum albumin (BSA) for 1 hour at room 
temperature. The membrane was then incubated overnight at 4°C with rabbit primary monoclonal 
antibodies for phospho-AMPKαThr172 (1:500) and β-actin (1:500) (both from Cell Signaling 
Technology, Danvers, MA, USA), and PGC-1α (1:500, Abcam, USA). The membranes were then 
washed with Tris-buffered saline (TBS, PH:7.6) with 0.1% Tween-20 (TBST) three times (5 
minutes each) and then incubated for 1 h with secondary anti-rabbit antibody (Horseradish 
Peroxidase 1:2000, Santa Cruz Biotech, CA, USA). After several washings with TBST and TBS, 
the membrane was incubated with the enhanced chemiluminescence western blotting detection kit 
(Thermo Fisher Scientific) for 3 min and the bands were observed and quantified using an Alpha 
Imager Gel Imaging System (Alpha Innotech). The results were finally normalized to their 
corresponding control β-actin. 
3.2.11. Mitochondrial membrane potential (ΔΨm) 
The mitochondrial membrane potential was measured using the fluorescent probe, 
tetramethlyrhodamine ethyl ester (TMRE) according to the manufacturer’s protocol (Invitrogen, 
USA). TMRE (a cationic fluorescent probe) is driven into the negatively-charged mitochondrial 
matrix due to its lipophilic feature and positive charge. Thus, the mitochondrial membrane 
potential is directly proportional to the intensity of red fluorescence signals [269]. HepG2 
hepatocytes at 3×104 per well were seeded in the black 96-well optical-bottom plates for 24 h in 
the medium containing 10% FBS. After 24 h, the old medium was replaced with fresh medium 
containing 10% FBS and 1% fatty acid-free bovine serum albumin and the cells were pre-treated 
with 10 µM polyphenols for 2 h followed by treatment with or without 1.5 mM oleic acid for 24 
h. After 24 h, the old medium was replaced with fresh medium (without FBS) containing TMRE 
at 500 nM final concentration and the cells were covered and incubated at 37 °C for 20 min. Excess 
dye was then removed and the cells were washed carefully 2-3 times with PBS and the mean 
fluorescence of 9 different spots of each well was measured using a microplate reader at an 
excitation 549 nm and emission 575 nm. The uncoupler carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) at 50 μM which collapses the mitochondrial membrane potential 
was used as a positive control and added 10 min before the cells being exposed to TMRE. The 
fluorescence images showing the mitochondrial membrane potential in HepG2 cells were captured 
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using a ZOE Fluorescent Cell Imager. Each experiment was repeated in triplicate with 3 replicate 
wells per experiment. 
3.2.12. Statistical analysis 
Results were expressed as mean values with their standard error of means (SEM) for the number 
of experiments indicated. Results were analyzed using the Statistical Package for the Social 
Science (SPSS 22) (IBM, USA). One-way ANOVA was used initially, and when any significance 
detected, Dunnett’s post hoc test was used to compare the mean of each group with the oleic acid 
alone condition. The level of significance was P<0.05. Correlation was determined by the 
Pearson’s R. 
3.3. Results  
3.3.1. Effects on HepG2 cell morphology  
By evaluating the cells with an inverted microscope, we found that untreated HepG2 hepatocytes 
have a healthy eye-shaped morphology (Figure 3.1). After treatment with oleic acid, some cells 
show large droplets of fat (macro-vesicular steatosis). However, most cells show micro-vesicular 
steatosis with numerous small droplets of fat (sometimes more than 13-14 small fat droplets).  
 
Figure 3. 1. Brightfield images (600x magnification) representative of the morphology of 
HepG2 cells before and after treatment with oleic acid.  
62 
 
Figure 3.2 shows representative images of the effect of polyphenols on HepG2 cell morphology. 
All of the polyphenols were effective in inhibiting oleic acid-induced lipid accumulation. HepG2 
cells pre-treated with different polyphenols were less steatotic and apparently healthier compared 
to the oleic acid alone condition. Fat droplets were smaller and more dispersed after treatment with 
polyphenols (fewer macro- and micro-vesicular droplets). Another important finding is that 
HepG2 cells pre-treated with polyphenols kept their eye-shaped morphology almost intact 
compared to the oleic acid alone condition in which the cells were rounded, swollen or distorted 
in morphology. 
 
Figure 3. 2. Brightfield images (400x magnification) representative of the morphology of 
hepatocytes after treatment with 10 µM polyphenols for 2 h followed by treatment with 1.5 
mM oleic acid for 24 h.  
 
3.3.2. The effect of polyphenols on oleic acid-induced intracellular lipid accumulation  
Figure 3.3 shows the Nile Red fluorescence captured by a fluorescence microscope representing 
intracellular triglyceride content. Higher red fluorescence in HepG2 cells exposed to oleic acid 
shows higher intracellular fat compared to untreated cells. Different polyphenols reduced the 
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fluorescence intensity, representing inhibition of oleic acid-induced lipid accumulation. These 
results are in accordance with the results shown in Figure 3.2.  
 
Figure 3. 3. Fluorescence images (400x magnification) using the Nile Red fluorescence probe 
for intracellular lipid content. Higher red fluorescence represents higher lipid content in 
HepG2 cells. 
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Intracellular lipid content was quantified using the Nile Red staining and a microplate reader. 
Treatment with oleic acid alone increased intracellular lipid content in HepG2 cells by 150% while 
treatment with 10 µM polyphenols inhibited accumulation of lipids by 42-58% (Figure 3.4).  
 
Figure 3. 4. Intracellular triglyceride content after quantification of the Nile Red 
fluorescence  
HepG2 cells were pretreated with 10 µM polyphenols for 2 h followed by treatment with 1.5 mM 
oleic acid for 24 h. Untreated cells were set at 100% and the data are presented as % of the untreated 
cells. The figure represents means ± SEM of 3 independent experiments with 3 replicate wells in 
each experiment. (*) Significantly different from the oleic acid alone condition at P<0.05. The 
significant difference between groups was tested with one-way ANOVA followed by Dunnett’s 
post-hoc test. 
3.3.3. Flow cytometry of HepG2 cells  
In order to find the effect of oleic acid and polyphenols on the size and morphology of the cells, 
HepG2 cells were evaluated by a flow cytometer. Compared to untreated cells, oleic acid produced 
less forward and higher side scattering (Figure 3.5), showing the cells have abnormal size, and 
distorted shape and morphology. Treatment with all polyphenols at 10 µM increased forward and 
decreased side scattering of HepG2 hepatocytes to be more similar to untreated cells. These results 
are consistent with the results shown in Figure 3.2 in which polyphenols preserved oleic acid-
induced distortion of HepG2 cell morphology. 
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Figure 3. 5. Representative plots of forward and side scattering of 10,000 cells using flow 
cytometry after treatment with 10 µM polyphenols for 2 h and 1.5 mM oleic acid for 24 h 
3.3.4. Effects of oleic acid and polyphenols on the mitochondrial membrane potential (ΔΨm)   
Fluorescence images captured by a ZOE Fluorescent Cell Imager represent how treatment with 
oleic acid or the uncoupler CCCP (used as a positive control) dissipated the mitochondrial 
membrane potential in HepG2 cells evidenced by decreased intensity of TMRE red fluorescence 
(Figure 3.6.A). Treatment with catechin, resveratrol, quercetin, and cyanidin prior to treatment 
with oleic acid protected against collapse of the mitochondrial membrane potential evidenced by 
higher intensity of the red fluorescence (Figure 3.6.A). Enlarged images of both healthy untreated 
hepatocytes and hepatocytes treated with oleic acid alone show the mitochondrial membrane 
potential dissipation in enlarged fat-laden hepatocytes (Figure 3.6.B). 
Quantification of TMRE fluorescence using a microplate reader shows that treatment of HepG2 
hepatocytes with 1.5 mM oleic acid decreased the mitochondrial membrane potential by 48%, even 
more than a mitochondrial uncoupler (CCCP) that was used as a positive control (Figure 3.6.C). 
Consistent with the images shown in Figure 3.6.A, treatment with polyphenols such as cyanidin, 
catechin, quercetin, and resveratrol prior to treatment with oleic acid protected against 
mitochondrial membrane potential collapse by 44-60%. Berberine and kuromanin did not give any 
significant protection. 
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Figure 3. 6. Effects of oleic acid and polyphenols on the mitochondrial membrane potential. 
(A) Fluorescence images (with their corresponding brightfield images) showing the effect of oleic 
acid and polyphenols on the mitochondrial membrane potential after TMRE staining. Images at 
20x magnification were captured using a ZOE Fluorescent Cell Imager 30 min after staining the 
cells with TMRE. (B) Enlarged images (digital zoom at 60x magnification) of HepG2 cells 
exposed to oleic acid alone (droplets of fat are obvious in the cells in corresponding brightfield 
images) compared to healthy untreated cells. (C) The mitochondrial membrane potential in HepG2 
cells after treatment with 10 µM polyphenols for 2 h and treatment with 1.5 mM oleic acid for 24 
h was measured by quantification of TMRE fluorescence using a microplate reader. Untreated 
cells were set at 100% and the data are presented as % of the untreated cells. The figure represents 
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means ± SEM of 3 independent experiments with 3 replicate wells in each experiment. (*) 
Significantly different from control group at P<0.05. 
3.3.5. Effects of oleic acid and polyphenols on genes involved in fatty acid β-oxidation 
(CPT1A1 and PPARα) 
Oleic acid significantly induced mRNA for carnitine palmitoyltransferase 1 (CPT1A1) by 200%, 
which appears to be an adaptive mechanism (Figure 3.7). Treatment of HepG2 cells with berberine, 
resveratrol, quercetin, catechin, and kuromanin further significantly increased CPT1A1 expression 
by 118, 87, 54, 52, and 50 %, respectively. Cyanidin had no significant effect on CPT1A1 
expression.  
 
Figure 3. 7. Expression of mRNA for carnitine palmitoyltransferase 1 (CPT1A1) and 
peroxisome proliferator-activated receptor alpha (PPARα). 
UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine. HepG2 cells were pretreated with 10 µM polyphenols for 2 h followed 
by treatment with 1.5 mM oleic acid for 24 h. Untreated cells were set at 100% and the data are 
presented as % of the untreated cells. The figure represents means ± SEM of 2 independent 
experiments with 3 replicate wells in each experiment. (*) Significantly different from the oleic 
acid alone condition at P<0.05.  
Oleic acid did not significantly affect the peroxisome proliferator-activated receptor alpha mRNA 
(PPARα) expression, while treatment with berberine and catechin significantly increased PPARα 
expression by 29, and 25%, respectively (Figure 3.7). Resveratrol, quercetin, and anthocyanins 
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had no significant effect on PPARα expression. 
3.3.6. The effect of oleic acid and polyphenols on expression of genes involved in lipogenesis 
(FAS and PPARγ) 
Figure 3.8 shows mRNA for fatty acid synthase (FAS) after treatment with polyphenols and oleic 
acid. Oleic acid significantly increased FAS by 43%. Resveratrol, quercetin, and kuromanin 
completely prevented the increase in FAS expression. Catechin, cyanidin, and berberine however, 
did not inhibit FAS mRNA. 
 
Figure 3. 8. mRNA expression for fatty acid synthase (FAS) and peroxisome proliferator-
activated receptor gamma (PPARγ). 
UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine. HepG2 cells were pretreated with 10 µM polyphenols for 2 h followed 
by treatment with 1.5 mM oleic acid for 24 h. Untreated cells were set at 100% and the data are 
presented as % of the untreated cells. The figure represents means ± SEM of 2 independent 
experiments with 3 replicate wells in each experiment. (*) Significantly different (P<0.05) from 
the oleic acid alone condition. 
Figure 3.8 shows the peroxisome proliferator-activated receptor gamma mRNA (PPARγ) 
expression in HepG2 hepatocytes. Oleic acid significantly inhibited PPARγ expression by 26% 
while berberine, quercetin, resveratrol, and catechin significantly reversed the expression by more 
than 100%. Anthocyanins had no significant effect on PPARγ expression. Berberine showed the 
strongest effect, increasing PPARγ expression by 68% over that of untreated cells.  
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3.3.7. Effects of oleic acid and polyphenols on the gene expression and activity of sirtuins 
Shown in Figure 3.9.A, oleic acid had no significant effect on the sirtuin 1 mRNA (SIRT1) 
expression while catechin, berberine, and resveratrol significantly induced SIRT1 mRNA by 46%, 
44%, and 35% respectively. Quercetin did not significantly induce SIRT1 expression (P=0.15). 
Anthocyanins also had no significant effect on SIRT1 mRNA expression.  
As with mRNA expression, oleic acid had no effect on SIRT1 activity, while resveratrol, catechin, 
and berberine significantly increased SIRT1 activity by 25, 19, and 17%, respectively (Figure 
3.9.B). Consistent with no effect on mRNA expression, quercetin and kuromanin had no effect on 
SIRT1 activity. An exception for a different effect on the mRNA expression and SIRT1 activity 
was cyanidin, which though it had no effect on the SIRT1 expression, it increased SIRT1 activity 
by 19%.  
Expression of mRNA for the mitochondrial sirtuin3 (SIRT3) was also investigated. Treatment with 
oleic acid alone had no significant effect on SIRT3 mRNA while only catechin increased its 
expression by 57% compared to the oleic acid alone condition (Figure 3.9.C). 
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Figure 3. 9. (A) SIRT1 mRNA, (B) SIRT1 activity and (C) SIRT3 mRNA. 
Experimental conditions were as described in Figure 3.4. UT: untreated, OA: oleic acid, Res: 
resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: kuromanin, Ber: berberine. HepG2 
cells were pre-treated with 10 µM polyphenols for 2 h and 1.5 mM oleic acid for 24 h. For SIRT1 
activity, the data are normalized to protein concentration. Untreated cells were set at 100% and 
data are presented as % of the untreated cells. The bars represent means ± SEM of 2 independent 
experiments for SIRT1 and SIRT3 expression and 3 independent experiments for SIRT1 activity 
with 3 replicate wells in each experiment. (*) Significantly different (P<0.05) from the oleic acid 
alone condition. 
3.3.8. Effects on the expression of proteins involved in mitochondrial metabolism and 
biogenesis (phosphorylated AMPKα and deacetylated PGC1α) 
Treatment of HepG2 cells with oleic acid did not change the phosphorylation of 5' AMP-activated 
protein kinase alpha (AMPKα) on threonine 172 (p-AMPKαThr172) while some polyphenols such 
as resveratrol, berberine, and catechin induced the phosphorylation by 35, 32, and 28%, 
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respectively (Figure 3.10). Quercetin, cyanidin, and kuromanin (cyanidin-3-glucoside) had no 
significant effect on the AMPKα phosphorylation. 
 
Figure 3. 10. Protein expression of p-AMPKαThr172 in HepG2 cells pre-treated with 10 
µM polyphenols for 2 h and 1.5 mM oleic acid for 24 h measured by Western blot. 
Experimental conditions were as described in Figure 3.4. Untreated cells were set at 100% and the 
data are presented as % of the untreated cells. The figure represents means ± SEM of 2 independent 
experiments. (*) Significantly different (P<0.05) from the oleic acid alone condition.  
Regarding the deacetylation of peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1α), oleic acid had no effect while only kuromanin and berberine increased protein 
expression of deacetylated PGC1α by 54 and 51%, respectively (Figure 3.11). Other polyphenols 
had no effect on the deacetylation of PGC1α. 
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Figure 3. 11. Protein expression of deacetylated PGC1α in HepG2 cells pre-treated with 10 
µM polyphenols for 2 h and 1.5 mM oleic acid for 24 h measured by Western blot. 
Experimental conditions were as described in Figure 3.4. Untreated cells were set at 100% and the 
data are presented as % of the untreated cells. The figure represents means ± SEM of 2 independent 
experiments. (*) Significantly different (P<0.05) from the oleic acid alone condition.  
3.3.9. Effects of oleic acid and polyphenols on intracellular ATP stores  
Intracellular ATP stores in HepG2 cells were determined after growing the cells in either glucose 
or galactose medium. In 5.5 mM glucose medium after 24 h, treatment of HepG2 cells with oleic 
acid and polyphenols had no effect on ATP stores except for slight (12 and 7%) but significant 
decreases by kuromanin and berberine (Figure 3.12). In glucose medium after 72 h, oleic acid 
increased ATP stores by 23%, and treatment with polyphenols had no effect on ATP stores except 
a slight (9%) but significant decrease by berberine (Figure 3.12).   
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Figure 3. 12. Intracellular ATP stores in HepG2 cells grown in glucose medium. 
UT: untreated, Rot: rotenone, Ant: antimycin, OA: oleic acid, Res: resveratrol, Que: quercetin, 
Cat: catechin, Cyn: cyanidin, Kur: kuromanin, Ber: berberine. (A) HepG2 cells were grown in 
glucose medium (5.5 mM) and pre-treated with 10 µM polyphenols for 2 h and 1.5 mM oleic acid 
for 24 h. Rotenone and antimycin (for 24 or 72 h) were used as positive controls to prevent the 
complex I and III activity, respectively. Untreated cells were set at 100% and the data are presented 
as % of untreated cells. The bars represent means ± SEM of 3 independent experiments with 3 
replicate wells in each experiment. (*) Significantly different from the oleic acid alone condition 
at P<0.05.  
When the cells were grown in galactose medium (to supress glycolysis) for 24h, treatment with 
oleic acid alone significantly decreased intracellular ATP stores by 11% while no polyphenol could 
protect against the inhibition (Figure 3.13). Berberine exacerbated the effect of oleic acid and 
together decreased ATP stores by 73% compared to untreated cells. In galactose medium for 72 h, 
oleic acid depleted intracellular ATP by 57% (Figure 3.13). Compared to the oleic acid alone 
condition, treatment with the polyphenols cyanidin, catechin, resveratrol, quercetin, increased 
ATP stores by 95, 88, 84, and 81%, respectively. Berberine and kuromanin did not give any 
protection.  
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Figure 3. 13. Intracellular ATP stores in HepG2 cells grown in galactose medium. 
UT: untreated, Rot: rotenone, Ant: antimycin, OA: oleic acid, Res: resveratrol, Que: quercetin, 
Cat: catechin, Cyn: cyanidin, Kur: kuromanin, Ber: berberine. HepG2 cells were grown in 
galactose medium (25 mM) and pre-treated with 10 µM polyphenols for 2 h and 1.5 mM oleic acid 
for 24 h. Rotenone and antimycin (for 24 or 72 h) were used as positive controls to prevent the 
activity of complex I and III, respectively. Untreated cells were set at 100% and the data are 
presented as % of the untreated cells. The bars represent means ± SEM of 3 independent 
experiments with 3 replicate wells in each experiment. (*) Significantly different from the oleic 
acid alone condition at P<0.05.  
3.4. Discussion 
This study was designed to investigate and compare the effects of different classes of polyphenols 
on steatosis (the “first hit”), lipid metabolism, and mitochondrial biogenesis and membrane 
potential in an in vitro model of non-alcoholic fatty liver disease. In contrast to many in vitro 
studies using high doses of polyphenols, a relatively low dose of polyphenols (10 µM) was used 
in the current study. In measurements of steatosis (cellular morphology, Nile Red staining, and 
flow cytometry), treatment of the HepG2 cells with oleic acid increased intracellular lipid 
accumulation, while different classes of polyphenols gave similar protection. Although the results 
from these measurements did not distinguish the different polyphenols, they are consistent with 
previous studies showing individual polyphenols to inhibit intracellular lipid accumulation in 
HepG2 cells treated with oleic acid [35-37] or palmitic acid [42].  
75 
 
In investigations on cell size and morphology, we found that oleic acid induced less forward 
scattering and higher side scattering. Forward and side scattering usually represent the cell size 
and granularity, respectively. Accordingly, higher side scattering in hepatocytes treated with oleic 
acid may be due to increased cytoplasmic granules (fatty acid droplets). Increased side scattering 
in these cells showed that the cells have distorted shape, morphology, and size. Consistent with 
the results on intracellular lipids, all the polyphenols showed similar protection and produced 
higher forward and lower side scattering in the cells. These results show that the polyphenols 
produced more normal cell size and morphology.  
The anti-steatotic effect of polyphenols in the current study may be partly explained by increased 
expression of enzymes involved in fatty acid β-oxidation such as the hepatic enzyme carnitine 
palmitoyltransferase 1 (CPT1A1), and decreased expression of enzymes involved in lipogenesis 
such as fatty acid synthase (FAS). However, this mechanism was not the case for cyanidin, which 
had no effect on these genes. Inhibition of steatosis by cyanidin in the current study may be 
partially explained by the higher expression of uncoupling protein 2 (UCP2) by this polyphenol, 
as shown in CHAPTER 4, which induces fatty acid metabolism. However, cyanidin may also 
affect other genes or proteins involved in lipogenesis or fatty acid oxidation that were not 
investigated in the current study [245]. 
In expression of CPT1A1, oleic acid and polyphenols acted in the same direction to increase the 
expression. Increased expression of CPT1A1 by oleic acid in the current study may be an adaptive 
mechanism to induce β-oxidation due to increased load of fatty acids which need to be metabolized 
in mitochondria. Consistent with our results, other studies show hepatic fatty acid oxidation and 
CPT1 expression or activity is often enhanced in rodents and patients with NAFLD and obesity 
(reviewed in [4]). We also found that all polyphenols except cyanidin further upregulated CPT1A1 
mRNA. These results are consistent with a few previous studies where individual flavonoids or 
flavonoid-rich extracts were shown to increase mRNA for CPT1 dose-dependently in HepG2 cells 
treated with free fatty acids [270], or CPT1 expression or activity in genetically obese or high-fat 
fed rats [95, 271]. 
To gain further insights into the effect on lipid metabolism by polyphenols we measured effects 
on the expression of PPARs (PPARα and PPARγ) and FAS. The transcriptional control of genes 
by PPARs has critical roles in lipid metabolism (particularly hepatic steatosis), inflammation, and 
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fibrosis [156]. PPARα, once activated, induces the expression of genes involved in β-oxidation 
such as CPT1A1 in NAFLD [156]. Although numerous studies report increased expression of 
PPARα in fatty liver disease, others are in accordance with our results observing unchanged or 
even less expression of PPARα in NAFLD [4, 48]. Polyphenols also had little effect on PPARα 
expression in the current study, in contrast to some studies in rodents fed polyphenols with a high-
fat diet [95, 243]. Some polyphenols such as cyanidin may be an agonist and a natural ligand for 
different PPARs [245], and therefore may affect PPAR activity without affecting expression. 
In the current study, treatment of HepG2 hepatocytes with oleic acid significantly decreased 
PPARγ expression while several polyphenols except anthocyanins reversed this inhibition. PPARγ 
induces genes involved in lipid uptake and adipogenesis [157]. While most evidence shows that 
PPARγ expression increases in diabetic or obesity models of NAFLD [159] and suggest a 
deleterious and lipogenic role for hepatic PPARγ in NAFLD [272, 273], others suggest a beneficial 
role for PPARγ [160, 161] . While some studies show that treatment of rodents on an obesogenic 
high-fat diet with polyphenols decreases PPARγ expression in NAFLD [48, 188], others are 
consistent with our study and showed higher hepatic expression of PPARγ by polyphenols favoring 
improved hepatic insulin signaling and decreased hepatic steatosis [274]. Therefore, enhanced 
expression of PPARγ in hepatocytes by polyphenols in our study may be a beneficial outcome in 
protection against NAFLD. However, more studies are needed to elucidate the controversial role 
of PPARγ in NAFLD.  
In the current study, oleic acid induced FAS. Fatty acid synthase (FAS) is an important enzyme in 
de novo lipogenesis which catalyzes the production of palmitic acid from malonyl-CoA [275]. In 
agreement with our findings, others found increased FAS in the liver of high fat-fed mice [276]. It 
was also shown by several researchers that the gene expression of FAS was increased in NAFLD 
patients [277], and FAS was suggested to be an intriguing therapeutic target for NAFLD [275]. 
We observed that several polyphenols prevented the increase in expression of FAS. Polyphenols 
have previously been reported to inhibit steatosis by decreasing mRNA and protein expression of 
FAS in HepG2 cells treated with oleic [37] or palmitic acid [270]. Although cyanidin decreased 
intracellular triglyceride in our study, it was unique in having no effect on both CPT1A1 and FAS, 
which suggests it may act through other mechanisms.  
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Other aspects of NAFLD and lipid metabolism that we investigated in the current study are those 
of mitochondrial biogenesis and energy metabolism. Numerous studies have shown that 
mitochondrial biogenesis is decreased in fatty liver disease and fewer mitochondria are available 
in hepatocytes to metabolize excess fat [19]. Increasing mitochondrial biogenesis can therefore be 
a promising approach in prevention or treatment of NAFLD/NASH. Accordingly, the effects of 
oleic acid and polyphenols were investigated on several factors involved in mitochondrial 
biogenesis. The results showed that the expression of SIRT1 and SIRT3 and the activity of SIRT1 
were not changed following treatment of HepG2 cells with oleic acid. In contrast to our findings, 
lower protein expression of SIRT1 was reported in rodents with NAFLD [250, 278]. However, 
resveratrol, catechin, and berberine increased both gene expression and activity of SIRT1 in our 
study. Different polyphenols such as berberine [252] and resveratrol [248] have been shown to 
induce SIRT1 expression in different models of NAFLD and insulin resistance. Mitochondria are 
one of the main targets of sirtuins’ action (including SIRT1 and SIRT3) leading to the regulation 
of metabolism. SIRT1 induces mitochondrial biogenesis through the deacetylation of PGC1α and 
activation of AMPK (through the deacetylation of serine/threonine liver kinase (LKB1) which 
phosphorylates AMPK) and therefore increases fatty acid β-oxidation that may help alleviate 
NAFLD [178]. In addition to the induction of mitochondrial biogenesis and fatty acid β-oxidation, 
SIRT1 inhibits the transcription of all genes involved in lipogenesis [183, 184]. SIRT1-knockout 
mice showed lower fatty acid oxidation and higher hepatic steatosis [182]. Among polyphenols, 
resveratrol has been widely studied with regard to SIRT1 since resveratrol is a potent activator of 
SIRT1 [279]. In agreement with this property, among all the polyphenols of interest in our study, 
resveratrol showed the strongest effect on SIRT1 activity. Consistent with the results on SIRT1 
expression and activity, we found higher phosphorylation of threonine 172 on AMPK catalytic α 
subunit by the same polyphenols (resveratrol, catechin, and berberine). AMPK activation induces 
mitochondriogenesis in hepatocytes and leads to increased ATP-producing pathways such as β-
oxidation and glycolysis but reduces energy-consuming pathways such as lipogenesis and 
gluconeogenesis [280]. Interestingly, the same polyphenols (resveratrol, catechin, and berberine) 
as well as quercetin induced several genes involved in mitochondrial biogenesis (shown in 
CHAPTER 4). However, only kuromanin and berberine induced the deacetylation of PGC1α in 
the current study. PGC1α is a key protein downstream of AMPK and SIRT1 which is involved in 
mitochondrial biogenesis and is a promising factor in prevention of NAFLD [178]. PGC1α protein 
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can be activated by either phosphorylation by kinases (such as AMPK) or deacetylation by SIRT1. 
Since some polyphenols such as catechin had no effect on deacetylation of PGC1α but increased 
AMPK phosphorylation in our study, it may be that such polyphenols activate PGC1α by 
phosphorylation but not deacetylation. 
Treatment with oleic acid in the current study depolarized the mitochondrial membrane potential 
in HepG2 cells by approximately 50%. Recent investigations show collapsed mitochondrial 
membrane potential in NASH compared to fatty liver and it was suggested that a lower activity of 
the mitochondrial respiratory chain could play a major role in this collapse [4]. Depolarization of 
mitochondria has a critical role in initiation of apoptosis and cell death particularly in fatty liver 
disease [281]. The results of the current study show that polyphenols differ in preserving the 
mitochondrial membrane potential. Resveratrol, catechin, quercetin, and cyanidin protected 
against oleic acid-induced collapse of the mitochondrial membrane potential, while kuromanin and 
berberine were not effective. Consistent with our results, others have shown that different 
polyphenols such as curcumin [20] or punicalagin polyphenols found in pomegranate [265] can 
protect against free fatty acid-induced dissipation of the mitochondrial membrane potential. This 
protection was also shown by flavonoids from Rosa laevigata Michx fruit in rodents fed a high-fat 
diet [282]. Therefore, it appears that preserving the mitochondrial membrane potential may be one 
of the mechanisms by which polyphenols prevent progression of simple steatosis to NASH, since 
it is one of the hallmarks of cell survival and functionality of mitochondria. 
In order to further compare the effectiveness of different classes of polyphenols for protection 
against mitochondrial dysfunction, intracellular ATP stores were determined. Hepatic ATP stores 
become depleted in NASH due to impaired or reduced activity of mitochondrial respiratory 
complexes [149]. The cellular ATP levels are important in maintaining the integrity of hepatic 
tissue, and ATP depletion may result in hepatocellular injury [266]. Mitochondrial injury and 
dysfunction is considered as an important contributor of low hepatic ATP stores in NASH [151]. 
Although mitochondrial function in our study was affected by oleic acid due to collapsed 
mitochondrial membrane potential, and lower mitochondrial biogenesis and complex activity 
(discussed in CHAPTER 4), we could not observe any depletion of ATP stores in HepG2 cells 
grown in glucose medium for 24 and 72 h. Numerous studies have shown that when mitochondrial 
oxidative phosphorylation is impaired in the cells (particularly cancer cells), they rely on 
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glycolysis to compensate for their reduced mitochondrial-mediated ATP production [283]. 
Replacing glucose with galactose is a way to shift metabolic pathways toward oxidative 
phosphorylation which increases the sensitivity and responsiveness to mitochondrial dysfunction 
[283, 284]. Therefore, in order to bypass glycolysis and more appropriately elucidate the effect of 
mitochondrial dysfunction on ATP production, HepG2 cells were grown in galactose medium. In 
this medium, treatment with oleic acid for 72 h depleted ATP stores by more than 50% while 
treatment with most polyphenols maintained ATP stores. These results are consistent with other 
studies showing treatment of hepatocytes with free fatty acids depletes while polyphenols preserve 
ATP stores [20, 255]. Interestingly, the results on ATP are consistent with the results of the 
mitochondrial membrane potential in which resveratrol, quercetin, catechin, and cyanidin showed 
significant effects while kuromanin and berberine had no effect on preserving both mitochondrial 
membrane potential and ATP stores. Also, in both experiments oleic acid showed approximately 
50% inhibition. It appears that when grown on galactose, ATP stores are dependant on the 
mitochondrial membrane potential and by inhibiting oleic acid-induced dissipation of ΔΨm and 
mitochondrial dysfunction, the effect of polyphenols in this study allowed mitochondria to 
maintain intracellular ATP stores.  
Another interesting finding of the current study was decreased ATP stores by berberine in both 
glucose and especially galactose medium after 24h, in contrast with most polyphenols which 
increased ATP stores. A previous study [285] showed that treatment of 3T3-L1 adipocytes or L6 
myotubes with 5 µM berberine for 0.5 to 16 h, increased the AMP/ATP ratio concomitant with 
lower oxygen consumption and inhibition of mitochondrial function, which induced the 
phosphorylation and activation of AMPK and eventually lead to higher ATP contents. In support 
of this mechanism, 10 µM berberine in our study in HepG2 cells grown on glucose increased p-
AMPKαThr172, concomitant with a decline of ATP stores. Also, while most polyphenols protected 
against the oleic acid-induced decline in the mitochondrial membrane potential, berberine did not. 
When grown in galactose medium for 24 h, berberine worsened the depletion of ATP stores 
compared to oleic acid alone, while after 72 h this worsening was not evident (although it still did 
not protect). The sharp depletion of ATP stores by berberine in galactose medium after 24 h was 
not evident in glucose medium after the same time point since it is reported that berberine can 
increase glucose metabolism through glycolysis to produce ATP [285], which may have partially 
compensated. 
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Another interesting finding is the difference of the ATP stores between 24 h and 72 h incubation 
in glucose or galactose medium. In the cells grown in glucose medium, ATP stores increased in 
the cells exposed to oleic acid after 72 h compared to untreated cells, and treatment with 
polyphenols had no effect. One possible explanation is that the cells adapted to glucose metabolism 
for producing ATP after 72 h to compensate for mitochondrial dysfunction. In galactose medium 
however, ATP stores were depleted after 72 h of exposure to oleic acid showing that the cells 
cannot produce enough ATP due to the mitochondrial defect that was evident at this time point 
(since both galactose and oleic acid require mitochondrial metabolism for net ATP production).    
In conclusion, oleic acid induced steatosis, distorted HepG2 cell morphology, modulated the 
expression of genes involved in lipogenesis and fatty acid oxidation, and induced mitochondrial 
dysfunction evidenced by the mitochondrial membrane potential collapse and depleted ATP stores. 
Treatment with different polyphenols prevented these changes. Although they differed in the 
strength with which they affected different mechanistic pathways, the different polyphenols 
showed similar protection against intracellular steatosis and mitochondrial dysfunction.  
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3.5. Transition to CHAPTER 4 
In CHAPTER 3, we focused on steatosis as the “first hit” of non-alcoholic fatty liver disease and 
how mitochondrial dysfunction may affect steatosis. We showed that oleic acid can induce 
steatosis and distort the morphology of HepG2 hepatocytes while all polyphenols of interest 
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showed similar protection. It was also shown that polyphenols can inhibit steatosis by modulating 
the expression of genes involved in lipogenesis and fatty acid oxidation. We also showed that oleic 
acid can induce mitochondrial dysfunction evidenced by collapse of the mitochondrial membrane 
potential and depletion of intracellular ATP stores while several polyphenols rescued these effects. 
Finally, the effects on different genes and proteins involved in metabolism such as SIRT1, SIRT3, 
AMPK, and PGC1α were evaluated. In the next chapter, we focus on oxidative stress and 
inflammation as the “second hits” of NAFLD, and their association with mitochondrial biogenesis 
and function and uncoupling protein 2. The expression of nuclear DNA-encoded mitochondrial 
complex I-V subunits has also been investigated.  
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CHAPTER 4: COMPARISON OF DIETARY POLYPHENOLS FOR PROTECTION 
AGAINST MOLECULAR MECHANISMS UNDERLYING NON-ALCOHOLIC FATTY 
LIVER DISEASE IN A CELL MODEL OF STEATOSIS 
 
Rafiei, H., Omidian, K., & Bandy, B. (2017). Comparison of dietary polyphenols for protection 
against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of 
steatosis. Molecular Nutrition & Food Research. doi: 10.1002/mnfr.201600781 
 
 
 
 
Abbreviations: 4-HNE, 4-hydroxynonenal; AMPK, AMP-activated protein kinase; ATP5F1, 
ATP synthase, mitochondrial Fo complex, subunit B1; ATP5G1, ATP synthase, mitochondrial Fo 
complex, subunit C1 (subunit 9); BSA, bovine serum albumin; COX6B1, cytochrome c oxidase 
subunit VIb polypeptide 1 (ubiquitous); DMSO, dimethyl sulfoxide; ETC, electron transport 
chain; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; MDA, malondialdehyde; Mn-
SOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; NAFLD, non-alcoholic 
fatty liver disease; NASH, non-alcoholic steatohepatitis; NDUFS8, NADH dehydrogenase 
(ubiquinone) Fe-S protein 8; NFκB, nuclear factor kappa b; NRF, nuclear respiratory factor; OA, 
oleic acid; OXPHOS, oxidative phosphorylation; PGC1α, peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha; ROS, reactive oxygen species; SDHb, succinate 
dehydrogenase complex, subunit B, iron sulfur; SOD, superoxide dismutase; TFAM, 
mitochondrial transcription factor A; TNFα, tumor necrosis factor alpha; UCP2, uncoupling 
protein 2; UQCRC1, ubiquinol-cytochrome c reductase core protein I; ΔΨ, mitochondrial 
membrane potential. 
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Abstract  
Scope: Dietary polyphenols have shown promise in protecting the liver against non-alcoholic fatty 
liver disease. The relative effectiveness and mechanisms of different polyphenols however is 
mostly unknown. 
Methods and results: In a cell model of steatosis using HepG2 hepatocytes, we evaluated the 
protective effects of different classes of polyphenols and the contributing mechanisms. Treatment 
of the cells with oleic acid increased ROS generation and mRNA expression of TNFα, decreased 
mRNA expression of UCP2 and decreased mitochondrial content and biogenesis (evidenced by 
MitoTracker Green and mRNA for PGC1α, NRF1 and mitochondrial complex I subunit 
NDUFS8). Treatment with 1-10 µM polyphenols (resveratrol, quercetin, catechin, cyanidin, 
kuromanin, berberine) all protected by more than 50% against the oleic acid-induced increase in 
ROS. Most of the polyphenols prevented the decrease in UCP2 mRNA, while several prevented 
the increase in TNFα mRNA, reversed decreases in mitochondrial biogenesis and increased 
expression of mitochondrial respiratory complexes and MnSOD. The anthocyanins were unique 
in decreasing ROS generation without inducing mitochondrial biogenesis or Mn-SOD mRNA 
expression. 
Conclusion: While different polyphenols similarly decreased cellular ROS in this model of 
steatosis, they differed in their ability to suppress TNFα expression and induce mitochondrial 
biogenesis and content.  
 
Keywords: non-alcoholic fatty liver disease, polyphenols, oxidative stress, mitochondrial 
biogenesis, respiratory proteins 
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4.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disease, affecting 10-35% of the 
general population in different communities [1] and 75% of obese patients with type 2 diabetes 
[286, 287]. NAFLD may result in serious complications such as non-alcoholic steatohepatitis 
(NASH), cirrhosis, and hepatocellular carcinoma. Among possible treatments, dietary polyphenols 
have been identified to offer a potential therapy for NAFLD and its progression to NASH [288, 
289].  
The leading hypothesis regarding development and progression of fatty liver disease is a ‘‘two-
hit’’ hypothesis [2]. This hypothesis suggests that hepatic accumulation of fats containing oleic 
acid [81] is the first hit which predisposes the liver to second hits such as oxidative stress and 
inflammation. Recently other second hits have been suggested to be involved, including insulin 
resistance and mitochondrial dysfunction [6, 290], which interplay in a concerted manner to 
exacerbate simple steatosis to steatohepatitis, cirrhosis, and fibrosis.  
Oxidative stress and inflammation are two “second-hits” that may be targeted by polyphenols. 
Oxidative stress has been demonstrated by numerous studies to have a central role in the liver 
damage and the progression of NAFLD to NASH and has been associated with depleted 
antioxidant activities [10]. Accordingly, maintaining redox homeostasis by polyphenol 
supplementation can be a possible strategy to prevent reactive oxygen species (ROS) production 
in NAFLD [250]. Inflammatory processes also have a major role in the liver damage and activation 
of collagen-producing hepatic stellate cells leading to fibrosis [21], and dietary polyphenols often 
show anti-inflammatory effects [289].  
Mitochondrial dysfunction is another aspect that could be targeted in therapies involving 
polyphenols. An accumulating body of evidence suggests NAFLD as a mitochondrial disease due 
to the abnormality in function and morphology of hepatic mitochondria [10, 11, 103, 152]. 
Correspondingly, mitochondrial dysfunction is correlated with the severity of the disease and its 
progression to NASH [12]. This involvement is due to the pivotal role of mitochondria in lipid 
metabolism, lipid peroxidation, ROS generation, cytokine production and apoptosis [13]. 
Polyphenols such as resveratrol have been observed to stimulate mitochondrial biogenesis in 
different tissues in a variety of dietary studies [251, 291]. 
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There are many studies on NAFLD in animal models or in vitro showing beneficial effects of 
polyphenols, including effects on oxidative stress [48, 226], inflammation [48, 270], steatosis [45, 
46, 241, 292], and mitochondrial biogenesis [20, 291]. However, most are with a single polyphenol 
or food source, so a major question might be which polyphenols are more effective and by what 
mechanisms. Therefore, in an in vitro model of steatosis we compared the effects of different 
classes of polyphenols on ROS generation, TNFα production, and mitochondrial biogenesis to 
explore the molecular mechanisms underlying NAFLD. 
4.2. Materials and Methods 
4.2.1. Materials 
Dichloro-dihydrofluorescein diacetate (DCFH-DA) was purchased from Sigma-Aldrich, USA. 
Malvidin and delphinidin were from Extrasynthese, France. MitoTracker Green was from 
Invitrogen, USA. For the rest of materials see section 3.2.1. 
4.2.2. HepG2 cells culture condition 
See section 3.2.2. 
4.2.3. Treatment with oleic acid/BSA and polyphenols 
See section 3.2.3. 
4.2.4. Measurement of intracellular total ROS    
Intracellular ROS was determined using 2’,7’-dichloro-dihydrofluorescein diacetate (DCFH-DA) 
according to the manufacturer’s protocol (Sigma-Aldrich, USA). DCFH-DA is a cell-permeant 
non-fluorescent probe. Following cleavage of the acetate moieties of DCFH-DA by intracellular 
deacetylases and consequently being trapped inside the cells, reactive oxygen species oxidize 
DCFH to DCF (2’,7’-dichlorofluorescein) which is highly fluorescent. Therefore, the intensity of 
DCF fluorescence is proportional to intracellular total ROS. HepG2 cells at 3×104 per well were 
cultured in black 96-well optical-bottom plates for 24 h in MEM medium containing 10% FBS. 
After 24 h, the old medium was replaced with fresh medium containing 10% FBS and 1% fatty 
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acid-free bovine serum albumin and the cells were pre-treated with different concentrations of 
polyphenols (1, 5, 10 µM) for 2 h (polyphenols were not removed thereafter and the cells were 
incubated with them for the next 24 h) followed by treatment with 1.5 mM oleic acid for 24 h. 
After 24 h, the old medium was removed and the cells were exposed to fresh medium (without 
FBS) containing DCFH-DA at 25 µM final concentration. H2O2 at 100 µM final concentration 
was used as positive control. After incubating with DCFH-DA for 20-30 min at 37oC, mean 
fluorescence of 9 different spots of each well was measured using a microplate reader at excitation 
485 nm and emission 528 nm. Fluorescence images were captured using a ZOE Fluorescent 
Imager. 
4.2.5. RT-qPCR 
See section 3.2.6. Sequences of primers of interest are shown in appendix (Table 7.2). 
4.2.6. Measurement of mitochondrial content using MitoTracker Green  
To determine mitochondrial content (mitochondrial biogenesis), HepG2 hepatocytes were labelled 
with a mitochondria-specific dye, MitoTracker Green according to the manufacturer’s protocol 
(Invitrogen, USA). Initially non-fluorescent in aqueous solutions, and insensitive to the 
mitochondrial membrane potential (ΔΨ), MitoTracker Green becomes highly fluorescent 
following accumulation in the mitochondrial lipid compartment [293]. Following passive diffusion 
across mitochondrial membrane, MitoTracker Green accumulates inside metabolically active 
mitochondria and labels mitochondria due to its mildly thiol-reactive chloromethyl moiety. 
Accordingly, resultant fluorescence is proportional to a cell’s mitochondrial number. Briefly, 
3×104 HepG2 cells were seeded per well. After 24 h, the old medium was replaced with fresh 
medium containing 1% fatty acid free bovine serum albumin and cells were pre-treated with 10 
µM polyphenols for 2 h followed by treatment with oleic acid for 24 h. After 24 h, the old medium 
was removed and cells were exposed to 100 nM final concentration of MitoTracker Green 
dissolved in medium (without FBS) and the plate was covered and incubated in 37oC for 20-30 
min. After incubation, the medium containing probe was removed and the cells were carefully 
washed 2-3 times with PBS and mean fluorescence of 9 different spots of each well was measured 
using a microplate reader at excitation 485 nm and emission 528 nm. Fluorescence images were 
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captured using a ZOE Fluorescent Cell Imager. 
4.2.7. Statistical analysis 
See section 3.2.12. 
4.3. Results 
4.3.1. Effects of oleic acid and polyphenols on ROS generation in HepG2 cells 
Treatment of HepG2 cells with 1.5 mM oleic acid for 24 h significantly increased ROS generation 
by 127% (Figure 4.1). All polyphenols at different concentrations (1, 5, 10 µM) except delphinidin 
(5, 10 µM) significantly decreased ROS generation. Compared to the oleic acid alone condition, 
cyanidin-3-glucoside (kuromanin) was the strongest polyphenol and at 10 µM decreased ROS by 
approximately 77%. Delphinidin inhibited significantly at 1 µM, but at 5 and 10 µM was unable 
to significantly prevent ROS generation.  
Fluorescence images of intracellular ROS captured by a ZOE Fluorescent Cell Imager are shown 
in the Appendix (Figure 7.1).  
Figure 4. 1. Effects of polyphenols on intracellular ROS production. 
UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Mal: malvidin, Del: delphinidin, Ber: berberine. Comparison of different classes of 
dietary polyphenols at 1, 5, and 10 µM on oleic acid-induced ROS generation. H2O2 at 100 µM 
was used as positive control. Untreated cells were set at 100% and the data are presented as % of 
the untreated cells. The figure represents means ± SEM of 3 independent experiments with 3 
replicate wells in each experiment. (*) Significantly different from the oleic acid alone condition 
(P<0.05). 
 
 
4.3.2. Effects of oleic acid and polyphenols on mitochondrial content 
Evaluating mitochondrial number by MitoTracker Green shows that oleic acid significantly 
decreased mitochondrial content in hepatocytes by 21 % and some of the polyphenols protected 
against this reduction (Figure 4.2 and 4.3). The strongest compound was berberine followed by 
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quercetin and resveratrol which reversed oleic acid-induced inhibition of mitochondrial content to 
levels higher than control cells. Anthocyanins along with catechin had no significant effect on 
mitochondrial content. 
 
Figure 4. 2. Fluorescence images of HepG2 cells showing mitochondrial content. 
The images were captured using a ZOE Fluorescent Cell Imager at 20x magnification after staining 
the cells with MitoTracker Green. Higher green fluorescence represents a higher number of 
mitochondria. 
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Figure 4. 3. Comparison of polyphenols on mitochondrial content after quantification of 
MitoTracker Green fluorescence using a microplate reader. 
(UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine). Untreated cells were set at 100% and the data are presented as % of 
the untreated cells. The figure represents means ± SEM of 3 independent experiments with 3 
replicate wells in each experiment. (*) Significantly different (P<0.05) from the oleic acid alone 
condition. 
4.3.3. The effect of oleic acid and polyphenols on the expression of genes of interest 
4.3.3.1. The effect on uncoupling protein 2 (UCP2)  
Figure 4.4a shows UCP2 mRNA after treatment with 10 µM different polyphenols for 2 h and 1.5 
mM oleic acid for 24 h. Oleic acid significantly inhibited UCP2 mRNA expression by 37%. 
Catechin, quercetin, cyanidin and kuromanin significantly reversed oleic acid-induced inhibition 
of UCP2 expression by more than 100%. Resveratrol and berberine did not rescue UCP2 
expression. 
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Figure 4. 4. Comparison of dietary polyphenols on mRNA expression of UCP2 (a), Mn-SOD 
(b), and TNFα (c) after treatment of HepG2 hepatocytes with 10 µM polyphenols for 2 h and 
1.5 mM oleic acid for 24 h. 
(UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine). Untreated cells were set at 100% and the data are presented as % of 
the untreated cells. The bars represent means ± SEM of 2 independent experiments with 3 replicate 
wells in each experiment. (*) Significantly different (P<0.05) from the oleic acid alone condition. 
4.3.3.2. The effect on mitochondrial manganese superoxide dismutase (Mn-SOD) 
Oleic acid alone had no significant effect on Mn-SOD expression (Figure 4.4b). Catechin, 
quercetin and resveratrol significantly increased Mn-SOD expression by 40, 39, and 35%, 
respectively compared to oleic acid alone. The anthocyanins and berberine had no significant 
effect on Mn-SOD expression. 
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4.3.3.3. The effect on the expression of TNFα  
Oleic acid elevated mRNA expression of TNFα by 147% while polyphenols could prevent this 
induction (Figure 4.4c). Resveratrol, berberine, catechin, and quercetin inhibited oleic acid-
induced TNFα expression by 98, 94, 75, and 60%, respectively. Anthocyanins (cyanidin and 
kuromanin) did not give any inhibition. 
4.3.3.4. The effects on genes involved in mitochondrial biogenesis (PGC1α, NRF1, TFAM) 
Oleic acid alone significantly inhibited PGC1α mRNA expression by 21% while berberine, 
resveratrol, quercetin, and catechin induced its expression by 84, 63, 42, and 37% compared to 
control cells, respectively (Figure 4.5). Moreover, oleic acid significantly decreased NRF1 mRNA 
expression by 26% and different polyphenols such as catechin, berberine, and quercetin 
significantly increased NRF1 expression by 66, 43, and 40% respectively compared to oleic acid 
alone. Additionally, while treatment with oleic alone had no significant effect on TFAM mRNA 
expression, berberine, catechin, and resveratrol significantly induced TFAM expression by 77%, 
71%, and 71% compared to oleic acid alone. Anthocyanins such as cyanidin and kuromanin were 
unique in having no significant effect on the expression of genes involved in mitochondrial 
biogenesis.  
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Figure 4. 5. Comparison of dietary polyphenols on mRNA expression of genes involved in 
mitochondrial biogenesis. 
(UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine). Untreated cells were set at 100% and the data are presented as % of 
the untreated cells. The bars represent means ± SEM of 2 independent experiments with 3 replicate 
wells in each experiment. (*) Significantly different from the oleic acid alone condition at P<0.05.  
4.3.3.5. The effects on mRNA for nuclear DNA-encoded mitochondrial respiratory complex 
subunits 
The effect of oleic acid and polyphenols on mRNA expression of nuclear DNA-encoded 
mitochondrial complex subunits is shown in Figure 4.6. While oleic acid alone significantly 
decreased mRNA expression of mitochondrial respiratory complex I subunit (NDUFS8) by 49 % 
compared to untreated cells, all polyphenols except cyanidin protected against this inhibition and 
in most cases increased the expression to the level more than untreated cells. Oleic acid alone had 
no significant effect on mRNA expression of SDHb (complex II subunit), mitochondrial complex 
III (UQCRC1), or IV (COX6B1) mRNA expression. Among polyphenols, only berberine increased 
expression of SDHb (by 81 %), while treatment with catechin, resveratrol and cyanidin 
significantly increased UQCRC1 expression (by 58, 46, and 45%, respectively), and berberine and 
catechin were able to significantly increase COX6B1 expression (by 34 and 31%, respectively). 
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While oleic acid alone significantly inhibited the expression of complex V subunit (ATP5G1) by 
29%, no polyphenol protected against this inhibition (Figure 4.6).  
 
Figure 4. 6. Comparison of dietary polyphenols on mRNA of nuclear DNA-encoded 
mitochondrial respiratory complex subunits after treatment of HepG2 hepatocytes with 10 
µM polyphenols for 2 h and 1.5 mM oleic acid for 24 h. 
(UT: untreated, OA: oleic acid, Res: resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: 
kuromanin, Ber: berberine). Untreated cells were set at 100% and the data are presented as % of 
the untreated cells. The bars represent means ± SEM of 2 independent experiments with 3 replicate 
wells in each experiment. (*) Significantly different from oleic acid alone condition at P<0.05. 
4.3.4. Correlation results 
In order to evaluate the relationship between different parameters involved in the progression of 
fatty liver disease, a set of correlation studies have been performed by Pearson’s R. Intracellular 
triglyceride had a high inverse correlation with mitochondrial membrane potential (r=-0.6, 
P<0.001) (Figure 4.7A). A fairly high inverse correlation was also found between ROS and TNFα 
with the mitochondrial membrane potential (r=-0.5, P<0.001; r=-0.43, P=0.003) representing 
along with accumulation of fat, higher oxidative stress and inflammation may result in 
mitochondrial dysfunction. A fairly high positive correlation was found between the expression of 
mitochondrial biogenesis markers such as SIRT1, PGC1α, and TFAM with CPT1A1 (r=0.48, r=0.5, 
and r=0.48, respectively) suggesting increased fatty acid oxidation concomitant with increased 
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mitochondrial number (Figure 4.7B). The gene expression of NDUFS8 (mitochondrial complex I 
subunit) was also positively correlated with the expression of CPT1A1 (r=0.56, P<0.001) showing 
higher mitochondrial activity leads to increased oxidation of excess fat in mitochondria (Figure 
4.7C). PGC1α expression was positively correlated with the expression of mitochondrial 
superoxide dismutase (Mn-SOD) (r=0.4, P=0.005) suggesting higher antioxidant defense along 
with elevated mitochondrial biogenesis (Figure 4.7D). An inverse correlation was also found 
between mRNA for mitochondrial biogenesis markers (PGC1α and NRF1) and TNFα (r=-0.54, 
r=-0.48, respectively) suggesting decreased inflammation along with elevated mitochondrial 
biogenesis (Figure 4.7E). There was also an inverse correlation between mRNA expression of 
UCP2 and ROS generation (r=-0.42, P=0.003) showing reduced level of ROS along with elevated 
uncoupling effect of UCP2 (4.7F). Finally, gene expression of complex I and III subunits 
(NDUFS8 and UQCRC1) was negatively correlated with expression of TNFα (r=-0.44, P=0.003, 
and r=-0.45, P=0.002 respectively) showing reduced inflammation along with increased 
mitochondrial activity (Figure 4.7G & H). 
 
Figure 4. 7. Correlations between different parameters of interest. 
These correlations are based on the results previously shown in figure 3.4 to 4.6. 
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4.4. Discussion 
Oxidative stress and inflammation have been suggested to accelerate the progression of simple 
steatosis to NASH [2]. Therefore, we compared the preventive effects of different classes of 
polyphenols on these stressors (hits) in an in vitro model of steatosis. We showed that 1.5 mM 
oleic acid significantly induced ROS generation in HepG2 cells (by 127%). Zhang et al. previously 
showed that oleic acid at 1 mM could increase ROS generation in HepG2 cells by 80% making it 
an effective stress to simulate oxidative stress found in fatty liver disease [292]. The higher 
concentration of oleic acid (1.5 mM) in our study gave a slightly greater increase in ROS 
generation (127%) compared to the previous study. Moreover, we found that oleic acid increased 
the expression of the inflammatory cytokine TNFα. In line with this finding, Liu et al. observed 
that 1.5 mM oleic acid, but not lower doses increased release of the liver inflammation markers 
ALT and AST, as well as ROS levels in HepG2 cells [88]. Together the results suggest that this 
model can be an effective in vitro model for studying molecular mechanisms underlying NAFLD, 
due to increased oxidative stress and inflammation. 
All of the tested polyphenols strongly inhibited oleic acid-induced ROS generation. One reason 
that they decreased ROS generation may have been direct antioxidant activities [227]. However, 
we also found increased expression of the antioxidant enzyme MnSOD by some polyphenols 
(resveratrol, catechin, and quercetin) and of the ROS-decreasing enzyme UCP2 in hepatocytes 
which may further explain the ROS-reducing effect of these compounds. Together these 
mechanisms resulted in decreased intracellular ROS, which by contribution to the cellular 
oxidative stress as one of the “second-hit” mechanisms may facilitate to progression of NAFLD 
to NASH [2]. In NAFLD, excess fatty acids are oxidized resulting in increased ROS generation. 
This increased ROS can result in mitochondrial dysfunction which increases hepatic steatosis in 
the liver, and this vicious circle finally leads to cirrhosis and hepatocellular carcinoma [294]. 
Therefore, our results show that by suppressing ROS generation in hepatocytes, polyphenols have 
the potential to break this vicious circle and to prevent mitochondrial dysfunction. Another study 
[292] was in agreement with our results showing polyphenol inhibition of ROS generation in 
HepG2 hepatocytes. In this study, different flavonoids had different potencies in inhibiting oleic 
acid-induced ROS generation and triglyceride accumulation. The potency was not clearly related 
to the extracellular radical-reducing potential of the flavonoid. This previous study included two 
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of the flavonoids in the current study (catechin and quercetin), but not anthocyanins or other 
polyphenols such as resveratrol described herein.  
Delphinidin was unique in showing lower protection with increasing concentration from 1 to 10 
µM. This effect may be due to higher concentrations producing more prooxidant activity [295]. 
Due to having three hydroxyl groups in the B-ring, delphinidin would have a lower reduction 
potential than the other flavonoids and be more easily oxidized by molecular oxygen (catalyzed 
by metals in the cell culture medium) to produce ROS.  
Another “second-hit” that we investigated in HepG2 cells was inflammation. The results showed 
strong oleic acid-induced TNFα expression and inhibition by the polyphenols (except cyanidin and 
kuromanin). An accumulating body of evidence shows that NAFLD-associated ROS and lipid 
peroxidation aldehydes (MDA and 4-HNE) result in increased release of cytokines such as TNFα 
and Fas ligand which play a major role in inflammation, cell death and fibrosis [13, 105]. Increased 
release of TNFα by hepatocytes, adipocytes and Kupffer cells (residing macrophages in liver) 
results through the activation of NFκB by ROS (reviewed in [296]) and may contribute to the 
severity of mitochondrial dysfunction seen in NASH patients [105]. Elevated levels of hepatic 
TNFα expression was reported in obese patients with NAFLD, and the level of TNFα was 
correlated with advanced hepatic fibrosis in these patients [135]. Other studies in experimental 
models of NAFLD have shown benefits of polyphenols against inflammation. In line with our 
result, treating HepG2 cells with oleic acid was previously shown to induce mRNA expression of 
TNFα by more than 2.5 fold, and quercetin at 10 µM was effective in its inhibition [35]. In studies 
on animals fed a high-fat diet, dietary quercetin inhibited hepatic steatosis and decreased the liver 
and plasma levels of the pro-inflammatory cytokines TNFα and IL-6 [48, 250].  
Because mitochondrial dysfunction is a major factor in NAFLD and progression to NASH [6], we 
investigated the effects of oleic acid and polyphenols on mitochondrial expression in the HepG2 
cell model. In the present study, we observed decreased mitochondrial biogenesis in HepG2 cells 
exposed to oleic acid, shown by decreased MitoTracker fluorescence, decreased expression of the 
mitochondrial biogenesis transcription factors PGC1α and NRF1, and decreased expression of the 
respiratory complex I and V subunits NDUFS8 and ATP5G1. An accumulating body of evidence 
reports that mitochondrial number and function are decreased in subjects with obesity and diabetes 
[19, 297] which are the major contributors of NAFLD/NASH. In line with our results, Koliaki et 
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al. also reported decreased hepatic mRNA expression of PGC1α, NRF1, and TFAM in patients 
with NAFLD and NASH [298]. Reduced number of hepatic and muscle healthy mitochondria 
result in reduced β-oxidation of fatty acids while producing more ROS.  
Other studies support that a high-fat diet decreases expression of mitochondrial respiratory 
complex proteins. In one study [299], feeding an isocaloric high-fat diet decreased expression of 
nuclear-encoded mitochondrial complex subunits in the skeletal muscle of rodents and humans. In 
a previous study on non-alcoholic steatohepatitis in mice [17], the authors found that the activity 
of all of the mitochondrial respiratory complexes in the liver was reduced by 50-60% by a high-
fat diet and this decline was particularly due to the decreased gene expression of mitochondrial 
DNA-encoded subunits. Those authors also found that due to the protection of vulnerable 
mitochondrial DNA against ROS, administration of antioxidants such as MnTBAP (a superoxide 
dismutase mimetic) and uric acid was effective to reverse these effects induced by high-fat diet. 
In the present study, we also show that most polyphenols increased mitochondrial content along 
with increased expression of genes involved in mitochondrial biogenesis (PGC1α, NRF1, and 
TFAM) to levels more than in control cells. The anthocyanins (cyanidin and kuromanin) however 
had no effect on mitochondrial biogenesis. This could be because anthocyanins, unlike other 
polyphenols such as resveratrol, reportedly have no direct effect on SIRT1 activity [279], which 
is shown to be one of the most important regulators of mitochondrial biogenesis by activating 
AMPK and PGC1α [178]. In agreement with our findings, resveratrol has been found to reverse 
the inhibition of mitochondrial biogenesis in the liver of mice fed a high-calorie high-fat diet [291]. 
Gomes et al. also observed that berberine could protect against high fat diet-induced inhibition of 
PGC1α and TFAM gene expression in the muscle of rats [252]. 
Interestingly, catechin induced the expression of genes involved in mitochondrial biogenesis 
without an effect on mitochondrial mass. One explanation may be that catechin increased 
mitochondrial differentiation more than mitochondrial replication. Mitochondrial differentiation 
affects pre-existing mitochondria and improves mitochondrial function by expanding the 
mitochondrial inner membrane with more cristae and increasing expression of mitochondrial 
proteins such as the respiratory complex subunits [141, 300]. Although having no effect on 
mitochondrial mass, catechin induced the expression of mitochondrial respiratory complex I, III, 
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and IV subunits. Accordingly, catechin appeared to have a more distinct effect on mitochondrial 
differentiation.   
Defective mitochondrial oxidative phosphorylation (OXPHOS) is reported in the liver of subjects 
with NASH [14], as well as in several models of NAFLD, including HepG2 hepatocytes treated 
with palmitate [15], obese ob/ob mice with NAFLD [16], and mice fed a high-fat diet [17]. It was 
suggested that a decrease in mitochondrial biogenesis (decreased number of healthy and functional 
mitochondria) and impaired expression and assembly of mitochondrial respiratory complex 
subunits may result in increased ROS production which is one of the main contributors to NAFLD 
[19]. Therefore, improving mitochondrial function and electron flow in the mitochondrial electron 
transport chain may be of vital importance to prevent ROS generation in NAFLD. We found that 
oleic acid inhibited complex I and V subunits (NDUFS8 and ATP5G1) expression. Importantly 
complex I is the entry point of electrons to the mitochondrial respiratory chain. Most polyphenols 
could protect against this inhibition and in many cases increased the expression of NDUFS8 to 
significantly more than control cells. Our present study suggests that in opposition to increased 
load of NADH and electrons to enter the mitochondrial electron transport chain (ETC) in fatty 
liver disease, polyphenols induce the expression of subunits of mitochondrial complexes to 
increase the flow of electrons, which may lead to increased fat oxidation and decreased ROS 
generation. 
We found a significant positive correlation between PGC1α and Mn-SOD mRNA expression, 
suggesting that this effect could be due to increased mitochondrial biogenesis and number by 
PGC1α. Additionally, PGC1α has been shown to have a major role in regulating ROS removal by 
inducing antioxidant defense such as glutathione peroxidase, SOD, and catalase [145, 301].  
The mitochondrial enzyme UCP2 is another enzyme implicated in mitochondrial ROS generation 
and fatty acid β-oxidation. In the present study, we found 37% decreased expression of UCP2 by 
oleic acid, while most polyphenols prevented this decrease. UCP2 is localized in the inner 
mitochondrial membrane and uncouples oxidative phosphorylation from ATP production [302], 
resulting in decreased electrochemical potential (ΔΨ) and decreased production of mitochondrial 
ROS [90, 303]. Studies report that even small changes in ΔΨ can have an order of magnitude effect 
in decreasing mitochondrial ROS generation [304]. In agreement with this connection we found 
an inverse correlation between UCP2 expression and ROS generation.  
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In line with our results with polyphenols, other evidence suggests that dietary polyphenols (such 
as resveratrol, and the flavonoid naringenin) can induce the hepatic expression of UCP2 in rats fed 
a high-fat or high-sucrose diet, alleviating NAFLD [171, 305]. In addition to decreasing ROS, 
induction of UCP2 expression by polyphenols can protect against NAFLD by increasing fatty acid 
β-oxidation [166] and export of toxic hydroperoxy fatty acids out of mitochondria [306]. 
Accordingly, due to these beneficial outcomes it is suggested that pharmacological induction of 
UCP2 can be a novel treatment for NAFLD [171].  
We also found a significant inverse correlation between PGC1α and TNFα in our study, suggesting 
that increased mitochondrial biogenesis is paralleled with decreased inflammation. In agreement 
with our findings other studies also show that PGC1α is inversely correlated with the expression 
of inflammatory markers. For instance, muscle-specific PGC1α knock-out animals show increased 
gene expression of TNFα, IL6 and other inflammatory markers in their muscle tissue [307]. 
Moreover, it was shown that genetic ablation of PGC1α in primary muscle cells induces mRNA 
expression of TNFα and IL6 while adenovirus-mediated expression of PGC1α in cultured 
myotubes reduced the expression of these inflammatory genes [307]. Although the molecular 
mechanisms by which PGC1α inhibits inflammation have not been identified, it is suggested that 
suppressed ROS generation by PGC1α may have a key role since oxidative stress and 
inflammation go together in pathological conditions such as NASH [308]. Interestingly, the gene 
expression of complex I and III subunits NDUFS8 and UQCRC1 was also negatively correlated 
with the expression of TNFα. It can be interpreted that increased flow of electrons in the 
mitochondrial electron transport chain due to increased activity of complexes I and III decreases 
the leak of electrons from these complexes which finally inhibits ROS production and 
inflammation. 
In conclusion, dietary polyphenols of different classes were similarly effective in decreasing oleic 
acid-induced ROS generation in human hepatocytes. As part of the mechanism all polyphenols 
except anthocyanins increased mitochondrial biogenesis and the expression of mitochondrial 
respiratory complex subunits. Figure 4.8 schematically represents how polyphenols may inhibit 
ROS production, decrease inflammation, and improve mitochondrial biogenesis and function in 
HepG2 cells exposed to oleic acid. 
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Figure 4. 8. Schematic representing the mechanisms by which polyphenols inhibit ROS 
production, inflammation, and improve mitochondrial biogenesis and function. 
Oleic acid inhibited mitochondrial biogenesis by blunting the expression of PGC1α and NRF1. 
However, polyphenols induced mitochondrial biogenesis in HepG2 cells leading to overexpression 
of the antioxidant enzyme Mn-SOD which further suppresses ROS production. Reduced ROS 
production by polyphenols in turn decreases TNFα expression and prevents inflammation. 
Polyphenols also protected against oleic acid-induced decrease of mitochondrial complex I subunit 
expression and increased the expression of complex III and IV subunits which may help flow of 
electrons. This flow of electrons most likely inhibits the leakage of electrons from complex I and 
III resulting in decreased ROS production. Polyphenols also reversed oleic acid-induced decrease 
of UCP2 expression which by facilitating import of H+ to the mitochondrial matrix suppresses 
ROS production and may improve flow of electrons in the electron transport chain.  
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4.5. Transition to CHAPTER 5 
So far, the effects of polyphenols were investigated in HepG2 cells on oleic acid-induced steatosis, 
oxidative stress, inflammation, and mitochondrial biogenesis and dysfunction (Chapters 3 and 4). 
Since endoplasmic reticulum stress is also involved in progression of fatty liver disease to NASH, 
we hypothesised that some polyphenols protect against endoplasmic reticulum stress (3rd 
hypothesis). In line with other studies however, oleic acid did not induce ER stress in HepG2 cells 
(Appendix, Figure 7.2). But my preliminary studies showed that the saturated fatty acid palmitic 
acid can induce ER stress in HepG2 cells. Therefore, in the next chapter the effects of polyphenols 
were investigated on concomitant ER stress (3rd hypothesis) and mitochondrial dysfunction 
induced by palmitic acid. 
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CHAPTER 5: PROTECTION BY DIFFERENT CLASSES OF DIETARY 
POLYPHENOLS AGAINST PALMITATE-INDUCED MITOCHONDRIAL 
DYSFUNCTION AND ENDOPLASMIC RETICULUM STRESS IN HEPG2 
HEPATOCYTES 
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AMPK, AMP-activated protein kinase; ATP5G1, ATP synthase, mitochondrial Fo complex, 
subunit C1 (subunit 9); CCCP, carbonyl cyanide 3-chlorophenylhydrazone; CHOP, CCAAT-
enhancer-binding protein homologous protein; COX6B1, cytochrome c oxidase subunit VIb 
polypeptide 1 (ubiquitous); EDEM1, ER degradation enhancing alpha-mannosidase like protein 
1; ER, endoplasmic reticulum; ERdj4, endoplasmic reticulum DnaJ homolog 4; GADD34, growth 
arrest and DNA damage-inducible protein; GRP78, 78 kDa glucose-regulated protein; iNOS, 
inducible nitric oxide synthase; MTATP6, mitochondrial DNA-encoded ATP synthase Fo subunit 
6; MTCO1, mitochondrially encoded cytochrome c oxidase I; MTCYB, mitochondrial DNA-
encoded subunit of respiratory Complex III; MTND1, mitochondrially encoded 
NADH:ubiquinone oxidoreductase core subunit 1; NADH dehydrogenase subunit 1; NAFLD, 
non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NDUFS8, NADH 
dehydrogenase (ubiquinone) Fe-S protein 8; NFκB, nuclear factor kappa b; ORP150, 150-kDa 
oxygen-regulated protein; p-eIF2α, phosphorylated eukaryotic translation initiation factor 2; 
PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; p-PERK, 
phosphorylated PKR-like ER-resident kinase; SIRT1, sirtuin 1; UPR, unfolded protein response; 
UQCRC1, ubiquinol-cytochrome c reductase core protein I. 
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Abstract 
Scope: Mitochondrial dysfunction and endoplasmic reticulum stress induced by dietary saturated 
fats have recently been implicated in the initiation and progression of NAFLD. Dietary 
polyphenols hold promise for the amelioration of NAFLD based on preventing steatosis and 
oxidative stress yet the mechanisms and effectiveness of different classes of polyphenols are 
largely unknown. Since, oleic acid was unable to induce ER stress (which is the main focus of this 
chapter), saturated palmitic acid was used as the stressor to investigate the protective effects of 
polyphenols on ER stress.  
Methods and results: In an in vitro model of steatosis using HepG2 hepatocytes, we investigated 
the effect of selected polyphenols (resveratrol, quercetin, catechin, cyanidin, kuromanin, and 
berberine) to abrogate the development of palmitic acid-induced steatosis, ROS production, 
mitochondrial impairments, and endoplasmic reticulum stress. Palmitic acid increased steatosis, 
increased intracellular ROS production, induced expression of iNOS and markers of endoplasmic 
reticulum stress, and decreased the mitochondrial membrane potential and markers of 
mitochondrial biogenesis. Treatment with different polyphenols prior to palmitic acid exposure 
protected against these effects, induced mRNA for nuclear and mitochondrial DNA-encoded 
respiratory complex subunits, and decreased expression of iNOS and genes responding to 
endoplasmic reticulum stress.  
Conclusion: Together the results show that different polyphenols all similarly protected against 
steatosis and oxidative stress induced by palmitic acid in HepG2 cells, but differed in mitigating 
adverse effects of palmitic acid on ER stress, the mitochondrial membrane potential, and 
mitochondrial biogenesis.  
 
Keywords: Non-alcoholic fatty liver disease, polyphenols, endoplasmic reticulum stress, ER 
chaperones, mitochondrial defect  
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5.1. Introduction 
Diets high in saturated fats have been widely implicated in the development of nonalcoholic fatty 
liver disease (NAFLD) [309, 310]. Palmitic acid is the most prevalent saturated fatty acid found 
in triglycerides of meats and dairy products, as well as in palm oils that are widely used by the 
food industry. Upon consumption of saturated fats, the liver is exposed to high levels of palmitic 
acid that can contribute to NAFLD. 
NAFLD is a public health burden with clinical and histological abnormalities that can progress to 
non-alcoholic steatohepatitis (NASH), cirrhosis, and fibrosis [54]. Besides hepatic fat 
accumulation, other hits such as oxidative stress and inflammation [2], mitochondrial dysfunction 
[4-6] and endoplasmic reticulum stress [7, 8] have been suggested to interplay in a concerted 
manner to cause progression of simple steatosis to NASH. A higher ratio of saturated to 
unsaturated fatty acids stored in the liver may contribute to the progression of NAFLD to NASH 
[311]. Although the molecular mechanisms by which saturated fats contribute to this effect are 
still unclear, reactive oxygen species, inflammatory cytokines, and endoplasmic reticulum stress 
have been implicated.  Therefore, it is suggested that saturated fatty acids may produce intrinsic 
second hits which cause progression to NASH [311]. 
Excess hepatic fats undergo β-oxidation in the mitochondria and peroxisomes of hepatocytes 
leading to mitochondrial dysfunction and production of reactive oxygen species (ROS) [116]. ROS 
are major contributors to the progression of simple steatosis to necroinflammation [90]. 
Mitochondria are a major source of ROS in cells [120], particularly when they are dysfunctional 
such as in NAFLD [10]. An increased load of electron donors such as NADH and FADH2 to the 
mitochondrial electron transport chain during NAFLD can be beyond the capacity of the 
mitochondrial respiratory complexes (particularly due to reduced activity of complexes). This 
increased load in turn brings about the leakage of electrons from complex I and III and 
consequently elevates ROS production [105]. The increased mitochondrial ROS also impairs 
mitochondrial function and biogenesis and consequently decreases the number of healthy and 
functional mitochondria [19]. Therefore inducing mitochondrial biogenesis may be a therapeutic 
strategy in prevention and treatment of NAFLD by inducing fatty acid β-oxidation [267], and 
suppressing ROS production [301] and inflammation [307].  
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Besides ROS, reactive nitrogen species (RNS) produced by the activity of inducible nitric oxide 
synthase (iNOS) may also contribute to the pathogenesis of NAFLD [312]. Higher mRNA and 
protein expression of iNOS has been demonstrated in different models of NAFLD and NASH 
[313, 314]. Increased iNOS and tyrosine nitrated proteins in the liver of ob/ob mice [16] are 
suggested as some of the contributors to mitochondrial respiratory complex dysfunction. 
Endoplasmic reticulum (ER) stress has also been suggested to be one of the “multiple hits” 
involved in the progression of NAFLD to NASH [22]. Several studies have reported increased ER 
stress in hepatocytes treated with palmitic acid [26], or in animals [27, 28] and humans [29, 30] 
with hepatic steatosis. Lipogenesis and insulin resistance have been shown to be affected by ER 
stress [24, 191]. While short term activation of ER stress and the unfolded protein response (UPR) 
is essential for homeostasis of metabolism, prolonged ER stress and UPR have deleterious effects 
on metabolism and may result in increased hepatic lipid accumulation, inflammation, insulin 
resistance, impaired lipid metabolism, and apoptosis.   
Polyphenols found in various fruits and vegetables have been shown to protect against NAFLD. 
Dietary polyphenols have been shown to protect against hepatic steatosis [95], oxidative stress 
[47], inflammation [50], insulin resistance [315], and mitochondrial dysfunction [255] leading to 
protection against NAFLD. These features of polyphenols make them promising candidates for 
prevention and treatment of NAFLD. Although polyphenols have been the subject of many studies 
on prevention and treatment of NAFLD, it is not known which polyphenols are the most potent in 
improving mitochondrial function and by what mechanisms. Moreover, due to the lack of 
evidence, the effects of polyphenols on hepatic endoplasmic reticulum stress and the UPR in 
NAFLD are largely unknown.  
Using HepG2 hepatocytes treated with palmitic acid, we compared different classes of polyphenols 
concomitantly on mitochondrial dysfunction and ER stress and explored the contributing 
mechanisms of protection. Decreased expression of mitochondrial DNA-encoded respiratory 
complex subunits in HepG2 cells treated with palmitic acid has recently been observed [15]. Here 
we show that different classes of polyphenols similarly inhibit steatosis and ROS generation but 
differ in protection against palmitic acid-induced mitochondrial dysfunction and ER stress. 
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5.2. Materials and Methods 
5.2.1. Materials 
Palmitic acid was from Sigma-Aldrich, USA. The rest of the materials were as indicated in sections 
3.2.1 and 4.2.1. 
5.2.2. HepG2 cell culture conditions 
See section 3.2.2. 
5.2.3. Treatment with palmitic acid/BSA and polyphenols 
Palmitic acid was dissolved in dimethyl sulfoxide (DMSO) in order to prepare 300 mM stock and 
kept at -20°C for further use. HepG2 cells at 3×104 cells/well were cultured in 96-well optical-
bottom plates for 24 h. The old medium was then replaced with fresh medium containing 10% 
FBS and 1% fatty acid-free bovine serum albumin (BSA). One percent BSA was used to ensure 
the solubility of palmitic acid in the medium. HepG2 cells were then pre-treated with different 
polyphenols at 10 µM for 2 h. After treatment of the cells with polyphenols for 2 h (polyphenols 
were not removed thereafter and the cells were incubated with them for the next 24 h), cells were 
treated with 500 µM palmitic acid for 24 h.  
5.2.4. Measuring intracellular lipid content  
See section 3.2.4. The only difference is using 500 µM palmitic acid instead of oleic acid.  
5.2.5. Measurement of intracellular ROS   
See section 4.2.4. However, only one dose of polyphenols (10 µM) was used and oleic acid was 
replaced with 500 µM palmitic acid.  
5.2.6. Measurement of mitochondrial content using MitoTracker Green  
See section 4.2.6. The only difference is using 500 µM palmitic acid instead of oleic acid.  
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5.2.7. Measuring the mitochondrial membrane potential (ΔΨm) 
See section 3.2.11. The only difference is using 500 µM palmitic acid instead of oleic acid.  
5.2.8. Measuring mRNA expression using reverse transcriptase RT-qPCR 
See section 3.2.6. The only difference is using 500 µM palmitic acid instead of 1.5 mM oleic acid. 
Sequences of primers of interest are shown in the Appendix (Table 7.3). 
5.2.9. Statistical analysis 
Results were expressed as mean values with their standard error of means (SEM) for the number 
of experiments indicated. Results were analyzed using the Statistical Package for the Social 
Sciences (SPSS 22) (IBM, USA). One-way ANOVA was used initially, and when any significance 
detected, Dunnett’s post hoc test was used to compare the mean of each group with the palmitic 
acid alone condition. The level of significance was P<0.05. Correlation was determined by 
Pearson’s R. 
5.3. Results 
5.3.1. Intracellular lipid accumulation 
Fluorescence images of intracellular lipids using Nile Red staining are shown in Figure 5.1A. 
HepG2 cells treated with palmitic acid alone show higher red fluorescence compared to untreated 
cells representing higher intracellular lipids. The images also show that compared to the cells 
treated with palmitic acid alone, the intensity of fluorescence is lower in HepG2 cells treated with 
different polyphenols, showing that polyphenols protected against steatosis.  
Figure 5.1B shows quantitation of the fluorescence due to intracellular triglyceride accumulation 
measured by a microplate reader. Treating HepG2 cells with 500 µM palmitic acid increased 
intracellular triglyceride by 39%. All of the polyphenols significantly protected against lipid 
accumulation ranging from 70-150% inhibition. Cyanidin was the strongest polyphenol with 150% 
protection.  
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Figure 5. 1. The effect of polyphenols on palmitic acid-induced intracellular lipid 
accumulation. 
(A) Fluorescence images were captured using a ZOE Fluorescent Cell Imager at 20x magnification 
after staining HepG2 cells with Nile Red fluorescence probe. Higher red fluorescence represents 
higher fat content. (B) Intracellular lipids were quantified from Nile Red fluorescence using a 
microplate reader. (UT: untreated, PA: palmitic acid, Res: resveratrol, Que: quercetin, Cat: 
catechin, Cyn: cyanidin, Kur: kuromanin, Ber: berberine). Untreated cells were set at 100% and 
the data are presented as % of the untreated cells. The figure represents means ± SEM of 3 
independent experiments with 3 replicate wells in each experiment. In each separate experiment, 
9 different spots for each well were read by the microplate reader in order to control for the number 
of cells in each well. (*) Significantly different from the palmitic acid alone condition at P<0.05. 
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5.3.2. Intracellular ROS generation 
Fluorescence images representative of intracellular ROS stained with the fluorogenic probe 
DCFH-DA along with their brightfield images are shown in Figure 5.2A. Compared to untreated 
cells, higher green fluorescence in HepG2 hepatocytes exposed to palmitic acid showed higher 
ROS in these cells. Treatment with polyphenols starting prior to treatment with palmitic acid 
decreased the intensity of fluorescence representative of decreased intracellular ROS.  
When the fluorescence signals were quantified using a microplate reader, it was revealed that 
treatment of HepG2 cells with palmitic acid increased intracellular ROS by 42% while treatment 
with all polyphenols prevented this increase ranging from 70-160% inhibition (Figure 5.2B). The 
most potent polyphenol was berberine with 160% inhibition, to a level less than untreated cells, 
and the weakest polyphenol was kuromanin which protected against ROS generation by 70%. 
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Figure 5. 2. The effect of polyphenols on palmitic acid-induced ROS generation. 
HepG2 hepatocytes were pre-treated with different polyphenols at 10 µM for 2 h and then treated 
with 500 µM palmitic acid for 24 h, and intracellular ROS was measured after staining with the 
fluorogenic probe DCFH-DA. (A) Fluorescence images along with their corresponding brightfield 
images were captured using a ZOE Fluorescent Cell Imager at 20x magnification. (B) DCF 
fluorescence was quantified using a microplate reader. (UT: untreated, PA: palmitic acid, Res: 
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resveratrol, Que: quercetin, Cat: catechin, Cyn: cyanidin, Kur: kuromanin, Ber: berberine). 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The figure 
represents means ± SEM of 3 independent experiments with 3 replicate wells in each experiment. 
In each separate experiment, 9 different spots for each well were read by the microplate reader in 
order to control for the number of cells in each well. (*) Significantly different from the palmitic 
acid alone condition at P<0.05. 
5.3.3. Mitochondrial membrane potential  
Figure 5.3A shows fluorescence images of HepG2 cells stained with a fluorescence probe (TMRE) 
specific for the mitochondrial membrane potential. The results show that the mitochondrial 
membrane potential is much lower in the cells treated with palmitic acid and increased in the cells 
treated with resveratrol, quercetin, catechin, and cyanidin.  
When fluorescence signals were quantified using a microplate reader it was revealed that treatment 
of HepG2 hepatocytes with palmitic acid alone significantly decreased the mitochondrial 
membrane potential by 22% (Figure 5.3B). When the cells were treated with 10 µM catechin, 
quercetin, cyanidin, or resveratrol, the decrease in the mitochondrial membrane potential was 
inhibited by 100, 73, 60, and 50%, respectively. Berberine and kuromanin did not protect against 
the palmitic acid-induced mitochondrial membrane potential decrease. 
 
112 
 
 
Figure 5. 3. Effects of palmitic acid and polyphenols on the mitochondrial membrane 
potential in HepG2 cells. 
Cells were treated with 10 µM polyphenols starting 2 h prior to the treatment with 500 µM palmitic 
acid for 24 h. (A) Fluorescence images representative of the mitochondrial membrane potential 
were captured using a ZOE Fluorescent Cell Imager at 20x magnification after staining HepG2 
cells with TMRE red. (B) The quantification of TMRE fluorescence using a microplate reader. 
Untreated cells were set at 100% and the data are presented as % of untreated cells. The figure 
represents means ± SEM of 3 independent experiments with 3 replicate wells in each experiment. 
In each separate experiment, 9 different spots for each well were read by the microplate reader in 
order to control for the number of cells in each well. (*) Significantly different from the palmitic 
acid alone condition at P<0.05. 
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5.3.4. Mitochondrial content 
As represented in Figure 5.4A, treatment with palmitic acid alone decreased the intensity of 
MitoTracker Green fluorescence (specific for mitochondrial content) representing fewer 
mitochondria in HepG2 cells. Treatment with all polyphenols at 10 µM however, increased 
mitochondrial content compared to palmitic acid alone. 
Quantification of the MitoTracker results with a microplate reader showed that treatment with 
palmitic acid alone for 24 h significantly decreased mitochondrial content in HepG2 cells by 33% 
while treatment with 10 µM cyanidin, catechin, berberine, and kuromanin protected against the 
inhibition by 76, 60, 58, and 55%, respectively (Figure 5.4B). Although higher green fluorescence 
has been shown in Figure 5.4A for resveratrol and quercetin, they did not reach significance when 
fluorescence was measured using a microplate reader. 
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Figure 5. 4. Effects of palmitic acid and polyphenols on mitochondrial content. 
(A) Fluorescence images were captured using a ZOE Fluorescent Cell Imager at 20x magnification 
representative of the mitochondrial content in HepG2 cells stained with MitoTracker Green. (B) 
Mitochondrial content was measured by quantification of the MitoTracker Green fluorescence 
using a microplate reader. Untreated cells were set at 100% and the data are presented as % of the 
untreated cells. The figure represents means ± SEM of 3 independent experiments with 3 replicate 
wells in each experiment. In each separate experiment, 9 different spots for each well were read 
by the microplate reader in order to control for the number of cells in each well. (*) Significantly 
different from the palmitic acid alone condition at P<0.05. 
 
115 
 
5.3.5. Expression of mRNA for nuclear and mitochondrial DNA-encoded respiratory 
complex subunits  
In measurements of mRNA for nuclear DNA-encoded mitochondrial respiratory complex 
subunits, treatment of HepG2 hepatocytes with palmitic acid alone for 24 h significantly decreased 
the expression of a subunit of complex V (ATP5G1), while having no effect on the expression of 
subunits for complex I (NDUFS8), III (UQCRC1), and IV (COX6B1) (Figure 5.5). Treatment with 
berberine increased the expression of all of the subunits (by 66, 35, 30, and 45% relative to palmitic 
acid alone). Catechin and kuromanin increased the expression of two of the subunits, and cyanidin 
increased one.  
 
Figure 5. 5. Effects of palmitic acid and polyphenols on the expression of nuclear DNA-
encoded mRNA for mitochondrial respiratory complex subunits. 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The bars 
represent means ± SEM of 2 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the palmitic acid alone condition at P<0.05. 
Treatment of HepG2 cells with palmitic acid alone had no significant effect on the mRNA for 
mitochondrial DNA-encoded subunits (Figure 5.6). Compared to palmitic acid alone, treatment 
with resveratrol increased the expression of three of the subunits (MTND1, MTCYB, and MTCO1 
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by 115, 40 and 28% respectively). Quercetin, cyanidin and berberine increased the expression of 
two of the subunits, and catechin increased one.  
 
Figure 5. 6. Effects of palmitic acid and polyphenols on mitochondrial DNA-encoded 
mRNA for the mitochondrial respiratory complex subunits. 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The bars 
represent means ± SEM of 2 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the palmitic acid alone condition at P<0.05. 
5.3.6. The expression of mRNA for inducible nitric oxide synthase (iNOS) 
Shown in Figure 5.7 palmitic acid increased mRNA for inducible nitric oxide synthase (iNOS) by 
245% while all polyphenols except berberine prevented this increase by 82-110%. Kuromanin was 
the strongest (110% protection) while berberine was the weakest polyphenol with no significant 
effect on iNOS mRNA expression. 
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Figure 5. 7. Effects of palmitic acid and polyphenols on mRNA expression of inducible 
nitric oxide synthase. 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The bars 
represent means ± SEM of 2 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the palmitic acid alone condition at P<0.05. 
5.3.7. ER stress and unfolded protein response   
5.3.7.1. ER chaperones 
Palmitic acid significantly increased mRNA for the endoplasmic reticulum chaperones GRP94, 
GRP78, ORP150, and co-chaperone ERdj4 by 60, 147, 184, and 170%, respectively (Figure 5.8). 
Compared to palmitic acid (PA) alone, quercetin decreased expression of four of the chaperones, 
catechin and cyanidin three, and kuromanin and berberine one. Resveratrol did not significantly 
affect expression of any of the chaperones.  
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Figure 5. 8. Effects of palmitic acid and polyphenols on the expression of mRNA for ER 
chaperones. 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The bars 
represent means ± SEM of 2 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the palmitic acid alone condition at P<0.05. 
5.3.7.2. Other endoplasmic reticulum stress markers and apoptotic CHOP 
While treatment of HepG2 cells with 500 µM palmitic acid alone for 24 h had no significant effect 
on the expression of ATF4, it significantly increased the expression of the other ER stress markers 
EDEM1 and GADD34 as well as the ER stress-mediated apoptotic marker CCAAT-enhancer-
binding protein homologous protein (CHOP) by 77, 140, and 171%, respectively (Figure 5.9). 
Quercetin decreased the expression of three of the markers, catechin two, and resveratrol and 
cyanidin one. Only the polyphenols catechin, quercetin, and cyanidin which strongly inhibited the 
increase in expression of several endoplasmic reticulum chaperones (Figure 5.8), showed 
protection against the increase in CHOP.  
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Figure 5. 9. Effects of palmitic acid and polyphenols on expression of mRNA for some ER 
stress markers as well as apoptotic CHOP. 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The bars 
represent means ± SEM of 2 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the palmitic acid alone condition at P<0.05. 
5.3.8. Correlation results 
In order to find the association between different parameters, we evaluated the correlation between 
several variables using Pearson’s R. Intracellular triglyceride in HepG2 hepatocytes was positively 
correlated with iNOS mRNA expression (r=0.55, P<0.001) (Figure 5.10A) and ER stress markers 
such as GRP78 and the apoptotic CHOP (r=0.40, P=0.005, and r=0.35, P=0.014 respectively) 
(Figure 5.10B). Expression of mRNA for ATP5G1 was positively correlated with NDUFS8 
(r=0.43, P=0.002), UQCRC1 (r=0.65, P<0.001), and COX6B1 (r=0.65, P<0.001). Expression of 
complex I subunits NDUFS8 and MTND1 was negatively correlated with ROS generation (r=-
0.50 P<0.001 and r=-0.49 P<0.001, respectively) (Figure 5.10C). The ER stress markers GRP78, 
GRP94, GADD34, and CHOP were negatively correlated with mitochondrial content (r=-0.46 
P=0.001, r=-0.37 P=0.009, r=-0.4 P=0.006, and r=-0.47 P=0.001, respectively) (Figure 5.10D). 
Cochaperone ERdj4 was also highly correlated with the other ER chaperones such as GRP94 
(r=0.65, P<0.001), GRP78 (r=0.59, P<0.001), ORP150 (r=0.6, P<0.001), and apoptotic CHOP 
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(r=0.74, P<0.001) respectively. Apoptotic CHOP mRNA expression was highly correlated with 
the expression of ER stress chaperones and cochaperone such as ORP150 (r=0.73, P<0.001), 
GRP78 (r=0.70, P<0.001), GRP94 (r=0.57, P<0.001), ERdj4 (r=0.74, P<0.001), as well as other 
ER stress markers including EDEM1 (r=0.65, P<0.001) (Figure 5.10E). Finally, a fairly high 
negative correlation was found between ER stress chaperones such as GRP78 (r=-0.52, P<0.001), 
ORP150 (r=-0.62, P<0.001), cochaperone ERdj4 (r=-0.61, P=0.000) and the apoptotic CHOP (r=-
0.57, P<0.001) with the mitochondrial membrane potential (Figure 5.10F).  
 
Figure 5. 10. Correlations between different parameters of interest.   
These correlations are based on the results previously shown in figure 5.1 to 5.9. (A & B) Positive 
correlation between iNOS and CHOP mRNA expression with intracellular triglyceride in HepG2 
cells. (C) Inverse correlation between the mitochondrially-encoded complex I subunit and ROS 
production. (D) Inverse correlation between the apoptotic CHOP mRNA expression and 
mitochondrial content. (E) Positive correlation between the ER chaperone ORP150 and the pro-
apoptotic CHOP. (F) Inverse correlation between the apoptotic CHOP expression and the 
mitochondrial membrane potential.  
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5.4. Discussion 
Steatosis and oxidative stress have been suggested to be the “first” and “second hits” of fatty liver 
progression to NASH [2] and therefore prevention of these outcomes may help prevent 
steatohepatitis. In the present study treatment with palmitic acid increased intracellular triglyceride 
and ROS production in HepG2 hepatocytes by 40 and 42%, providing an in vitro model of 
steatosis. Although some studies suggest that simple steatosis is not always progressive in humans 
provided that it is as the form of neutral lipids, it can be harmful when it is associated with ROS 
generation or insulin resistance leading to inflammation [316]. Consistent with our results, other 
studies show similar effects of palmitic acid on steatosis and ROS generation. In one study 
treatment of HepG2 cells with 400 µM palmitic acid increased intracellular triglyceride and ROS 
production by 50 and 200% respectively while the polyphenol luteolin protected against the 
increase [317]. However, some studies report a higher level of steatosis [42] or contrarily no 
steatosis [318] in HepG2 hepatocytes exposed to palmitic acid. But even when no steatosis was 
observed with 1 mM palmitic acid, the palmitic acid impaired insulin signaling [318].  
Treatment with all polyphenols of interest in our study protected against palmitic acid-induced 
steatosis and ROS generation. Consistent with these findings, others also show that polyphenols 
can have strong anti-steatotic [48, 95] and antioxidant effects [47, 238], can inhibit the expression 
of genes involved in lipogenesis, and can induce genes involved in fatty acid oxidation [44, 73] 
leading to protection against NAFLD. In the current study, all of the investigated polyphenols 
similarly and almost completely prevented the increase in ROS induced by palmitic acid. 
We also observed that exposure of HepG2 cells to palmitic acid depolarized the mitochondrial 
membrane potential by about 20%, while most polyphenols (resveratrol, quercetin, catechin, and 
cyanidin) protected against the depolarization. Interestingly, the same polyphenols protected 
against the ΔΨm decline with palmitic acid as we observed with oleic acid (Figure 3.6). Collapse 
of the ΔΨm may be an early sign or requirement for apoptosis [319] and hepatocyte apoptosis is 
involved in progression of NAFLD to NASH and hepatic fibrosis [320]. Preventing the decline in 
the mitochondrial membrane potential by polyphenols therefore may have a key role in decreasing 
hepatocyte apoptosis in NASH. In agreement with our results, polyphenols such as punicalagin 
(an ellagitannin polyphenol found in pomegranate) [265], curcumin [20], and flavonoids from 
Rosa laevigata Michx fruit [282] have been observed to preserve the mitochondrial membrane 
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potential in hepatocytes exposed to palmitic acid or in the liver of rodents fed a high-fat diet. 
Therefore, it appears that one of the mechanisms by which polyphenols protect against 
mitochondrial dysfunction and lipoapoptosis in NAFLD is via preserving the mitochondrial 
membrane potential.  
One mechanism by which polyphenols may protect against mitochondrial dysfunction caused by 
palmitic acid is by inducing mitochondrial biogenesis. Mitochondrial biogenesis is defined by both 
mitochondrial replication and differentiation. Mitochondrial replication involves synthesis of 
mitochondrial DNA (leading to higher mitochondrial number), while mitochondrial differentiation 
results in higher expression of mitochondrial proteins (such as respiratory complex subunits), and 
developing crista of mitochondria leading to improved function of pre-existing mitochondria 
[141]. In the current study, we evaluated the effect of palmitic acid and polyphenols on both 
mitochondrial replication and differentiation. We found that palmitic acid decreased mitochondrial 
content of HepG2 cells by more than 30% and polyphenols could protect against this effect. 
Mitochondrial content has been shown to be suppressed in HepG2 cells exposed to palmitic acid 
[255] and in the liver of animals in experimental models of NAFLD and NASH [143, 254, 291]. 
Consistent with our findings, other studies have also shown polyphenols such as curcumin to 
protect against free fatty acid-induced inhibition of mitochondrial biogenesis in hepatocytes [20] 
and such as berberine, resveratrol, and berry anthocyanins to increase mitochondrial biogenesis in 
the hepatic and skeletal muscle tissue of rodents fed a high-fat diet [291], or in other models of 
NAFLD [254, 267]. Increased mitochondrial biogenesis leads to increased ability to metabolize 
excess fatty acids in the liver and this may be an effective and efficient outcome to prevent 
pathogenesis of NAFLD to progress to NASH. Higher mitochondrial biogenesis is shown by 
different studies to be negatively associated with ROS production via increased expression of 
antioxidant enzymes in mitochondria [301]. Mitochondrial biogenesis is also associated with 
higher fatty acid oxidation [267] and lower inflammation [307] which all can be beneficial for 
ameliorating NAFLD. 
Unlike in our previous study where we found resveratrol at 10 µM to protect against oleic acid-
induced inhibition of mitochondrial biogenesis in HepG2 cells (Figure 4.3), resveratrol did not 
significantly increase mitochondrial content (as measured by MitoTracker Green) in the current 
study on palmitic acid. In the current study however, resveratrol was the strongest polyphenol in 
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inducing the expression of mRNA for mitochondrial DNA-encoded subunits of the respiratory 
chain, suggesting that it increased mitochondrial differentiation and function.  
While palmitic acid inhibited mitochondrial content in our study by 33% it had no significant effect 
on the expression of nuclear and mitochondrial DNA-encoded respiratory complex subunits 
(except ATP synthase subunit, ATP5G1). In contrast to our results, Garcia-Ruiz et al. [15] found 
decreased activity and assembly of all mitochondrial complexes by palmitic acid. Although they 
found a decline in mRNA expression for all mitochondrial DNA-encoded but not nuclear DNA-
encoded respiratory complex subunits in HepG2 cells exposed to palmitic acid, we only observed 
decreased expression of ATP5G1 which is a nuclear DNA-encoded subunit.  
Consistent with the results for mitochondrial biogenesis however, polyphenols in our study 
increased the expression of both nuclear and mitochondrial DNA-encoded subunits, which 
consequently would bring about improved mitochondrial function. In agreement with these 
findings, another study [255] showed increased expression of the mitochondrial respiratory 
complex subunits by polyphenols in HepG2 cells exposed to palmitic acid. Along with inducing 
mitochondrial biogenesis and increasing the expression of mitochondrial respiratory complex 
subunits, polyphenols in our study also preserved the mitochondrial membrane potential, which 
suggests that they can protect against mitochondrial defects in hepatocytes. 
ER stress and UPR were other aspects of NAFLD investigated in the current study. Treatment of 
HepG2 hepatocytes with palmitic acid was found to induce ER stress and UPR evidenced by an 
adaptive increase in gene expression of several chaperones (GRP58, GRP78, GRP94, ORP150, 
EDEM1, GADD34, co-chaperone ERdj4, and apoptotic CHOP). Consistent with these results, 
others have shown that treatment of hepatic cells with saturated fatty acids [26, 321] or of rodents 
with a high-fat diet [25], induces hepatic ER stress which exacerbates NAFLD. Improved proper 
folding of unfolded/misfolded proteins by treatment with oral chemical chaperones such as 
taurine-conjugated ursodeoxycholic acid (TUDCA) and 4-phenyl butyric acid (4-PBA) have 
shown promise in ameliorating ER stress in diabetic and obese ob/ob mice which consequently 
resulted in alleviation of fatty liver disease, hyperglycemia, and increased insulin sensitivity [192]. 
Since activation of ER stress markers have been shown to be highly associated with hepatic 
steatosis, inflammation, impaired insulin signaling, and apoptosis (all implicated in the progression 
of NAFLD to NASH) [322], we hypothesized that dietary polyphenols may mimic beneficial 
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effects of chaperones, which by facilitating proper folding of unfolded proteins protect against ER 
stress in the liver. The polyphenols would thereby inhibit endogenous expression of chaperones 
that results from ER stress. We observed that treatment of HepG2 cells with different polyphenols 
prior to treatment with palmitic acid alleviates expression of these chaperones, and therefore ER 
stress. The effect of polyphenols on hepatic ER stress has been looked at in only a few studies 
[256-258] . In line with our findings, those studies show that treatment with polyphenols can 
alleviate ER stress evidenced by decreased ER stress markers such as GRP78, ATF4, CHOP, p-
eIF2α, and p-PERK. Resveratrol has also previously been shown to alleviate palmitate-induced 
ER stress in HepG2 hepatocytes by decreasing gene expression of apoptotic CHOP, and protein 
expression of p-PERK as well as increasing gene expression of ORP150 in a SIRT1-mediated 
pathway [257]. In contrast to our results showing berberine had a weak effect on alleviating ER 
stress markers, berberine was recently shown to suppress ER stress as well as prevent hepatic lipid 
accumulation, inflammation, and fibrosis in diabetic db/db mice and in methionine choline-
deficient mice (MCD), and consequently protected against progression of simple hepatic steatosis 
to steatohepatitis [258]. These researchers also showed that berberine at 5 µM protected against 
palmitate/oleate- and tunicamycin-induced ER stress in vitro. The study design however, was 
different from our study (different cell models have been used) and used different stressors which 
may partly explain the differences between the results. 
A potential mechanism by which polyphenols decrease ER stress is by acting as chemical 
chaperones. Zhang et al. [258] showed a potential chaperone activity of berberine which 
consequently prevented accumulation of misfolded or unfolded proteins in a hepatocyte cell line 
and primary hepatocytes. This was apparently the first study revealing that polyphenols such as 
berberine possess direct chaperone activity whereby the protein-stabilizing function inhibits 
aggregation of unfolded/misfolded proteins responsible for initiation and progression of ER stress 
[258]. Since some polyphenols such as catechin, quercetin, and cyanidin in our study decreased 
the expression of several endoplasmic reticulum chaperones such as ORP150, GRP78, GRP94, 
and GRP58, these polyphenols may possess chaperone activity similar to that shown by Zhang et 
al. [258] and consequently decrease expression of ER chaperones by negative feedback. Our 
results show that treatment of HepG2 hepatocytes with polyphenols can prevent palmitic acid-
induced steatosis at least partially due to protection against ER stress. Due to the lack of evidence 
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in this field, more studies need to be conducted in order to find the chaperonic effect of polyphenols 
in alleviating ER stress. 
Palmitic acid treatment also increased expression of mRNA for the pro-apoptotic protein CHOP, 
while some polyphenols protected against the increase. Numerous studies show that hepatocyte 
apoptosis is enhanced in NASH and this is one of the main mechanisms involved in progression 
of the disease [323]. Failure of the UPR to resolve ER stress can also result in cell death through 
different mechanisms including CHOP which is one of the main UPR-mediated proapoptotic 
factors [7]. Therefore, suppression of CHOP may have a beneficial role in prevention of NAFLD. 
Consistent with our findings in human hepatocytes, others have also shown that polyphenols such 
as resveratrol attenuated ER stress and consequently decreased protein expression of CHOP in the 
liver of rats fed a high-fat diet, which led to decreased hepatic steatosis in these rats [256]. 
However, the role of CHOP in rodents with fatty liver is still controversial since it is reported that 
while CHOP null (-/-) mice have lower steatosis in the liver, they are not protected against ethanol-
induced fatty liver disease [324]. Therefore, it has been suggested that CHOP has different roles 
in apoptosis in humans vs. rodents [321]. While increased expression of CHOP by palmitic acid in 
HepG2 cells and primary human hepatocytes was shown to induce cellular death through 
activation of a CHOP-NF-κB pathway, this signalling pathway was not conserved in primary 
rodent hepatocytes and could not induce apoptosis in these cells [321]. The authors suggested that 
in human cells UPR activation has a major role in the pathogenesis of NASH by inducing 
expression of CHOP. Therefore, since we used human hepatocytes, we suggest that polyphenols 
in our study protect against palmitic acid-induced apoptosis in these cells by inhibiting CHOP 
expression as well as protecting against mitochondrial membrane potential dissipation.  
We found a positive correlation between iNOS mRNA and intracellular fat in HepG2 cells. Hepatic 
expression of iNOS has been shown to be increased in ob/ob mice [16], and iNOS knockout (iNOS-
/-) mice are resistant to a high-fructose diet and accumulate less fat in their livers [312]. By reacting 
with cytochrome c oxidase (complex IV), NO may result in mitochondrial respiratory chain 
dysfunction, further impairing electron transfer and leading to hepatic lipid accumulation [325]. 
Our findings also show a negative correlation between the expression of ER stress markers such 
as GRP78 and CHOP with mitochondrial biogenesis and the mitochondrial membrane potential. 
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An ER-mitochondrial stress crosstalk has been suggested by some studies [326], so ER stress and 
mitochondrial dysfunction may work synergistically to exacerbate NAFLD. This ER-
mitochondrial stress crosstalk has also been observed in studies regarding apoptosis [327] and 
hepatic insulin resistance [328]. This crosstalk between mitochondrial dysfunction, ER stress, and 
depleted ATP stores may promote progression of NAFLD to NASH by inducing apoptotic cell 
death and necrosis [326], while treatment with polyphenols may protect against these outcomes.   
In conclusion, we found that the saturated fat palmitic acid can induce steatosis, increase ROS 
generation, decrease the mitochondrial membrane potential, inhibit mitochondrial biogenesis and 
function while inducing ER stress in human hepatocytes. We show that several polyphenols can 
protect against these changes. The results and correlations show that there might be a crosstalk 
between mitochondrial dysfunction and endoplasmic reticulum stress which may facilitate 
progression of simple steatosis to NASH and apoptosis. More studies are needed to prove this 
crosstalk and to explore molecular mechanisms behind progression of NAFLD to NASH, and the 
inhibition of these pathways by dietary polyphenols.  
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5.5. Transition to CHAPTER 6 
So far, CHAPTER 3 and 4 have dealt with the first and second hypotheses (mitochondrial 
dysfunction and ROS generation) and CHAPTER 5 dealt with the third hypothesis (ER stress). 
Regarding the fourth hypothesis we could not find any synergism between resveratrol and cyanidin 
in protection against oleic acid-induced ROS generation (Figure 5.11). Oleic acid significantly 
induced ROS generation by 123%, and except resveratrol at 1 µM, resveratrol and cyanidin at all 
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doses (1, 5, 10 µM) alone or in combination gave significant inhibition. However, we could not 
observe any synergism between resveratrol and cyanidin in inhibition of oleic acid-induced ROS.  
CHAPTER 6 deals with breakdown/digestion products of polyphenols. It is still a matter of debate 
whether breakdown/digestion products of polyphenols contribute to the protection against fatty 
liver disease. For example, in vitro studies (including our results in CHAPTER 4) show that 
anthocyanins do not induce mitochondrial biogenesis in the cells while studies in rodents show the 
opposite with capability of inducing mitochondrial biogenesis by anthocyanins. It is believed that 
the effects observed in vivo are due to the breakdown/digestion products of polyphenols formed 
after ring fission of parent polyphenols by colonic microbiota. CHAPTER 6 will present 
investigations into the ability of the breakdown/digestion products of polyphenols (quercetin and 
cyanidin) to contribute to the protective effects against NAFLD.  
 
 
Figure 5. 11. Evaluation of synergism between resveratrol and cyanidin in inhibiting oleic 
acid-induced ROS generation.  
UT, untreated; OA, oleic acid; Res, resveratrol; Cyn, cyanidin. ROS generation was measured after 
treatment with different concentrations of resveratrol or cyanidin alone and in combination for 2 
h followed by treatment with 1.5 mM oleic acid for 24 h. Untreated cells were set at 100% and the 
data are presented as % of the untreated cells. The bars represent means ± SEM of 3 independent 
experiments with 3 replicate wells in each experiment. (*) Significantly different from the oleic 
acid alone condition at P<0.05. The significant difference between groups was tested with one-
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way ANOVA followed by Dunnett’s post-hoc test. Two-way ANOVA showed no significant 
interaction between resveratrol and cyanidin. 
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CHAPTER 6: PHENOLIC BREAKDOWN PRODUCTS OF QUERCETIN AND 
CYANIDIN CONTRIBUTE TO THE PROTECTION AGAINST STEATOSIS, 
OXIDATIVE STRESS, AND MITOCHONDRIAL DYSFUNCTION IN AN IN VITRO 
MODEL OF STEATOSIS 
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Abstract 
Scope: Although dietary polyphenols have been shown to induce mitochondrial biogenesis and 
ameliorate non-alcoholic fatty liver disease (NAFLD) in experimental models, it is largely 
unknown whether these effects are due to the parent polyphenols or their breakdown/digestion 
products.  
Methods and results: In an in vitro model of steatosis using HepG2 hepatocytes, we investigated 
the effects of quercetin and cyanidin, and their phenolic breakdown/digestion products (caffeic 
acid, protocatechuic acid, and 2,4,6-trihydroxybenzaldehyde) on steatosis, reactive oxygen species 
(ROS) generation, and mitochondrial biogenesis and function. Treatment with oleic acid for 24 h 
induced steatosis, and increased ROS generation, while treatment with quercetin and cyanidin and 
their breakdown/digestion products for 2 h (and thereafter for 24 h) all similarly protected against 
these inductions. Oleic acid also impaired mitochondrial function evidenced by a decreased 
mitochondrial membrane potential, while both the parent polyphenols and their 
breakdown/digestion products prevented the decrease. Oleic acid also decreased the cellular 
mitochondrial content while 24 h incubation with cyanidin or the breakdown/digestion products 
protected against this decrease. Interestingly, when HepG2 hepatocytes were incubated with the 
parent polyphenols or their breakdown/digestion products for only 1 h (to limit spontaneous 
degradation of quercetin and cyanidin to phenolic products in the medium), only the 
breakdown/digestion products protected against the oleic acid-induced decrease in mitochondrial 
content. Moreover, 1 h incubation of HepG2 cells with breakdown/digestion products, but not the 
parent polyphenols, induced mitochondrial content in the absence of oleic acid.   
Conclusion: The results suggest that breakdown/digestion products of polyphenols may contribute 
to the protective effects of parent polyphenols against NAFLD. This can partly explain the 
conflicting results found between in vitro and in vivo studies on the induction of mitochondrial 
biogenesis by anthocyanins. 
 
Keywords: flavonoids, phenolic degradation products, steatosis, mitochondrial membrane 
potential, mitochondrial biogenesis 
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6.1. Introduction 
In the last two decades, plant phytochemicals have received growing evidence for their health 
promoting effects [329]. Recently, the polyphenols found in fruits and vegetables have been 
extensively studied for their potential health effects against various diseases including obesity, 
diabetes, cardiovascular diseases, and cancer [330-333]. One disease for which flavonoids may 
provide a health benefit is non-alcoholic fatty liver disease (NAFLD) [46, 48]. 
At least part of the health benefits of dietary flavonoids, or of effects observed in vitro, may be 
due to their phenolic digestion/breakdown products. A portion of flavonoids including quercetin 
and anthocyanins are not absorbed in the small intestine and they reach the colon intact. These 
flavonoids are digested (broken down) by colonic microbiota resulting in production of phenolic 
acids including protocatechuic acid (from cyanidin [334] and quercetin [335, 336] ), and 2,4,6-
trihydroxybenzaldehyde (from cyanidin and other anthocyanins [334]) which are then absorbed. 
Until recently, little attention was paid to the breakdown/digestion products of flavonoids.  
Also in vitro, the instability of flavonoids in cell culture media may produce phenolic products that 
contribute to the observed effects. Although many studies on quercetin have been conducted in 
vitro, instability of the flavonol in the cell culture medium [337, 338] is not often considered, and 
complicates interpretation of the results. Similarly with anthocyanins under experimental [339] 
and biological conditions [340, 341], spontaneous degradation to phenolic acids may occur which 
may contribute to the observed effects. Moreover, doses of flavonoids used in numerous in vitro 
studies are more than are relevant in vivo (≤10 µM) and sometimes 100 µM or more has been used 
[342-344], which is above the physiologically relevant concentrations found in human serum. 
In vivo, despite the absorption of some part of ingested flavonoids such as anthocyanins in the 
small intestine [218, 345], a large proportion may undergo ring fission in the colon and their 
breakdown/digestion products [340, 346] may be absorbed.  These phenolic breakdown products 
have been suggested to contribute to the beneficial effects in vivo [207, 334, 336] and therefore 
future research on flavonoids bioactivity should take degradation/digestion products into account 
[329]. While in vitro studies for instance show no effect of anthocyanins on sirtuin 1 (SIRT1) 
activity [279], in vivo studies show beneficial effects of anthocyanins on mitochondrial biogenesis 
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[254]. It is still a question whether the effects of anthocyanins observed in vivo is due to the parent 
compounds or their phenolic digestion/breakdown products.  
In the current study, 10 µM quercetin and cyanidin and their phenolic breakdown/digestion 
products were investigated for their protection against free fatty acid-induced steatosis, ROS 
generation, and decreases in the mitochondrial membrane potential and mitochondrial content. The 
results suggest that breakdown products can contribute to the protective effects of the parent 
polyphenols against NAFLD. 
6.2. Materials and Methods 
6.2.1. HepG2 cells culture condition 
See section 3.2.2. 
6.2.2. Treatment with oleic and palmitic acid/BSA and polyphenols 
See section 3.2.3. 
6.2.3. Measuring intracellular lipid content using Nile Red staining 
See section 3.2.4. 
6.2.4. Measurement of intracellular ROS   
See section 4.2.4. 
6.2.5. Measurement of mitochondrial content using MitoTracker Green 
To determine mitochondrial content, HepG2 hepatocytes were labelled with a mitochondria-
specific dye, MitoTracker Green according to the manufacturer’s protocol (Invitrogen, USA). 
Briefly, 3×104 HepG2 cells were seeded per well in 96-well clear-bottom plates. After 24h, the old 
medium was replaced with fresh medium containing 1% fatty acid-free bovine serum albumin and 
the cells were pre-treated with 10 µM parent polyphenols, quercetin and cyanidin, or their 
breakdown/digestion products protocatechuic acid, caffeic acid, and 2,4,6-
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trihydroxybenzaldehyde for either 1 h (and removed after 1 h) or 2 h (incubated for 24 h thereafter) 
followed by treatment with or without oleic acid for 24 h. After 24 h, the old medium was removed 
and the cells were exposed to 300 nM final concentration of MitoTracker Green dissolved in 
medium (without fetal bovine serum) and the plate was covered and incubated at 37oC for 20-30 
min. After incubation, the medium containing probe was removed, the cells were carefully washed 
3-4 times with phosphate buffered saline (PBS) and the mean fluorescence of 9 different spots of 
each well was measured using a microplate reader at excitation 485 nm and emission 528 nm. 
Fluorescence images were captured using a ZOE Fluorescent Cell Imager. 
6.2.6. Measuring mitochondrial membrane potential  
See section 3.2.11. 
6.2.7. Statistical analysis 
Results were expressed as mean values with their standard error of means (SEM) for the number 
of experiments indicated. Results were analyzed using the Statistical Package for the Social 
Sciences (SPSS 22) (IBM, USA). One-way ANOVA was used initially, and when any significance 
was detected, Dunnett’s post hoc test was used to compare the mean of each group with the oleic 
or palmitic acid alone condition. The level of significance was P<0.05. Correlation was determined 
by Pearson’s R. 
6.3. Results 
6.3.1. Intracellular lipid accumulation  
Fluorescence images of HepG2 cells stained with Nile Red show that oleic acid increased 
intracellular lipids while treatment with quercetin, cyanidin, or their phenolic breakdown products 
inhibited the accumulation (Figure 6.1A). When the fluorescence signals were quantified using a 
microplate reader, it was revealed that 1.5 mM oleic acid increased intracellular fat in HepG2 cells 
by 182% while quercetin, cyanidin and all of their breakdown products at 10 µM protected against 
the increase by 44-52% (Figure 6.1B). The protective effect against steatosis was similar between 
polyphenols and their breakdown products.  
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Figure 6. 1. Effects of quercetin, cyanidin and phenolic breakdown products on oleic acid-
induced intracellular lipid accumulation. 
(UT: untreated, OA: oleic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: 
protocatechuic acid, THB: 2,4,6-trihydroxybenzaldehyde). HepG2 cells were treated with 10 µM 
quercetin or cyanidin, or phenolic acids for 2 h (and 24 h thereafter), followed by treatment with 
1.5 mM oleic acid for 24 h. Intracellular lipids were stained with the Nile Red fluorescence probe. 
(A) Representative fluorescence images captured using a ZOE Fluorescent Cell Imager at 20x 
magnification. (B) Intracellular lipids quantified from the Nile Red fluorescence using a microplate 
reader. Untreated cells were set at 100% and the data are presented as % of the untreated cells. The 
figure represents means ± SEM of 3 independent experiments with 3 replicate wells in each 
experiment. (*) Significantly different from the oleic acid alone condition at P<0.05.  
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When the cells were treated with 500 µM palmitic acid, intracellular lipid was increased by 48% 
while polyphenols and their phenolic products similarly prevented the increase by almost 100% 
(Figure 6.2). Compared with the oleic acid experiment (Figure 6.1), quercetin, cyanidin, and their 
phenolic breakdown products showed stronger protection against steatosis from palmitic acid 
(albeit at a lower concentration than oleic acid).  
 
Figure 6. 2. The effect of quercetin, cyanidin and phenolic breakdown products on palmitic 
acid-induced intracellular lipid accumulation 
(UT: untreated, PA: palmitic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: 
protocatechuic acid, THB: 2,4,6-trihydroxybenzaldehyde). HepG2 cells were pre-treated with 10 
µM quercetin or cyanidin, or phenolic acids for 2 h (and 24 h thereafter), followed by treatment 
with 500 µM palmitic acid for 24 h. Untreated cells were set at 100% and the data are presented 
as % of the untreated cells. The figure represents means ± SEM of 3 independent experiments with 
3 replicate wells in each experiment. (*) Significantly different from the palmitic acid alone 
condition at P<0.05.  
6.3.2. Intracellular ROS 
Fluorescence images of HepG2 cells stained with 2,7-dichlorodihydrofluorescein diacetate 
(DCFH-DA) show that oleic acid increased intracellular ROS while treatment with quercetin and 
cyanidin, and their phenolic breakdown products prevented the increase (Figure 6.3A). 
Quantification of the fluorescence signals revealed that when the cells are pre-treated with oleic 
acid, intracellular ROS was increased by 73% and all the phenolic products as well as quercetin 
prevented the increase by almost 100%. Cyanidin protected by 71% (Figure 6.3B). With palmitic 
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acid, the same trend was observed in which palmitic acid increased ROS production by 66% while 
quercetin and the phenolic products gave similar protection (~85%) and cyanidin gave 56% 
protection (Figure 6.4).  
 
Figure 6. 3. The effect of quercetin and cyanidin and their phenolic breakdown products on 
intracellular ROS production. 
(UT: untreated, OA: oleic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: 
protocatechuic acid, THB: 2,4,6-trihydroxybenzaldehyde). HepG2 hepatocytes were pre-treated 
with different polyphenols at 10 µM for 2h (and 24 h thereafter) and then treated with 1.5 mM 
oleic acid for 24h. Experimental conditions were as in Figure 6.1, and ROS generation was 
measured using the fluorogenic probe DCFH-DA. (A) Representative fluorescence images at 20x 
magnification captured by a ZOE Fluorescent Cell Imager after staining HepG2 cells with DCFH-
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DA. Higher green fluorescence represents higher intracellular ROS content. (B) Quantification of 
ROS generation. DCF fluorescence was measured using a microplate reader. Untreated cells were 
set at 100% and the data are presented as % of the untreated cells. The figure represents means ± 
SEM of 3 independent experiments with 3 replicate wells in each experiment. (*) Significantly 
different from the oleic acid alone condition at P<0.05. 
 
Figure 6. 4. The effects of quercetin, cyanidin and phenolic breakdown products on 
palmitic acid-induced ROS generation. 
Experimental conditions were as in Figure 6.2, and ROS generation was measured using the 
fluorogenic probe DCFH-DA. DCF fluorescence was measured using a microplate reader. (UT: 
untreated, PA: palmitic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: protocatechuic 
acid, THB: 2,4,6-trihydroxybenzaldehyde). Untreated cells were set at 100% and the data are 
presented as % of the untreated cells. The figure represents means ± SEM of 3 independent 
experiments with 3 replicate wells in each experiment. (*) Significantly different from the palmitic 
acid alone condition at P<0.05. 
6.3.3. Mitochondrial membrane potential 
Fluorescence images of HepG2 cells stained with tetramethylrhodamine, ethyl ester (TMRE) show 
that oleic acid depolarized the mitochondrial membrane potential while treatment with quercetin 
and cyanidin, and their phenolic breakdown products protected against the depolarization (Figure 
6.5A). Quantification of fluorescence signals revealed that when the cells were pre-treated with 
oleic acid, the mitochondrial membrane potential decreased by almost 40% while quercetin and 
cyanidin, and their phenolic breakdown products rescued the potential by 46-82% (Figure 6.5B). 
Protocatechuic acid was the strongest polyphenol with 82% protection while quercetin was the 
weakest one with 46% protection.   
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Figure 6. 5. The mitochondrial membrane potential in HepG2 cells. 
(UT: untreated, OA: oleic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: 
protocatechuic acid, THB: 2,4,6-trihydroxybenzaldehyde). The effect of oleic acid and 
polyphenols and their phenolic breakdown metabolites on the mitochondrial membrane potential 
(ΔΨm) after staining HepG2 cells with TMRE red. (A) Representative fluorescence images 
captured using a ZOE Fluorescent Cell Imager at 20x magnification (B) Quantification of the 
mitochondrial membrane potential. Experimental conditions were as in Figure 6.1, and the 
mitochondrial membrane potential was measured using TMRE. TMRE red fluorescence was 
quantified using a microplate reader. Untreated cells were set at 100% and the data are presented 
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as % of the untreated cells. The figure represents means ± SEM of 3 independent experiments with 
3 replicate wells in each experiment. (*) Significantly different from the oleic acid alone condition 
at P<0.05. 
6.3.4. Mitochondrial content 
Represented in Figure 6.6A, treatment with oleic acid decreased the mitochondrial content 
evidenced by lower green fluorescence, while treatment with cyanidin and phenolic breakdown 
products for 2 h (and incubation with them for 24 h thereafter) appeared to inhibit the decrease. 
When the fluorescence signals were quantified (Figure 6.6B), it was revealed that oleic acid 
significantly decreased mitochondrial content by 21%, while 2,4,6-trihydroxybenzaldehyde, 
protocatechuic acid, caffeic acid, and cyanidin protected against this decrease by 157, 100, 95, and 
71%, respectively. Quercetin had no significant effect. Interestingly, the effect of phenolic 
breakdown products was stronger than the parent polyphenols (Figure 6.6B).  
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Figure 6. 6. Effects of oleic acid, quercetin, cyanidin and phenolic breakdown products on 
mitochondrial content. 
Experimental conditions were as in Figure 6.1, and mitochondrial content was measured after 
staining with MitoTracker Green. (A) Fluorescence images were captured using a ZOE 
Fluorescent Cell Imager at 20x magnification. (B) The MitoTracker Green fluorescence was 
quantified using a microplate reader. (UT: untreated, OA: oleic acid, Que: quercetin, Cyn: 
cyanidin, Caf: caffeic acid, PCA: protocatechuic acid, THB: 2,4,6-trihydroxybenzaldehyde). 
Untreated cells were set at 100% and the data are presented as % of the untreated cells. The figure 
represents means ± SEM of 3 independent experiments with 3 replicate wells in each experiment. 
(*) Significantly different from the oleic acid alone condition at P<0.05. 
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In another experiment, HepG2 hepatocytes were incubated with quercetin and cyanidin, and their 
phenolic breakdown products for only 1 h and then removed prior to treatment with oleic acid for 
24 h (Figure 6.7). In this experiment, 1 h treatment with the phenolic breakdown products (caffeic 
acid, protocatechuic acid, 2,4,6-trihydroxybenzaldehyde) prevented the oleic acid-induced 
decrease in mitochondrial content, while the parent polyphenols quercetin and cyanidin had no 
significant effect. 
 
Figure 6. 7. Effects of 1 h treatment with polyphenols on oleic acid-induced suppression of 
mitochondrial content. 
HepG2 cells were incubated with 10 µM quercetin, cyanidin or their phenolic breakdown products 
for 1 h and then removed prior to treatment with 1.5 mM oleic acid for 24 h. (UT: untreated, OA: 
oleic acid, Que: quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: protocatechuic acid, THB: 2,4,6-
trihydroxybenzaldehyde). The MitoTracker Green fluorescence was quantified using a microplate 
reader. Untreated cells were set at 100% and the data are presented as % of the untreated cells. The 
figure represents means ± SEM of 3 independent experiments with 3 replicate wells in each 
experiment. (*) Significantly different from the oleic acid alone condition at P<0.05. 
To test whether the polyphenols inhibited an effect of oleic acid or themselves increased 
mitochondrial content, the cells were incubated with quercetin, cyanidin, or their phenolic 
breakdown products for 1 h and then removed prior to incubation for 24 h in the absence of oleic 
acid (Figure 6.8). The results showed that incubation with only protocatechuic and caffeic acid 
induced mitochondrial content by 37 and 23%, respectively while incubation with the parent 
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polyphenols quercetin and cyanidin, or the phenolic product 2,4,6-trihydroxybenzaldehyde had no 
induction of mitochondrial content.   
 
Figure 6. 8. Effects of 1 h treatment with polyphenols on mitochondrial content after 24 h. 
HepG2 cells were incubated with 10 µM quercetin, cyanidin or their phenolic breakdown products 
for 1 h and then removed prior to incubation for 24 h (without oleic acid). (UT: untreated, Que: 
quercetin, Cyn: cyanidin, Caf: caffeic acid, PCA: protocatechuic acid, THB: 2,4,6-
trihydroxybenzaldehyde). The MitoTracker Green fluorescence was quantified using a microplate 
reader. Untreated cells were set at 100% and the data are presented as % of the untreated cells. The 
figure represents means ± SEM of 3 independent experiments with 3 replicate wells in each 
experiment. (*) Significantly different from UT control at P<0.05. 
6.4. Discussion 
In this study, we compared the effects of the parent flavonoids quercetin and cyanidin, and their 
degradation products on steatosis, oxidative stress, mitochondrial membrane potential and 
mitochondrial content in an in vitro model of steatosis. We aimed to discover if the phenolic 
breakdown products have strong enough effects that they might account for some of the protective 
benefits observed from these flavonoids in vivo, or in vitro. 
The results showed that three of the main breakdown/digestion products of quercetin and cyanidin, 
(protocatechuic acid, caffeic acid, and 2,4,6-trihydroxybenzaldehyde) had at least equal, and in 
some measures greater effects than the parent compound. In oleic acid-induced intracellular 
triglyceride accumulation for example quercetin and cyanidin and their breakdown/digestion 
products showed similar protection. Consistent with these results, other in vitro and in vivo studies 
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have shown that phenolic acids such as protocatechuic acid [347], caffeic acid [348], and 2,4,6-
trihydroxybenzaldehyde [349] have anti-steatotic effects. In addition to steatosis, quercetin and 
cyanidin and their breakdown/digestion products also showed similarity in the prevention of 
intracellular ROS production. In agreement with these results, other in vitro studies [350] have 
shown that phenolic acids such as protocatechuic acid have potent antioxidant activity and can 
inhibit oxidative stress.  
The results showed that the effectiveness of flavonoids and their breakdown/digestion products on 
steatosis depended on the type and concentration of free fatty acids used. The protective effect of 
flavonoids and their breakdown/digestion products against steatosis was stronger when palmitic 
acid was used to induce steatosis in which polyphenols completely prevented lipid accumulation. 
This could be due to the lesser steatotic effect of palmitic acid (which increased steatosis by only 
48%) compared to the higher steatotic effect of oleic acid (which increased steatosis by 182%).  
The results also showed that exposure to oleic acid decreased the mitochondrial membrane 
potential in HepG2 cells by 40%, while quercetin and cyanidin and their breakdown/digestion 
products all protected against the decrease. Protection by the phenolic acids protocatechuic acid or 
caffeic acid against a mitochondrial membrane potential decline has been shown previously in 
cultured cells exposed to a mitochondrial toxin [351] or ethanol [352]. Since the current study 
showed that parent flavonoids and their degradation products similarly protected against the 
mitochondrial membrane potential decline, the breakdown/digestion products of parent 
polyphenols (quercetin and cyanidin) may contribute to in vivo protection against mitochondrial 
dysfunction and mitochondria-mediated apoptosis in NAFLD. However, studies on the effect or 
comparison of phenolic degradation products and parent flavonoids on mitochondrial dysfunction 
and the membrane potential in NAFLD are very limited.  
Previous research has shown some protective effects of the investigated flavonoids and phenolic 
breakdown products against NAFLD. Quercetin [44], cyanidin-3-glucoside [249], and 
protocatechuic acid [347] have been shown to decrease hepatic steatosis in rodents fed an 
atherogenic diet. Similar protection of quercetin and cyanidin and their phenolic breakdown 
products against intracellular lipid accumulation in HepG2 cells, suggest that each of these 
polyphenols independently possess a lipid lowering effect. In a recent study, 2,4,6-
trihydroxybenzaldehyde was also shown to decrease hepatic fat accumulation in mice fed a high-
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fat diet [349]. The authors also reported that 2,4,6-trihydroxybenzaldehyde decreased intracellular 
fat in 3T3-L1 adipocytes although very high doses (50, 100 µM) of this phenolic compound were 
used [349]. A protective effect against steatosis was also shown with caffeic acid in HepG2 cells 
treated with oleic acid [348]. Again, very high doses of caffeic acid (100, 150 µM) were used in 
that study that may not be achievable in human blood. In the current study, we showed that doses 
more relevant to human serum concentrations can have protective effects.  
Decreased content of mitochondria in hepatocytes was another aspect of NAFLD that we 
investigated for the effects of phenolic breakdown products compared to the parent compounds. 
Our previous work (Chapter 4) showed that treatment of HepG2 cells with oleic acid decreased 
mitochondrial content by 20%, and quercetin but not cyanidin could significantly protect against 
the decrease. In the current study, oleic acid similarly decreased mitochondrial content by 20%, 
while in this case cyanidin but not quercetin significantly protected against this decrease. The 
reason for the discrepancy between the two studies is not known. Interestingly however, the 
phenolic breakdown products had stronger effects than the parent flavonoids in protecting against 
the decrease in mitochondrial content. Although previous studies have shown protective effects of 
quercetin and anthocyanins in NAFLD [249, 250], a question is whether the observed effect of 
quercetin or anthocyanins in vivo is due to the parent polyphenol or their degradation products. 
Previous studies show that anthocyanins for instance, unlike other polyphenols such as quercetin, 
have no effect on SIRT1 activity in vitro [279], but increased liver SIRT1 mRNA and protein 
expression from dietary anthocyanins has been observed in vivo [353]. These results support the 
possibility that the degradation products of anthocyanins from the colonic microbiota may be 
responsible for this effect.  
The current results also suggest that caution is needed interpreting in vitro studies of cells 
incubated with flavonoids. It is likely that incubation of HepG2 cells with quercetin or cyanidin in 
culture medium for 24 h produced spontaneous degradation products, as previously shown by other 
studies [334, 338]. One of those studies [334] reported that after incubation of cyanidin in cell-free 
medium (DMEM) for 4 h, 96 percent of cyanidin had degraded to primarily protocatechuic acid 
and 2,4,6-trihydroxybenzaldehyde. Similarly, incubation of quercetin in DMEM resulted in more 
than 90% degradation to phenolic products after 3 h [338]. Accordingly, the bioactivity of 
quercetin and cyanidin in the current study may be at least partially attributed to their degradation 
145 
 
products since we observed similarity between parent flavonoids and their breakdown products 
(after 24 h of incubation) in inhibiting steatosis and ROS generation. Unknown however is the 
extent to which the parent flavonoid enters the cells in the early part of the incubation, and thereby 
contributes to some of the effects.  
In order to further investigate whether the effects of cyanidin and quercetin is due to the parent 
polyphenols or their breakdown/digestion products, we incubated the cells with quercetin and 
cyanidin and their breakdown/digestion products for only 1 h and then replaced the medium with 
fresh medium containing no polyphenols. This short-term treatment may result in quick uptake of 
the flavonoids by HepG2 cells and avoid the majority of the spontaneous degradation which occurs 
following long incubation (24 h) with culture medium. Interestingly, the results show that after 1 
h of pre-incubation, only the phenolic degradation products prevented the decrease in 
mitochondrial content produced by oleic acid, while the flavonoids quercetin and cyanidin had no 
significant effect. Moreover, in experiments without oleic acid 1 h exposure to the phenolic acids 
protocatechuic acid and caffeic acid, but not the flavonoids or 2,4,6-trihydroxybenzaldehyde 
increased the mitochondrial content in HepG2 cells after 24 h. These results suggest that the 
observed induction of mitochondrial biogenesis in animal models by flavonoids such as 
anthocyanins [254] may be due to the phenolic degradation products produced by the colonic 
microbiota. 
In conclusion, parent flavonoids quercetin and cyanidin and their breakdown/digestion products 
similarly protected against steatosis, ROS generation, and the mitochondrial membrane potential 
decline induced by oleic acid in HepG2 hepatocytes, but only the phenolic degradation products 
induced mitochondrial biogenesis. The results suggest that phenolic breakdown/digestion products 
of the flavonoids quercetin and cyanidin are responsible for the observations of protection in cell 
culture, and for protection by these dietary flavonoids against NAFLD. 
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CHAPTER 7: GENERAL DISCUSSION AND CONCLUDING REMARKS 
 
 
7.1. General discussion 
The main goal of this thesis was to compare the effects of different classes of dietary polyphenols 
on molecular mechanisms underlying NAFLD. We were interested to know which polyphenols 
are the most effective in protecting against the disease and by what molecular mechanisms. In the 
first manuscript (CHAPTER 3), we investigated the effects of polyphenols on steatosis as the “first 
hit” of NAFLD, and mitochondrial dysfunction. Treatment of HepG2 cells with oleic acid 
increased intracellular lipid accumulation and distorted morphology of the cells. However, 
treatment with different polyphenols inhibited steatosis and preserved the eye shape morphology 
of HepG2 cells. Although protective effects of individual polyphenols against steatosis have been 
previously shown in studies in vitro [35-37] and in vivo [48, 73], we found different classes of 
polyphenols show similar effectiveness in the context of protection against lipid accumulation. To 
further elucidate the mechanism of protection, we did a gene expression study and we found that 
different polyphenols inhibit steatosis by inducing the expression of genes involved in fatty acid 
oxidation and inhibiting those of lipogenesis. Polyphenols also modulated the expression of 
PPARs favoring amelioration of NAFLD. In the second manuscript (CHAPTER 4), we found that 
oleic acid induces oxidative stress and inflammation (“second hits” of NAFLD), while polyphenols 
prevent these outcomes by inducing the expression of the antioxidant enzyme Mn-SOD, inducing 
uncoupling protein 2, and suppressing TNFα mRNA. Again, different classes of polyphenols 
similarly protected against ROS production while they differed in inhibiting TNFα expression in 
which anthocyanins showed no protection. We further found that inducing mRNA and activity of 
SIRT1, and producing phosphorylation of AMPKαThr172 and deacetylation of PGC1α are some of 
the mechanisms of protection by dietary polyphenols against steatosis, oxidative stress, and 
inflammation. Interestingly, all these factors (SIRT1, p-AMPKαThr172, PGC1α) have key roles in 
induction of mitochondrial biogenesis. As discussed earlier, decreased mitochondrial biogenesis 
and fewer healthy and functional mitochondria have been reported in different models of 
NAFLD/NASH [20, 143, 354] as well as in our study. In line with our previous results, we found 
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different polyphenols concomitantly induce the expression of other genes involved in 
mitochondrial biogenesis such as PGC1α, NRF1, and TFAM. Increased mitochondrial biogenesis 
correlates with reduced ROS generation by inducing the expression of mitochondrial antioxidant 
enzymes via PGC1α [145, 301]. Mitochondrial biogenesis can also lead to increased fatty acid β-
oxidation [267] and decreased inflammation [307] which contribute to the alleviation of 
NAFLD/NASH. Although most polyphenols in this study similarly induced mitochondrial 
biogenesis, anthocyanins were unique in that they ameliorated steatosis and oxidative stress 
without inducing mitochondrial biogenesis. This may be partly explained by the fact that 
anthocyanins have no effect on SIRT1 activity in vitro [279]. Anthocyanins however, strongly 
protected against the oleic acid-induced decrease of UCP2 mRNA which may partly explain their 
protective effects against steatosis and ROS generation. Higher mitochondrial content (volume) 
was further observed by polyphenols when we stained mitochondria with the mitochondria-
specific dye MitoTracker Green. Due to the pivotal roles of mitochondria in lipid metabolism, 
ROS generation, lipid peroxidation, cytokine production and apoptosis [13], induction of 
mitochondrial content may have a critical role in prevention of progression of fatty liver to NASH.  
In addition to mitochondrial content, mitochondrial function is also affected in NAFLD. An 
accumulating body of evidence suggests NAFLD as a mitochondrial disease due to the abnormality 
in function and morphology of hepatic mitochondria [4, 10, 17]. Therefore, it is not surprising that 
progression of the disease is correlated with defective mitochondrial function. Treatment of HepG2 
hepatocytes with oleic acid also induced mitochondrial dysfunction evidenced by the lower 
expression of mitochondrial respiratory complex I and V subunits, depleted intracellular ATP 
stores (when bypassing glycolysis using galactose medium), and decreased mitochondrial 
membrane potential. However, different polyphenols protected against these effects and induced 
the expression of mitochondrial respiratory complex I-IV subunits, replenished intracellular ATP 
stores, and prevented depolarization of the mitochondrial membrane potential. We also found 
inverse correlations between mitochondrial content and function with ROS production and TNFα 
expression.    
Although oleic acid induced steatosis, increased ROS generation, decreased mitochondrial 
content, and induced mitochondrial dysfunction, it was unable to induced ER stress. In the third 
manuscript (CHAPTER 5), palmitate was shown to induce endoplasmic reticulum stress 
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concomitant with the induction of mitochondrial dysfunction (evidenced by lower mitochondrial 
content, and decreased mitochondrial membrane potential). As discussed earlier, endoplasmic 
reticulum stress has been suggested to be one of the “multiple hits” involved in the progression of 
NAFLD to NASH [22]. Several studies have reported increased ER stress in hepatocytes treated 
with palmitic acid [26], or in animals [27] and humans [29] with hepatic steatosis. We found that 
palmitic acid increases the expression of several endoplasmic reticulum chaperones and apoptotic 
CHOP. Polyphenols differed in their effect on alleviating ER stress and only quercetin, catechin, 
and cyanidin were able to inhibit the expression of several chaperones concomitant with decreasing 
pro-apoptotic CHOP. We hypothesize that dietary polyphenols mimic beneficial effects of the 
chemical chaperones which by facilitating proper folding of unfolded proteins protect against ER 
stress in the liver, and therefore inhibit endogenous expression of chaperones that results from ER 
stress. A potential chemical chaperone activity of a polyphenol has been shown previously by 
Zhang et al. [258], who showed a potential chaperone activity of berberine which consequently 
prevented accumulation of misfolded or unfolded proteins in a hepatocyte cell line and primary 
hepatocytes. It appears that polyphenols such as berberine possess direct chaperone activity which 
by its protein-stabilizing function ameliorates ER stress and therefore inhibits aggregation of 
unfolded/misfolded proteins responsible for initiation and progression of ER stress [258]. Since 
some polyphenols such as catechin, quercetin, and cyanidin in this study decreased the expression 
of several endoplasmic reticulum chaperones simultaneously, it is most likely that these 
polyphenols possess a chaperone activity similar to what was shown by Zhang et al. and 
consequently decrease expression of most ER chaperones by negative feedback. 
In addition, we found that besides inducing the expression of nuclear DNA-encoded respiratory 
complex subunits, polyphenols can induce the expression of mitochondrial DNA-encoded subunits 
(CHAPTER 5). This shows that by improving the assembly of mitochondrial complexes and 
therefore improving mitochondrial function, polyphenols may prevent progression of simple fatty 
liver to advanced stages like NASH.  
We also found a correlation between ER stress and mitochondrial dysfunction. Our findings show 
inverse correlations between the expression of ER stress markers such as GRP78 and CHOP and 
mitochondrial content and the mitochondrial membrane potential. These correlations are 
consistent with findings that a synergistic steatohepatitis induced by moderate obesity and alcohol 
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results in increased level of GRP78 and CHOP while inhibiting genes involved in mitochondrial 
biogenesis such as PGC1α, NRF1, and TFAM in the liver of mice [326]. Therefore, it is likely that 
ER stress and mitochondrial dysfunction work synergistically to facilitate progression of NAFLD 
to NASH and fibrosis. 
In this study, both oleic and palmitic acids have been used as the stressors. The effects of oleic and 
palmitic acid were different in some aspects. Although oleic and palmitic acid both increased ROS 
generation, and decreased mitochondrial content, oleic acid was stronger in inducing steatosis and 
mitochondrial dysfunction (evidenced by lower mitochondrial membrane potential and mRNA 
expression of mitochondrial complex subunits). Palmitic acid was however stronger in inducing 
ER stress and less potent in inducing mitochondrial dysfunction. The difference in fatty acid 
saturation and even doses (1.5 mM vs. 500 µM) may partly explain the difference in the observed 
effects. It has been shown by many studies that treatment of the cells or animals with palmitic acid 
activates ER stress and induces lipotoxicity [355-357]. Along with tunicamycin, palmitic acid has 
been used as a common model for inducing ER stress in cells. This is likely because palmitic acid 
does not effectively induce triglyceride synthesis [358] and may not effectively be incorporated 
into neutral triglycerides [359]. Another reason is that palmitic acid may induce ER stress by 
modification of calcium concentration in the ER lumen [360] likely due to increasing the stiffness 
of the ER membrane. Palmitic acid is the most prevalent saturated fatty acid found in triglycerides 
of meats and dairy products, as well as in palm oils that are widely used by the food industry. Upon 
consumption of saturated fats, the liver is exposed to high levels of palmitic acid that can contribute 
to NAFLD. Oleic and palmitic acid are the most abundant fatty acids in hepatic triglycerides of 
healthy subjects and patients with fatty liver disease [201]. Since the results show that polyphenols 
can prevent ER stress while inducing mitochondrial biogenesis and function, and protect against 
the deleterious effects induced by oleic or palmitic acid, they may be effective in protection against 
NAFLD. Well-designed randomized clinical trials however, should be conducted to prove the 
efficacy of polyphenols in protection against NAFLD/NASH in humans.  
Since using either oleic or palmitic acid in the cell models of steatosis has its own advantages and 
limitations, some studies suggest using the mixture of these fatty acids (oleate/palmitate 2:1 ratio). 
This has been suggested by some studies as an effective in vitro model of steatosis due to the 
higher steatotic effect of oleic acid and lipotoxicity of palmitic acid [361].  
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In the last manuscript (CHAPTER 6), we aimed to answer the question of whether the effects of 
polyphenols in NAFLD are due to the parent polyphenols or due to their breakdown/digestion 
products. For example, in vitro studies (including our results in CHAPTER 4) show that 
anthocyanins such as cyanidin and cyanidin-3-glucoside do not increase SIRT1 activity [279] in 
the cells while studies on rodents show the opposite with the capability of inducing mitochondrial 
biogenesis by purified anthocyanins from black currant and bilberry [254]. It is still largely 
unknown whether the effects observed in vivo by anthocyanins are due to their 
breakdown/digestion products after ring fission of the parent flavonoids by colonic microbiota. 
Interestingly, we observed that 24 h treatment of HepG2 cells with polyphenols such as quercetin 
and cyanidin and their breakdown/digestion products (2,4,6-trihydroxybenzaldehyde, 
protocatechuic acid, and caffeic acid) similarly decreased oleic acid-induced steatosis, ROS 
generation, and induced mitochondrial function. Moreover, when the cells were pre-treated with 
these polyphenols and their breakdown products for only 1 h (to prevent spontaneous degradation 
of the parent flavonoids by medium), only breakdown/digestion products but not the parent 
flavonoids induced mitochondrial biogenesis. This further demonstrates that the 
breakdown/digestion products of polyphenols may contribute to the preventive effects of the 
parent polyphenols against NAFLD. 
7.2. Concluding remarks 
In conclusion, it seems that mitochondrial biogenesis and dysfunction and endoplasmic reticulum 
stress contribute to the progression of NAFLD while different polyphenols, with similar 
effectiveness but somewhat different mechanisms, can protect against these changes. Different 
polyphenols similarly protected against the increase in intracellular lipid accumulation and ROS 
generation but differed in their effects on mitochondrial content, mitochondrial dysfunction, and 
ER stress. There was no clear trend to the effects of different polyphenols, but they may use 
different mechanisms to protect against NAFLD. Due to the differences in structure and properties 
of different classes of polyphenols, such differences may be expected. More studies on animals 
and humans are needed to elucidate the contributing mechanisms.   
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7.3. Limitations of the study 
There are some limitations for this study: 
1. The model that we used here was an in vitro model of steatosis: Although in vitro 
models are good models for identifying and testing the molecular mechanisms, they do not 
show all the features of NAFLD and NASH in humans. NAFLD and NASH are complex 
diseases in which many factors and even other tissues can affect the disease initiation and 
progression. For example, inflammatory cytokines and adipokines (such as adiponectin, 
resistin, and leptin) produced by adipose tissue can have negative effects on the steatotic 
liver. Infiltrating macrophages in the liver (Kupffer cells) which are a critical source of 
ROS and inflammatory cytokines are also missing in our model. In the liver, hepatic stellate 
cells are also available which produce collagen and result in fibrosis which is also missing 
in an in vitro model of steatosis. Investigating all of these contributors and their intertwined 
mechanisms is not possible in an in vitro model of steatosis.  
2. The activity of the mitochondrial respiratory complexes has not been measured: In 
order to investigate the effects of free fatty acids and polyphenols on mitochondrial 
dysfunction, we measured the mitochondrial respiratory complex subunits mRNA 
expression, the mitochondrial membrane potential, and intracellular ATP stores. Another 
limitation was that for exploring the effects on mitochondrial function however, the activity 
of mitochondrial respiratory complexes was not measured that could give us a better idea 
about the effectiveness of polyphenols on mitochondrial function.  
3. Lack of direct measurement of mitochondrial function: due to the lack of a Seahorse 
XF analyzer, we could not measure the real-time oxygen consumption and activity of 
mitochondria in the cells. The Seahorse XF analyzer is a very useful instrument for 
studying mitochondria that would give real-time data about mitochondrial function, ATP 
stores, and a shift of metabolism from glycolysis to oxidative phosphorylation. 
7.4. Future directions 
The effects of different classes of polyphenols on mitochondrial dysfunction and endoplasmic 
reticulum stress should be measured in in vivo experimental models. Investigating protective 
effects of polyphenols and their breakdown/digestion products of polyphenols on genetically obese 
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mice on a methionine- and choline-deficient diet will also be interesting as this model will develop 
the main features of human NASH and fibrosis. A Seahorse XF analyzer can also be used to 
evaluate the mitochondrial activity of isolated hepatic, adipose tissue and muscle cells of rodents 
fed polyphenols and a high-fat high-sucrose diet. Doing microarrays or investigating genomics 
and proteomics of the liver, adipose or muscle tissue of rodents treated with different classes of 
polyphenols and an atherogenic diet can be excellent future goals to elucidate the contributing 
genes or proteins affected in NAFLD/NASH. Animal models overexpressing or null for SIRT1 (-
/-) can also be a great future direction to further elucidate the role of mitochondrial biogenesis in 
prevention of NAFLD.  
Moreover, translating the results to humans with NAFLD/NASH is difficult due to invasiveness 
of a liver biopsy. In order to translate the results, some of the experiments however can be 
investigated on the liver, or adipose tissue biopsy of obese subjects who undergo bariatric surgery.  
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7.5. Appendix  
 
Figure 7.1. Effect of polyphenols on intracellular ROS production. Fluorescence images (at 
40x magnification) captured by a fluorescence microscope showing effect of polyphenols on oleic 
acid-induced ROS generation after staining HepG2 cells with DCFH-DA. Higher green 
fluorescence represents higher intracellular ROS content 
 
 
Figure 7.2. mRNA expression of some of the ER stress markers after treatment with 10 µM 
polyphenols for 2 h and 1.5 mM oleic acid for 24 h. Oleic acid did not induce ER stress in 
HepG2 cells. 
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Gene Species Primer sequence (5'-3') Cycles (Ct 
values) 
SIRT1 Human Forward: AGT GGC AAA GGA GCA GAT TAG 
Reverse: CTG CCA CAA GAA CTA GAG GAT AAG 
24 
SIRT3 Human Forward: GAA AGC CTA GTG GAG CTT CTG  
Reverse: GGG CAG CCATCA TCC TAT TT 
24 
PPARα Human Forward: TCC TCG GTG ACT TAT CCT GT 
Reverse: GCGTGG ACT CCGTAATGA TAG 
27 
PPARγ Human Forward: GCCTGC ATC TCC ACCTTATTA 
Reverse: ATC TCC ACA GAC ACG ACATTC 
23 
CPT1A1 Human Forward: AGC GTT CTT CGT GAC GTT AG 
Reverse: CGG CCGTGT AGT AGA GAT TTG 
24 
FAS Human Forward: TGT CCT GGG AGG AGT GTA AA 
Reverse: CTG CTC CAC GAA CTC AAA CA 
21 
GAPDH Human Forward: ATG GGT GTG AAC CAT GAG AAG 
Reverse: GAGTCC TTC CAC GAT ACC AAA G 
17 
 
Table 7.1. The sequences of primers used to measure the expression of genes of interest in 
CHAPTER 3 
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Gene Species Primer sequence (5'-3') Cycles (Ct 
values) 
UCP2 Human Forward: GAA CGG GAC ACCTTT AGA GAA G 
Reverse: CAG CAA CAA GAC GAG ATA GAG G 
26 
Mn-SOD Human Forward: GGA GAT GTT ACA GCC CAG ATA G 
Reverse: CGT TAG GGCTGA GGTTTG T 
19 
PGC1α Human Forward:  TGA ACT GAG GGA CAGTGA TTT C 
Reverse: CCC AAG GGT AGCTCA GTT TAT C 
23 
NRF1 Human  Forward:  GTATCT CAC CCT CCA AAC CTA AC 
Reverse: CCA GGATCA TGC TCT TGT ACT T 
24 
TFAM Human Forward:  ATA GGC ACA GGA AAC CAGTTA G 
Reverse: GCA GAA GTC CAT GAG CTG AAT A 
24 
TNFα Human Forward: GGA TGG ATG GAG GTG AAA GTA G 
Reverse: TGA TCC TGA AGA GGA GAG AGA A  
33 
NDUFS8 Human Forward: GAT CCC GAG ATG GAC ATG AAG 
Reverse: TTC TCG AAC GGGTAGTTG ATG 
23 
SDHb Human Forward: CAT TCT CTG TGC CTG CTG TA 
Reverse: GGA GTC AAT CAT CCA GCG ATA G 
23 
UQCRC1 Human Forward: GAG CAC CAG CAA CTG TTA GA 
Reverse: TGA AGC GGC ATG GAGTAA G 
21 
COX6B1 Human Forward: CCA ACC AGA ACC AGA CTA GAA A 
Reverse: GTA CCATTC GCA CAC AGA GAT A 
21 
ATP5G1 Human Forward: TGT CTG CCT CCT TCT TGA ATA G 
Reverse: ACA ACA CTG GTCTGG AACTC 
21 
ATP5F1 Human Forward: GTC CCT TTG TTG CAG ACT TTG 
Reverse: CCT GTT GTG ACT TCT CCGTAT C  
21 
GAPDH Human Forward: ATG GGT GTG AAC CAT GAG AAG  
Reverse: GAGTCC TTC CAC GAT ACC AAA G  
17 
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Gene Species Primer sequence (5'-3') Cycles (Ct 
values) 
iNOS Human Forward: TGTTTGAACACATCTGCAGACACG 
Reverse: CAAGGTCAGGTGGGATTTCGAAGA 
36 
NDUFS8 Human Forward: GAT CCC GAG ATG GAC ATG AAG 
Reverse: TTC TCG AAC GGGTAGTTG ATG 
23 
UQCRC1 Human Forward: GAG CAC CAG CAA CTG TTA GA 
Reverse: TGA AGC GGC ATG GAGTAA G 
20 
COX6B1 Human Forward: CCAACCAGAACCAGACTAGAAA 
Reverse: GTACCATTCGCACACAGAGATA 
21 
ATP5G1 Human Forward: TGTCTGCCTCCTTCTTGAATAG 
Reverse: ACAACACTGGTCTGGAACTC 
21 
MTND1 Human Forward: CTT AGCTCT CAC CAT CGCTCT T 
Reverse: AGATTG TTT GGG CTA CTG CTC G 
19 
MTCYB Human Forward: GAT CCT CCA AAT CAC CAC AGG AC 
Reverse: GGA GGATAATGC CGATGT TTC AG 
17 
MTCO1 Human Forward: GAG CTG GGC CAG CCA GGC AA 
Reverse: GGA AAC GCC ATATCG GGG GCA 
15 
MTATP6 Human Forward: GCC GCA GTA CTG ATC ATT CTA TTT C 
Reverse: TCG GTT GTT GAT GAG ATA TTT GGA 
14 
GRP58 Human Forward: CCT ATC CCA GAG AGC AAT GAT G 
Reverse: TAC AAT GAC CAC ACC AAG GG 
19 
GRP78 Human Forward: AACCATCCCGTGGCATAAA 
Reverse: GGACATACATCAAGCAGTACCA 
17 
GRP94 Human Forward: CGC CTT CCT TGT AGC AGATAA 
Reverse: CGT CCT AGA GTGTTT CCT CTT G 
18 
ORP150 Human Forward: TAA CAC CACTGC CCA GAATAT C 
Reverse: CAT CCC AGCTTC CTT AGT CTT C 
21 
ERdj4 Human Forward: ATGTGTTTGGTTCCAGCCTA 
Reverse: GACCTAAGAGTGCCAACAACTA 
24 
ATF4 Human Forward: GGA GAT AGG AAG CCA GAC TAC A 
Reverse: GGC TCA TAC AGA TGC CAC TAT C 
19 
EDEM1 Human Forward: GTGCCCTCCCTGAGAGATATAA 
Reverse: GATTCTTGGTTGCCTGGTAGAG 
23 
GADD34 Human Forward: GAA CCT CTA CTT CTG CCT TGT C 
Reverse: GTC TTC CTG GCT CCT TTA CTT C 
23 
CHOP Human Forward: CTCACTCTCCAGATTCCAGTCA 
Reverse: GACCACTCTGTTTCCGTTTCC 
21 
GAPDH Human Forward: ATG GGT GTG AAC CAT GAG AAG 
Reverse: GAGTCC TTC CAC GAT ACC AAA G 
16 
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